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Abstract 
Despite improvements in material and design, prosthetic heart valves are still 
prone to thrombosis due to the non-physiological blood flows introduced to the heart. 
Yet, at present, there are no satisfactory methods for assessing valve thrombogenicity 
prior to clinical trials. The inadequacy of animal testing was recently demonstrated 
by the failure of sheep trials to detect thrombosis in the Medtronic Parallel valve, a 
bileaflet prosthesis that subsequently suffered from excessive thrombosis in humans. 
This failure revived interest in the development of alternative tools for thrombogenic-
ity assessment. 
An in vitro technique has been developed at Edinburgh University that uses 
renneted milk as a blood analogue fluid for assessing the flow-induced clotting of 
heart valves. Previous work at this institute demonstrated similarities between the 
clotting of blood and milk on both a microscopic and macroscopic scale. Additionally, 
preliminary tests identified similarities between blood and milk clotting on three 
mechanical valves that have been used clinically. However, to date, all valves have 
been tested in rigid chambers that do not mimic the physiologic shape of the true 
heart. The extent to which this impacts in vitro clotting is unknown. 
There were two main objectives with the curent research. The first aim was to 
further confirm the milk technique's ability to simulate thrombus formation, and 
the second aim was to assess the impact of test conditions on in vitro clotting. In 
support of the first aim, confocal laser scanning microscopy (CLSM) was utilised to 
observe milk coagulation in a stagnation point flow chamber at different shear rates, 
for comparison with platelet deposition. Comparison of the coagulation of milk with 
that of whole blood was achieved by testing twelve different heart valves, representing 
all available valve types, in the existing heart chamber and comparing localised milk 
clotting with sites of reported thrombus formation. Valves were then retested in a 
new heart chamber, which consisted of a flexible model of the left ventricle and a 
straight walled aortic section, or one incorporating the sinuses of Valsalva, mounted 
on top. Lastly, the rennet concentration and valve orientation were varied to assess 
the impact of these conditions on clotting. 
Deposition of milk in the stagnation point flow chamber was dependent on shear 
stress; there was a minimum shear stress for protein alignment, and a maximum shear 
stress above which proteins did not deposit. This compared favourably with reports 
of limiting shear stresses for the growth of platelet aggregates, which have also been 
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shown to align with flow in the presence of sufficient shear forces. The milk test suc-
cessfully generated clots in specific, reproducible locations on all of the rigid valves 
tested, and this clotting compared favourably to reported sites of thrombus forma-
tion in vivo. However, localised milk clot did not form on a flexible trileaflet valve 
prototype; it was suspected that this may have been due to the valve not functioning 
properly under the current test conditions. Clot development was affected by both 
chamber design and exposure time to rennet, the latter being significant for all valve 
types. Localised clotting was not observed if the valve was exposed to renneted milk 
in the primary stage of coagulation. Clot formation on the caged-ball valves and the 
monoleafiet valves appeared to be independent of the test chamber shape, but clot 
formation on the bileaflet valves was not; interaction of the downstream flow with 
the chamber wall appeared to govern clot development. Valve orientation appeared 
to have minimal impact on localised clotting, although it did impact valve operation; 
the Omniscience valve only worked in one orientation in the mitral position of the 
flexible chamber. 
These results confirmed the potential of the milk test to mimic in vivo clotting of 
heart valves. Combined with velocimetry studies of specific valve segments, the use of 
renneted milk could be an important tool in thrombogenicity assessment. However, 
the ideal test system has yet to be developed. Further work is needed to develop a 
system that can accurately simulate clotting in both the mitral and aortic positions 
of the test chamber. 
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1.1 The Heart, Its Valves, and Their Defects 
1.1.1 The human heart 
The human heart is a fairly simple organ in terms of engineering principles. It is 
comprised essentially of two pumps, driven by electricity [1]. The first pump, the 
right side of the heart, receives oxygen-depleted blood from the body and sends it to 
the lungs to be reoxygenated. The second pump, the left side of the heart, receives 
the oxygenated blood from the lungs and pumps it back to the body. Figure 1.1 is 
a schematic diagram of the heart, showing the two different sides. Each side of the 
heart consists of a receiving chamber, the atrium, connected to a pumping chamber, 
the ventricle. In between each of the chambers, there are non-return valves that keep 
the blood flowing in the right direction. The tricuspid valve is located between the 
right atrium and right ventricle, and the pulmonary valve is located at the exit of 
the right ventricle. In the left side of the heart, the mitral valve separates the left 
atrium from the left ventricle, while the aortic valve is at the left ventricle exit. 
Pumping in the heart is achieved by contraction and relaxation of the myocardium, 
the muscle forming the walls of the heart. The myocardial cells convert chemical en-
ergy to mechanical energy; when a cardiac pulse is sent to the cells, ion exchange 
occurs across the cell membrane [1]. This induces an influx of calcium ions that 
triggers the cellular changes associated with contraction. When the calcium ions dis-
sociate, the cells relax and the heart returns to its relaxed size. The phase where the 
myocardium contracts is referred to as systole, while the relaxation phase is referred 
to as diastole. 
The phases of the cardiac cycle are depicted in Figure 1.2. During ventricular 
1 





Figure 1.1: Diagram of the human heart [2]. The right side pumps deoxygenated 
blood to the lungs, while the left side pumps oxygenated blood back to the body. 
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Figure 1.2: Pressure waveforms in the left side of the human heart, with a pulse rate 
of 80 bpm. VS=Ventricular Systole. VD=Ventricular Diastole. Atrial systole occurs 
at the end of ventricular diastole, from time zero to (1) on the graph. The mitral 
valve closes at (1) and the ventricle begins to contract. This forces open the aortic 
valve at (2). The aortic valve closes at (3) and the ventricle relaxes. The mitral valve 
then opens at (4). [3] 
systole, the backpressure in the ventricle closes the mitral and tricuspid valves (1). 
Once the ventricular pressure exceeds that in the downstream arteries (2), the aortic 
and pulmonary valves open, ejecting blood from the ventricle. When the ventricle 
relaxes during diastole, the pressure drops and the aortic and pulmonary valves close 
(3). The mitral and tricuspid valves then open when the ventricular pressure equals 
the atrial pressure (4), and blood can flow into the ventricle. During the latter stage 
of ventricular diastole, the atrial walls contract to push the remaining blood through 
the atrioventricular valves; this period is referred to as atrial systole. After atrial 
systole, ventricular systole begins and the cycle repeats. The average human heart 
repeats this cycle 70-80 times per minute, representing nearly 3 billion pulses in a 
70-year life span. 
The pressure in the left side of the heart is significantly higher than that in the 
right because the left side of the heart pumps blood to the entire body whereas 
the right side of the heart only pumps it to the lungs. This means that the heart 
; 
t) initial valve  
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Figure 1.3: The native valves of the left side of the human heart [1] 
valves on the left side are more prone to structural failure [4] and, therefore, to need 
replacement. The remainder of this work is concerned with the left side of the heart. 
1.1.2 The mitral and aortic valves 
Both the mitral and aortic valves open to allow blood to flow through a central orifice, 
and then close when downstream fluid pushes back against their leaflets. Figure 1.3 
shows a native mitral valve at dissection, as viewed from the left atrium and with the 
left ventricle filled with fluid. The mitral valve is essentially composed of two leaflets 
with a single, semicircular line of closure. The native aortic valve, on the other hand, 
consists of three separate leaflets and three straight lines of closure. A picture of this 
valve is also shown in Figure 1.3. 
The aortic leaflets extend into the aorta, and are surrounded by three sinuses that 
help support them, referred to as the sinuses of Valsalva. It is suspected that the 
sinuses of Valsalva aid in closure of the leaflets during diastole [5]. 
1.1.3 Valvular defects 
There are two main types of valvular defects that may cause a valve to stop working 
properly and need replacement: stenosis and regurgitation [6]. Stenosis is the nar-
rowing of flow through the valves due to valve thickening, scarring, or other abnor-
malities which prevent the valve from fully opening [4]. A stenotic valve is essentially 
CHAPTER 1. INTRODUCTION 	 5 
a converging-diverging nozzle: flow moves from a reservoir through a narrow throat 
into another reservoir. In accordance with Bernoulli's equation, as the stenosis be-
comes more severe, the velocity of flow through the throat increases [7]. Then, when 
this high velocity jet of fluid suddenly expands downstream of the valve, it may in-
troduce turbulence to the blood flow and damage blood components. The stenotic 
throat also causes an increase in pressure drop across the valve, making it harder for 
the heart to pump against it, and this may lead to cardiac arrest [8]. 
The other type of valvular disease is regurgitation (also referred to as incompe-
tence or insufficiency). Regurgitation is the backflow of blood through a valve, either 
due to incomplete closing of the valve, leaflet tearing, or congenital malformation 
[4, 8]. Many people are actually born with small holes in their valves, detected by 
'heart murmurs' [9], but the volume of backfiow is not sufficient to impair normal 
heart functioning. However, if the amount of backflow does become significant, then 
an increased blood volume can build up in the affected heart chamber, stretching 
the myocardium. This increases the strain on the heart and can also lead to cardiac 
arrest. 
In some cases, it is possible to repair the damaged valves with treatment or 
surgery, but often they must be replaced. Since 1952, surgeons have been saving lives 
with replacement heart valves [10]. 
1.2 Prosthetic Heart Valves 
Figure 1.4 shows a selection of prosthetic heart valves. There are two main categories 
into which these valves are divided: tissue valves (a-b) and mechanical valves (c-f). 
Tissue valves are either derived from animal tissue, referred to as bioprostheses, 
or human tissue, referred to as homografts and autografts. They have the same 
shape as the native aortic valve, providing physiological heart flows [11]. However, 
over time, tissue valves tend to degenerate [12]. Leaflets often calcify and become 
stenotic, leading to a need for valve replacement. Reoperations for valve replacement 
have a significant risk associated with them [13] and cannot be considered trivial. 
Mechanical heart valves tend to be more durable than tissue valves [12] but are 
prone to thrombosis, or clotting, due to the introduction of a foreign surface and 
non-physiological blood flows [14]. Modern mechanical valves fall into three different 
categories: ball and cage valves, tilting disc valves, and bileaflet valves [15, 16, 101. 
Ball and cage valves contain a poppet that is free to move within a cage. Blood 
flows annularly around the poppet and may cause turbulence [11]. Tilting disc valves 
(b) bovine bioprosthesis (a) porcine bioprostliesis 
0 
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Figure 1.4: Prosthetic heart valves 
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contain a free-floating single disc which pivots about an axis [10], resulting in a region 
of major flow and a region of minor flow through the valve with flow separation 
in between [15]. Bileafiet valves contain two small leaflets, held in place by hinge 
mechanisms [10]. Flow through these valves is separated into three distinct regions, 
with the minor flow region through the center and flow separation in between [15]. 
Despite reported improvements with valve design, none of these is perfect. They are 
all still associated with thrombus formation and bleeding events [17, 18, 19]. 
There are essentially two main risks associated with thrombus formation: the 
thrombus may break free, forming an embolism that could have detrimental effects 
on the patient, or the thrombus could interfere with proper functioning of the valve. 
When a valve thrombus is detected, treatment options include reoperation or throm-
bolysis. As noted previously, reoperations carry with them a significant risk [13] 
and would preferably be avoided. However, thrombolysis, which involves the use of 
chemicals to break down the clot, is also risky: it can lead to increased emboli in 
the patient, increasing the rates of morbidity and mortality [20, 21]. In any case, the 
ideal alternative is to prevent thrombi from occurring in the first place. 
To reduce the risk of thrombosis, mechanical heart valve recipients must be placed 
on anticoagulants for the rest of their lives. However, this leaves them susceptible to 
anticoagulant-related hemorrhage. The risk of bleeding is strongly associated with 
the intensity of anticoagulation [22], so reducing thrombosis with anticoagulation 
is just exchanging one risk for another [23]. However, it is a necessary risk with 
mechanical heart valves. Inadequate anticoagulation has been repeatedly associated 
with increased incidences of thromboembolism [24, 25, 26, 27, 28]. 
Since mechanical heart valves leave patients vulnerable to thromboembolism and 
bleeding, while tissue valves frequently need to be replaced, neither valve is perfect 
for every patient. Generally younger patients are more likely to receive a mechanical 
valve, while the elderly receive bioprostheses [29]. Other factors, including predis-
position to clotting or hemorrhaging must also be considered. Unless a durable 
antithrombogenic valve is developed, it seems likely that use of both valve types will 
continue. 
The future hope for mechanical heart valves seems to lie in a flexible, polyurethane, 
trileaflet heart valve. Its design is based on the native aortic valve, incorporating the 
best aspects of both bioprostheses (central flow and flexibility) and mechanical heart 
valves (durability) [30, 31]. This valve is still in its developmental stages, so only 
time will tell if this novel design is finally able to eliminate thrombosis associated 
with mechanical heart valves. 
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1.3 Assessment of Heart Valves 
As thrombosis remains a problem with all mechanical heart valves, and since man-
ufacturers are still attempting to develop heart valves with reduced thrombogenic 
potential, there is a need for understanding which design features contribute to clot-
ting. The logical first step in developing this understanding would be to note the 
specific valve locations subject to thrombus formation in existing valves and to assess 
valve thrombogenicity according to valve type. Unfortunately such a comparison is 
difficult to achieve. 
1.3.1 Retrospective assessment from clinical data 
Most clinical reports of heart valve performance merely mention rates of embolism 
and valve thrombosis, with no description of where the thrombus actually occurred 
[32, 33, 34, 35, 36]. One reason for this is that thrombolysis is often the chosen 
method for treating thrombosis [37, 38], so the heart is never opened to visualise 
the clotted valve. If reoperation is attempted, the surgeon is understandably more 
concerned with saving the patient's life than documenting the nature of the clot. 
Of those cases where the thrombus has been documented, bulk clotting has often 
occurred, preventing visualisation of the thrombus origin [39, 40]. Information about 
the thrombus initiation site is crucial to the understanding of valve clotting. 
Most reports on mechanical heart valves include a description of their "throm-
boembolism rate". This number is generally quoted as the percentage of patients 
per year who experience a thrombotic or embolic event. The number is intended to 
provide an indication of the thrombogenicity of the valve, but the usefulness of the 
data is debatable. A survey of published reports by Akins revealed that reported 
thromboembolism rates can vary from less than 2%/pt-yr to almost 13%/pt-yr for 
the same valve implanted in different centres [6]. There are two possible causes for 
these differences: either centres are differing in their abilities to detect and report 
thromboembolic events, or the centres are somehow contributing to the rates them-
selves. In either case, the huge variances in rates between centres casts doubt on 
their significance for discriminating between one valve model and another. 
Although most centres now follow the guidelines set forth by Edmunds et al [41] 
in reporting thromboembolic events, these guidelines do not require a detailed de-
scription of anticoagulant treatment. Guidelines for anticoagulation levels vary for 
different countries [42, 43, 44], and even for different valves [42, 43]. Additionally, 
Butchart et al found a huge degree of variability between different cardiac surgeons 
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and anticoagulant clinics across the UK alone [45]. Since the level of anticoagula-
tion influences the likelihood of clotting, comparing thromboembolism rates between 
centres is meaningless without a concomitant description of the anticoagulant treat-
ment [45]. Akins has proposed a composite thromboembolism and bleeding index for 
valves [16] in an attempt to account for anticoagulation variability between centres. 
However, Sour et al showed that changes in anticoagulation have a much larger effect 
on bleeding rates than on thromboembolism [46], so the composite index still does 
not provide the full picture with regard to valve thrombosis. Given the additional 
fact that thrombobemboli are repeatedly associated with inadequate anticoagulation, 
reported thrombus rates may be more representative of the adherence of a particular 
group of patients to their anticoagulant regimen than of the relative thrombogenicity 
of a particular valve. 
There are some studies in which a single centre has actually performed a ran-
domised trial of different heart valves [47, 48, 49, 50, 51] but the results of these 
studies just seem to confuse the matter. Mikaeloff et al found that the St. Jude 
Medical valve had a significantly lower thromboembolic rate than the Björk-Shiley 
and the Starr-Edwards valves [48]. On the other hand, Vogt et al found a slightly 
lower rate of thromboembolism with the Bjork-Shiley valve than the St. Jude valve 
In Fiore's study, the percentage of patients free from thromboembolism at 10 
years was identical for patients receiving either St. Jude or Medtronic Hall valves 
Yet, a group in the Netherlands found the Medtronic-Hall valve to have a 
higher rate of thromboembolism than the Bjöork-Shiley valve [51]. Clearly, these 
results illustrate the difficulties in assessing the thrombogenic potential of existing 
heart valves. As long as this is the case, it is not going to be possible to determine 
if 'improved haemodynamics' really makes one type of valve better than another in 
terms of thrombogenicity. 
1.3.2 Animal testing 
Despite the dubious nature of reported thromboembolism rates, manufacturers con-
tinue to quote them [52, 53] as proof that their valves are less thrombogenic than 
other valves on the market. Additionally, work continues on trying to make new 
valves that are less thrombogenic than their predecessors. Given the difficulties of 
correlating changes in valve design with demonstrated improvements in thrombogenic 
potential, how can new valves be assessed before being placed in humans? Currently, 
the only acceptable method is by animal trials. 
Before a valve can go to clinical trial, it must be tested in six animals for six 
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months alongside two control valves of similar style [54]. During that test, the valve 
must prove to be at least as good as the control in order to move on to clinical trials. 
Unfortunately, there are problems with this assessment method. 
There is disagreement in the medical community over which animal is actually the 
best model for thromboembolism studies. The blood biochemistry, heart shape, and 
blood flows of animals all differ from one another as well as from humans, and each 
may impact valve performance. In addition, factors including animal age, health, 
husbandry, and ease of surgical treatment must be considered [55]. Different studies 
report testing in sheep [56, 57, 581, pigs [59], calves [60], dogs [58], and even baboons 
[61]. Yet, despite the disagreement over which animal is the best model, most valves 
are only tested in one type. 
A recent failure of the Medtronic Parallel valve has shown the limitations of such 
a trial. The valve performed perfectly in sheep, with no thromboembolic events, but 
then it had an unusually high number of cases of valve thrombosis when it went to 
clinical trial [62]. Grehan et at subsequently tested the valve in pigs and found that 
the valve did clot, but the pigs had an advanced chronic tissue response that resulted 
in a fibrous growth impairing most of the implants, making the follow-up difficult 
[59]. This response is faster in pigs than in other animals and is not known to occur 
in humans. 
The results with the Medtronic Parallel valve illustrate some of the biggest prob-
lems with animal trials, the most important being that the clotting reactions in 
animals differ to those in humans. Different animals may provide different results, 
and these results may not correspond with what will actually happen when the valve 
is placed in a human. While testing the valves in multiple animal types would help 
increase the chance of observing all potential failure modes, the extensive cost of 
animal testing discourages manufacturers from doing this voluntarily. Even if they 
did, there is still no guarantee that animal testing would always work. 
1.3.3 In vitro assessment 
After the failure of animal trials to detect thrombosis in the Medtronic Parallel valve, 
interest returned to developing an in vitro method for assessing the thrombogenic 
potential of mechanical heart valves. Laser doppler velocimetry (LDV) was used to 
evaluate flow through the hinge regions of both the Parallel valve and the St. Jude 
Medical valve, the bileaflet valve that is generally accepted as the industry standard. 
The purpose of the velocimetry testing was to determine whether any flow features 
could be identified that predisposed the Parallel valve to excessive thrombosis [63, 64, 
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65]. Gross et al. [63] identified significant areas of stasis and recirculation zones in the 
Parallel valve that persisted throughout the entire cardiac cycle; a subsequent study 
[64] found that similar recirculation zones were wiped free in the hinge pockets of 
the St. Jude valve. During retrograde flow, Ellis et al. [65] observed turbulent shear 
stresses in the Parallel hinge region that were twice as high as the turbulent shear 
stresses found in the St. Jude valve. This work showed that velocimetry studies have 
the potential to identify fluid mechanical features of heart valves that may lead to 
thrombosis. While this is a significant advancement in the tools available for assessing 
artificial heart valves, there are limitations to its use. Firstly, velocimetry work can 
only identify factors that may cause thrombosis; it cannot confirm that these factors 
will actually lead to clotting. Additionally, LDV involves detailed imaging of flow 
through a specific valve segment. This means that the researcher needs to have an 
idea of where thrombus is likely to occur so that the study can be focused on that 
area [63, 64]. 
The use of blood flow loops has been pursued by a few research groups [66, 67, 68]. 
However, this work either involves animal blood [67, 681, which may not reflect true 
human blood clotting, or it is focused around a small, specific region of the valve [66], 
as with the velocimetry work. It would take a significant volume of human blood to 
simulate clotting around the entire valve, something that is not always practical in a 
laboratory setting. Additionally, in order to use blood in vitro, anticoagulants must 
be added to prevent the blood from clotting indiscriminately in the testing system 
[68]. Clotting factors are then added externally to the blood to allow it to clot around 
the valve in the test [67]. This means that the inherent blood-clotting cascade does 
not propagate in the same manner as it would in vivo, essentially turning in vitro 
blood into a blood analogue fluid. 
The use of renneted milk as a blood analogue fluid for testing heart valves was 
first proposed by Lewis and Macleod in 1983 [69]. When rennet is added to milk, 
it initiates a clotting reaction that is similar to that resulting from the action of 
thrombin on fibrinogen in blood [70]. Both ultimately lead to the formation of an 
adherent, insoluble clot. There are, of course, obvious differences between the milk 
clotting reaction and thrombosis. The enzyme, rennet, must be added externally 
to the milk system whereas the thrombin is already present in the blood, albeit 
normally in an inactivated state. Thrombosis requires the activation of platelets to 
initiate the clotting cascade, while the milk clotting reaction begins immediately upon 
addition of the rennet. There is evidence to suggest, however, that the implantation 
of mechanical heart valves causes a patient's blood to be in a hypercoagulable state 
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[71]. In this case, the exposure of valves to enzyme-activated milk is not really so 
different. 
Lewis investigated milk clotting in an artificial heart chamber around the two 
main commercial valves available at the time of his work: the Starr-Edwards valve, 
and the Björk Shiley valve [72]. Subsequent work in this laboratory by Christy [73], 
Marosek [74], and Curtis [75], as well as work at the University of Sheffield [76], 
have further demonstrated the ability of milk clot to form around heart valves and 
fixed test bodies in a cylindrical chamber. Additionally, Marosek and Curtis's work 
demonstrated the potential for the milk test to provide real-time monitoring of clot 
formation via the use of ultrasound. 
1.4 Objectives of the Current Work 
The current work essentially had two main objectives: to reaffirm the ability of 
renneted milk to accurately model thrombosis on mechanical heart valves and to 
assess the impact of the testing system on in vitro clotting. 
Improvements in microscopy techniques since the time of Lewis's work led to 
a renewed interest in observing clot formation under microscopic flow conditions. 
Tippe, Reininger A, and Reininger C have studied the effects of shear and stagnation 
on platelet and fibrin deposition [77, 78, 79, 80], and it was desired to replicate some 
of their work with milk for comparison. The purpose of this work was to further 
delineate the effects of fluid mechanics on the microscopic development of milk clot, 
for comparison with blood clot development. 
To assess the viability of using renneted milk for the detection of potential clotting 
sites on heart valves, it was necessary to ascertain whether the milk test would 
properly predict clotting on all possible valve types. Prior to this work, the only 
commercially-available mechanical valves that had been tested with renneted milk 
in the heart chamber in this laboratory were the Starr-Edwards and Björk-Shiley 
Standard valves. Since several other valves have been introduced to the market since 
the time of that work, it was desired to test as many of those valves as possible in 
the existing heart chamber. The purpose of this was to determine whether the milk 
clotting test could work on all of the valve types and whether the milk clot locations 
compared favorably with reported thrombus locations of these valves in vivo. 
The original heart chamber developed in this laboratory was a relatively simple 
model with axisymmetrical rigid sections designed to have the same hydraulic radii 
found in the human heart [72]. In contrast, the chambers of the native heart are not 
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symmetrical, and the heart walls expand and contract to push blood through the 
valves. The extent to which these differences may impact in vitro thrombogenicity 
assessment is unknown. There is a significant degree of variability in the heart cham-
bers used by different centres for fluid mechanical studies, both in the ventricular 
section and in modeling the aorta. Some groups use rigid chambers [81, 82], while 
others use compliant models of the left ventricle [83, 84]; some utilize axisymmetrical 
models of the sinuses of Valsalva [85, 86], while other groups have incorporated three 
separate sinuses [83, 87]. Since any of these features may impact valve performance, 
it was decided to compare in vitro clot formation on heart valves in different testing 
systems. The objective of this work was to determine the impact of test chamber 
design and test conditions on in vitro clotting, with an aim toward establishing a 
standard for subsequent in vitro thrombogenicity work. 
Chapter 2 
Thrombosis 
There are two different processes which may lead to blood clotting in the circulatory 
system: haemostasis and thrombosis. Haemostasis refers to the processes that protect 
the vascular system from leaks [88]. The inner walls of the veins, arteries, and 
capillaries are all composed of a layer of endothelial cells. When these cells are 
ruptured, the bloodstream is exposed to chemicals that trigger a platelet response 
[89]. Activated platelets adhere to the wound forming a 'platelet plug' to seal up 
the injured site. The resultant blood clot is reinforced with fibrin strands, which 
also trap additional red blood cells, giving it a characteristic dark colour. When the 
vasculature is sufficiently healed, the haemostatic plug is removed via the process of 
fibrinolysis. Haemostasis is necessary for survival; those people with compromised 
haemostatic systems, such as haemophiliacs, are at an increased risk of catastrophic 
bleeding events. 
Thrombosis, on the other hand, is the pathologic clotting of blood [90] and is 
induced by local flow conditions. A thrombus may be either white or red, depending 
on the flow environment in which it is formed [91]. In regions of high flow, for 
instance in the arteries, white thrombi form that are primarily composed of platelets 
and reinforced by some fibrin strands. However, in regions of low flow, such as in the 
veins, red thrombi form, which are composed of comparatively fewer platelets but 
more fibrin and red blood cells. While a haemostatic clot is necessary for survival, 
a thrombus represents a hazard to the circulatory system [88]. In recent years, deep 
vein thrombosis has generated particular concern among the general public. This 
occurs when blood flow in the legs is severely restricted for a long period of time, 
as in long-haul flights. Blood may be activated elsewhere and then coagulate in 
the region of stasis in the veins [91]. While such thrombi are usually small and 
asymptomatic, they present two potential hazards to the victim: they may restrict 
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Figure 2.1: Virchow's triad 
blood flow through the vasdulature, or they may break free, forming emboli that 
could lead to a stroke or, in the worst scenario, death. In all cases, thrombosis is an 
undesirable circulatory event. 
There are three concomitant factors that determine whether or not a thrombus 
will form. They were first elucidated over 100 years ago by Virchow and are now 
known as Virchow's triad [92]: blood chemistry, surface chemistry, and fluid dynam-
ics. Figure 2.1 shows a schematic of these factors and some aspects of each. 
2.1 Blood Chemistry 
Blood is a colloidal suspension of formed elements and proteins transported in a 
fluid solution called plasma. The formed elements of the blood are erythrocytes (red 
blood cells), leukocytes (white blood cells), and platelets; these account for 40% of 
the blood volume [93]. The erythrocytes are anucleate biconcave discs responsible 
for oxygen transport in the body. The leukocytes are the only true blood cells, 
containing nuclei, and they are responsible for defending against disease. Platelets 
are anucleate discoid cell fragments responsible for blood coagulation. Although all 
of the formed elements may be found trapped in a thrombus, the platelets are the 
elements specifically responsible for triggering coagulation, and will subsequently be 
the focus of the remainder of this section'. 
'Erythrocytes enhance thrombus formation by transporting platelets toward the periphery of the 
blood vessels [80, 94], but are not central to the coagulation process 
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Figure 2.2: Structure of a platelet. Coagulation factors are contained in the dense 
granules and alpha granules [88]. 
2.1.1 Platelets 
The structure of a platelet is shown in Figure 2.2. The outer membrane of the 
platelet is rich in glycoproteins that are receptors for various coagulation ligands, 
including thrombin, collagen, and fibrinogen [95]. The glycoproteins also provide 
platelets with a strong negative surface charge, which presumably prevents unstim-
ulated platelets from aggregating, due to electrostatic repulsion [88, 96]. The layer 
below the glycoprotein-rich membrane contains phospholipids that are also involved 
in coagulation. These phospholipids have the ability to migrate to the surface of a 
stimulated platelet, providing a substrate for some of the coagulation reactions [97]. 
Arachidonic acid may also be cleaved from the phospholipids and then converted to 
Thromboxane A2 by the platelets [98]. Thromboxane A2 is a powerful stimulus for 
platelet aggregation [96]. Other important coagulation factors are contained within 
the platelets in storage granules, and are secreted during the coagulation process [99]. 
There are three stages in platelet coagulation: adhesion, activation, and aggrega-
tion. Platelets circulating in the blood will normally not adhere to the vessel walls 
or to each other [88]. However, when certain proteins 2 of the subendothelium, or 
attached to a foreign surface, interact with blood, platelet adhesion is possible [95]. 
After the platelets have adhered to the non-endothelial surface, they may become ac-
tivated, undergoing a shape change that transforms them into 'spiny spheres' [91, 98] 
with pseudopodia. In the presence of strong activation factors, platelets may also 
2 e.g. fibrinogen, collagen, thrombospondin 
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release the contents of their storage granules, activating other platelets in the blood-
stream and accelerating the coagulation cascade [98]. Once platelets are activated, 
aggregation may occur, resulting in the formation of a platelet plug. This aggregation 
will be reversible or irreversible, depending on the strength of stimulus applied [96]. 
Platelet adhesion in a flowing system is complicated by the existence of shear, 
which tends to pull a platelet away from the nonendothelial surface. To counteract 
the shear effects, platelet adhesion requires von Willebrand factor (vWF) [100, 101]. 
vWF is a large multimeric protein that is present both in the plasma and the storage 
granules of platelets. vWF binds platelets to the nonendothelial surface by coupling 
with the GPIb receptor on the activated platelet. This response occurs rapidly in 
flowing blood, serving as a temporary glue between the platelet and foreign surface. 
Once the platelets are held in place by vWF, further reactions have time to proceed, 
allowing for reinforcement of platelet adhesion [100, 101]. 
Activation of platelets may be chemically induced by a number of agonists, includ-
ing ADP, platelet activating factor (PAF), and thrombin. The agonists have been 
classified according to whether or not activation is mediated by aggregation [102]. 
ADP and PAF are weak agonists; if primary (reversible) aggregation is blocked, they 
will only induce platelet shape change, and the contents of the storage granules will 
not be released. On the other hand, thrombin is a strong agonist, capable of inducing 
platelet release even in the absence of primary aggregation. 
Activation of platelets causes Ca 2 ions to mobilise into the platelet cytoplasm 
[96]. The Ca2+  ions then trigger the release of the storage granules and the produc-
tion of thromboxane A2. Thromboxane A2 activates receptors on the platelet surface 
which can bind to adhesive proteins that hold activated platelets together, forming a 
platelet aggregate. The adhesive proteins are suspected to include fibrinogen, vWF, 
thrombospondin, fibronectin, and P-selectin [103, 104]. Recent studies have largely 
focused on fibrinogen and vWF, suggesting a common receptor for the proteins of 
GPIIb-IIIa on the platelet surface [104, 101, 105]. Fibrinogen appears to be the driv-
ing force behind aggregation at low shear rates, while vWF binds platelets together 
at shear rates higher than 100 sec 1 . 
2.1.2 Fibrin 
Reinforcement of the platelet plug is accomplished by a network of fibrin strands, 
without which the platelets could be dislodged by flow [88]. The precursor to fibrin 
is fibrinogen, one of the most abundant proteins circulating in the plasma [106]. The 
structure of fibrinogen, obtained from X-ray crystallography, is shown in Figure 2.3. 
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Figure 2.3: Structure of fibrinogen. Triangles show sites of thrombin cleavage on the 
a-chain. [106, 107] 
It contains 2 each of three coiled polypeptide strands, having a subunit formula of (a, 
, 'y) [106, 108]. The chains are arranged in a symmetrical, dimeric fashion, with the 
amino-terminal ends at the centre (as shown in the diagram). Thrombin cleaves two 
fibrinopeptides each from the amino-terminal ends of the a and the 0 chains, leaving 
fibrin behind [109]. The cleaved ends of fibrin may be considered as 'knobs' which fit 
into 'holes' on other fibrin molecules [108]. Initially, two-molecule thick linear poly-
mers called protofibrils are formed, followed by branching, and finally the formation 
of an entire 3-D fibrin mesh [108, 110]. A schematic of this polymerisation is shown 
in Figure 2.4. Reinforcement of the fibrin clot is accomplished by Factor XIIIa, which 
covalently cross-links the fibrin strands [110]. As with other stages in coagulation, 
fibrin polymerisation is enhanced by the presence of Ca 2 [111]. Mosesson et al [112] 
showed that a fibrin network formed in a buffer containing 10 mmol/L CaC12 was 
much denser than the fibrin network formed without CaC12. The scanning electron 
microscopy (SEM) photo of the fibrin clot formed in the presence of CaCl2 is shown 
in Figure 2.5. 
In addition to being the precursor of fibrin, fibrinogen has its own roles to play in 
coagulation. At low shear rates it serves as a powerful mediator of platelet aggregation 
by binding to GPIIb-IIIa [104, 111], cross-linking platelets in the platelet plug [96]. 
Fibrinogen also acts as a substrate for platelet adhesion to foreign surfaces [113]: 
when flowing blood is exposed to a foreign material, plasma fibrinogen can deposit 
on its surface. Several studies have shown that platelets will then adhere to the 
adsorbed fibrinogen [114, 115, 116], potentially initiating thrombus formation. 
2.1.3 The coagulation cascade 
The mechanism responsible for generating the fibrin network is the coagulation cas-
cade. There are two different pathways through which the cascade may be initiated; 
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Figure 2.4: Stages in fibrinogen cleavage and fibrin polymerisation [106] 
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Figure 2.5: SEM image of a fibrin clot formed in a buffer containing 10 mmol/L 
CaC12 [112]. Bar = 10 microns. 
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Figure 2.6: The coagulation cascade, showing both the intrinsic and the extrinsic 
pathways of initiation [89]. 
traditionally, these have been referred to as the extrinsic pathway and the intrin-
sic pathway [88, 91]. The extrinsic pathway is so-named because platelet activation 
requires a coagulation factor that is not normally present in the plasma, but that 
becomes available once the endothelium is ruptured. In contrast, all the coagulation 
factors involved in the intrinsic pathway are already present in the plasma, albeit 
in an inactivated form. The steps involved in the coagulation cascade are shown in 
Figure 2.6. 
The coagulation cascade involves a series of steps in which inactivated precursors, 
or zymogens, in the blood are transformed to activated coagulation factors, which, in 
turn, activate additional factors [89]. For simplicity, the factors have been identified 
with Roman numerals, and the activated factors are given the suffix 'a'. The common 
names and functions of the pro-coagulation factors are listed in Table 2.1. It should 
be noted that this is not an inevitable chain of events. In addition to the activation 
of procoagulant factors shown in the diagram, anticoagulant factors, or inhibitors, 
are activated as well. Table 2.2 lists the main inhibitors of the coagulation cascade. 
Coagulation propagates when the level of procoagulants in the area exceeds that of 
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Factor Common Name Function of active form 
I Fibrinogen Forms fibrin gel 
II Prothrombin Activates fibrinogen 
 Tissue thromboplastin Stimulates activation of F VII 
 Calcium ions Necessary for interaction of surface 
phospholipid and coagulation factors 
V Proaccelerin Stimulates activation of F II 
VII Proconvertin Activates F X 
VIII Antihaemophilic factor A Stimulates activation of F X 
IX Christmas factor Stimulates F X 
X Stuart-Prower factor Activates F II 
XI Plasma-thromboplastin Activates F IX 
antecedent 
XII Hageman factor Activates F XI 
XIII Fibrin stabilising factor Stabilises the fibrin network 
Table 2.1: The functions of the main coagulation factors [88]. 
Inhibitor Enzymes inhibited 
Antithrombin III Thrombin, Xa, IXa, XIa, XIIa 
C1K inhibitor Cl, kallikrein, plasmin, XIIa, XIa 
a2 Macroglobulin Thrombin, kallikrein 
al Antitrypsin XIa 
a2 Antiplasmin Plasmin, kallikrein, thrombin, XIIa, XIa, Xa 
Heparin cofactor II Thrombin, Xa 
Protein C Va, Villa 
Protein S Cofactor for activated Protein C 
Activated protein C inhibitor Inhibits activated protein C 
Table 2.2: The anticoagulation factors [117]. *C1  is the first component of the 
complement system. 
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anticoagulants [118]. 
The intrinsic pathway may be initiated by the contact activation system, involving 
the conversion of Factor XII to XIIa and prekallikrein to kallikrein in the presence of 
high molecular weight kininogen (HMWK) at a foreign surface [119, 117]. Factor XIIa 
can then activate Factor XI, triggering the intrinsic pathway. The extrinsic pathway, 
on the other hand, is dependent upon the Factor Vu-tissue factor (TF) complex. 
TF is not normally present in the plasma, but it is present in the subendothelium, 
becoming available for coagulation when the endothelium is ruptured [117]. TF-
initiation of the extrinsic pathway is crucial to normal haemostasis. The intrinsic 
and extrinsic pathways converge with the production of factor Xa, which is a cofactor 
in the transformation of prothrombin to thrombin. Thrombin is a powerful agonist, 
which activates platelets, cleaves fibrinogen to form fibrin, and activates factor XIII, 
which crosslinks the fibrin strands to reinforce the blood clot [118]. 
Localisation of the coagulation process occurs because most of the activation reac-
tions occur on specific cell surfaces [120]. For example, tissue factor (TF) is exposed 
on the surface of a subendothelial cell and binds to Factor VII [118]. The Factor 
VIIa/TF complex then activates Factors IX and X at the surface of the same cell 
[118, 120]. Factor IXa then migrates from the TF cell and adheres to Factor V, which 
is bound to glycoprotein Tb on the surface of a platelet. The GpIb/IXa/V complex 
must then be brought into contact with its cofactor Xa to activate prothrombin. 
Thus, thrombin production is normally localised to the site of endothelial rupture. 
This prevents runaway clotting from occurring in the vasculature. 
Modern theories of the coagulation cascade do not view the intrinsic and extrinsic 
pathways as independent [89, 120]. Rather, it has been suggested that the extrinsic 
pathway is the initiation pathway, while the intrinsic pathway is the propagation 
pathway. Once thrombin is generated by the extrinsic pathway, it can trigger the 
intrinsic pathway by activating factor XI, amplifying coagulation. However, while 
this model seems likely for haemostasis or injury-related thrombosis, it does not fully 
account for thrombosis induced by artificial surfaces. 
Although contact activation of the intrinsic pathway is one proposed mechanism 
for biomaterial-induced coagulation, in recent years the significance of factor XII 
activation has been challenged [121]. While factor XIIa has been associated with 
exposure to biomaterials [122, 123], it has not been shown to consistently correlate 
with the amount of thrombin produced [123, 1241. Frank et al [124] studied extra-
corporeal circulation in three different haemodialysers, where the blood is exposed 
to a foreign surface. They found that one haemodialyser was considerably more 
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thrombogenic than the others, showing a correlation between FXIIa and thrombin 
production, but in the others, thrombin levels increased even when levels of FXIIa 
did not. In fact, in one of the haemodialysers, thrombin was produced to the same 
extent in FXII-deficient blood as in normal blood. This corresponds clinically to the 
fact that patients with FXII-deficient blood do not demonstrate higher bleeding ten-
dencies [119]. This indicates that an alternative method for activation in the presence 
of foreign surfaces must also exist. 
Recent research has indicated two possible mechanisms for the surface-mediated 
initiation of the clotting cascade that support the revised theory of coagulation. 
Both mechanisms involve the interaction of monocytes, which account for 5% of the 
leukocytes circulating in the blood [93]. Parratt and Hunt [125] tested patients on 
cardiopulmonary bypass machines and found that monocytes were responsible for 
directly activating factor X, which could then generate thrombin and initiate the 
intrinsic pathway. Other groups have shown that monocytes may provide the tissue 
factor necessary to initiate the extrinsic pathway [126, 127]. As mentioned previously, 
when platelets are activated, they can secrete the contents of their storage granules, 
which migrate to the surface of the platelet. One of these substances is P-selectin, 
an adhesive protein that aids in the binding of platelets to other surfaces, including 
monocytes [128]. Platelet-monocyte conjugates have been shown to express tissue 
factor [127], which can then trigger the extrinsic pathway of coagulation. Research 
into these alternative mechanisms of biomaterial-induced clotting is still at an early 
stage, but they shed some light on the difficulty of creating a truly 'inert' biomaterial. 
2.1.4 Fibrinolysis 
Fibrin is not intended to be permanent, so an alternative system exists for the system-
atic breakdown of a fibrin clot: fibrinolysis. The main component of the fibrinolytic 
system is plasmin, which, similar to the coagulation factors, circulates in the plasma 
as an inactivated precursor called plasminogen [129, 130]. Plasminogen can bind to 
either fibrin or fibrinogen, but can only be activated efficiently on fibrin [130, 131]. 
Fibrin has an additional binding site for tissue plasminogen activator (tPA), which 
converts plasminogen to plasmin. The plasmin is then able to digest the fibrin, con-
verting it to soluble fibrin degradation products that are removed from the clot. 
The fibrinolytic system is linked to the coagulation cascade through multiple 
feedback loops. tPA is released from the endothelium in the extrinsic pathway of 
coagulation. In the contact activation system, kallikrein acts on plasminogen to form 
plasmin [129]. Plasmin is also capable of inhibiting additional coagulation factors, 
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including factors V and VIII [130]. The presence of mulitple feedback loops between 
the procoagulation cascade and the fibrinolytic system ensures that the appropriate 
amount of fibrin is generated at the non-endothelial surface. 
2.1.5 Anticoagulants 
When patients are at an increased risk of thrombosis, e.g. due to lifelong exposure to 
an artificial heart valve, it is necessary to inhibit the coagulatory response to prevent 
thrombosis. In such cases, the patient must be placed on anticoagulant therapy. 
There are a wide number of drugs available to minimise the risk of thrombosis, and 
the coagulatory path inhibited by each drug varies. Selection of the appropriate 
drug and level of treatment is critical in order to minimise pathologic clotting while 
maintaining the normal haemostatic response. 
Perhaps the best-known anticoagulant is aspirin, although this has a fairly limited 
antithrombotic effect. Aspirin is an antiplatelet agent, capable of irreversibly inhibit-
ing cyclooxygenase within the platelets [132]. This blocks the release of platelet 
granules and prevents secondary aggregation when platelets are activated by weak 
agonists [102]. However, aspirin cannot prevent platelet aggregation in the presence 
of strong agonists such as thrombin, and it does not interfere with the coagulation 
cascade. 
One of the most powerful anticoagulants is heparin, a member of the glycosamino-
glycan family [133]. Heparin is a highly heterogeneous molecule, diverse both in size 
and function. It may be taken either intravenously or subcutaneously [134], and is 
generally monitored in a clinical setting. There are two main types of heparin given 
therapeutically: unfractionated heparin and low molecular weight heparin (LMWH). 
The larger, unfractionated heparin binds with antithrombin III to inactivate thrombin 
while the LMWH inhibits factor Xa [133, 132]. Additionally, heparin is capable, to 
a lesser degree, of inactivating factors XIIa, XIa, and IXa [134]. Unfortunately, hep-
arin is also capable of directly activating platelets, which may lead to life-threatening 
thrombocytopenia [135]. Its use is therefore generally limited to a fixed therapeutic 
course of treatment. 
One current area of research involves the development of alternative antithrombin 
agents, the most potent of which is hirudin [136]. Hirudin is a natural agent found in 
the salivary glands of leeches. It forms an equimolar complex with human o-thrombin, 
inhibiting both thrombin-mediated platelet aggregation and the coagulation cascade 
[137]. Hirudin does not impact aggregation induced by other platelet agonists. 
Long-term thrombosis prevention is generally accomplished by the use of oral 
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anticoagulants, taken in the form of pills. The most common of these is warfarin 
[132], which interferes with vitamin K metabolism. Several of the coagulation factors 
are dependent on vitamin K, including prothrombin, VII, IX, and X [138]. Vitamin 
K is responsible for the carboxylation of glutamic acid residues on these factors, 
which is necessary for the Ca 2 -mediated interaction of the factors and phospholipids 
[132, 138]. In order for vitamin K to mediate carboxylation, it must first be reduced 
to its quinol form [132]. Warfarin is suspected to block this reduction, interfering 
with the availability of catalytically-active vitamin K as a coagulation cofactor. 
2.2 Surface Chemistry 
Surface chemistry refers to the interaction of a foreign (nonendothelial) surface with 
the blood. This may be influenced by surface charge, surface topography, and sur-
face composition [139, 140]. For the remainder of this work, only the surfaces of 
biomaterials will be considered. 
The first step in the interaction between a foreign material and blood is the 
deposition of a protein layer on the foreign surface [139, 141]. As mentioned in 
Section 2.1.2, fibrinogen is one of the proteins that may be deposited. After the 
biomaterial surface is 'conditioned' with a suitable protein layer, platelet adhesion 
may occur, potentially accompanied by activation of the coagulation cascade and 
the immune system. The term 'haemocompatibility' is generally used to refer to the 
material's ability not to activate those systems. 
Surface charge was initially considered to be the crucial determinant of a mate-
rial's haemocompatibility [142, 143]. Sawyer et al tested caged-ball prosthetic heart 
valves made of different metals and concluded that surfaces with a net positive charge 
induced thrombus formation, while negatively-charged surfaces inhibited it 3 [143]. 
These results were justified by the logic that, because blood cells have a negative sur -
face charge, they would be repelled by other negatively-charged surfaces. Extensive 
advances in the understanding of the haemostatic system since that time have re-
vealed the oversimplicity of that tenet. For one thing, factor XII can be activated by 
negatively-charged surfaces [88, 144], triggering the intrinsic pathway of coagulation. 
In fact, extensive research in the last decades have shown that surface charge has 
little impact on adhesion in a biological fluid. Any electrical charge, be it positive or 
negative, can encourage deposition, so an electrically neutral biomaterial is generally 
desired [139]. 
3They attributed any aberrant results to contamination of the valves prior to testing 
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Surface topography refers to the roughness and porosity of a surface. Topography 
is suspected to have a significant impact in high flow regimes [140], as are found in 
the vicinity of prosthetic heart valves. The presence of pores or surface imperfections 
may affect the microscopic flowfields near the material surface, influencing thrombus 
formation. Wurzinger et al tested PVC polymer films and found that the presence 
of surface irregularities larger than a single platelet increased platelet deposition by 
50% [145]. Therefore, careful polishing of biomaterial surfaces is generally desired to 
improve haemocompatibility. 
Surface composition may be the most important factor governing haemocompat-
ibility, especially at low flow conditions [139, 140]. The exact materials present on 
the surface determine the wettability and reactivity of the surface. A biomaterial 
that is to be brought into contact with flowing blood should demonstrate suitable 
wettability, minimising resistance to flow at the surface. The reactivity of the mate-
rial with blood components is also of crucial importance, affecting both binding of 
proteins to the surface and degradation of the biomaterial. The balls in some early 
prosthetic valves reacted with lipids in the bloodstream, becoming pliable and occa-
sionally fracturing [1]. Today, tissue valves ultimately fail because they calcify over 
time, changing their shape and function [12]. 
Most modern mechanical heart valves are made of pyrolytic carbon with highly 
polished surfaces. While these newer valves have shown improvements in haemo-
compatibility, they are still not ideal. Goodman et al performed a scanning electron 
microscopy (SEM) analysis of the leaflets from St. Jude Medical and CarboMedics 
valves, and found that both exhibited surface roughness with features up to a micron 
in size [146]. Platelet activation on the leaflets was found to be extensive. Yang et al 
implanted discs made of pyrolytic carbon alongside discs made of three other materi-
als in the superior and inferior vena cava of sheep and found that considerably more 
thrombus deposited on pyrolytic carbon than on titanium [147]. Yet, in a review 
of the Omni style of valves, Phillips discovered that the thrombogenic potential of 
the Omnicarbon valve was statistically less than that of the Omniscience valve, but 
the only difference between the two is that the housing of the Omniscience valve is 
made of titanium whereas the rest of the valve, and all of the Omnicarbon valve, 
is made of pyrolytic carbon [148]. This would indicate that pyrolytic carbon is less 
thrombogenic than titanium in situ. 
Clearly, there is still room for improvement in the field of biomaterials as it relates 
to heart valves. While today's materials are thromboresistant, they are not truly non-
thrombogenic [149]. This means that there is still potential for platelet adhesion and 
CHAPTER 2. THROMBOSIS 	 27 
the activation of the coagulation cascade. Whether a truly inert material will ever be 
developed remains a matter for debate [150, 121]. Basmadjian et al calculated that 
even an 8-fold reduction in factor XII activation would not prevent activation of the 
coagulation cascade [150]. The recent evidence that leukocytes and the complement 
system  may also contribute to biomaterial thrombosis [121] indicates that develop-
ment of a truly nonthrombogenic material is even more complicated than previously 
anticipated. 
2.3 Fluid Dynamics 
Since all modern biomaterials are capable of initiating a thrombogenic response, 
thrombosis management is crucial. As mentioned in Section 2.1.5, one method of 
accomplishing this is by the use of anticoagulants. The other method is by controlling 
the third aspect of Virchow's triad: fluid dynamics. 
An artificial heart valve introduces nonphysiolgical flows to the blood, including 
increased velocities, shear stress, regions of stasis, and turbulence, all of which may 
promote thrombus development [152, 153]. Convective transport and diffusion in 
the blood stream also play significant roles in thrombosis, carrying platelets and 
coagulation factors into potential activation zones [154, 155]. In recent decades, 
significant research has been conducted to develop an understanding of how each of 
these factors contributes to thrombosis. 
2.3.1 Mass transfer 
Mass transfer is responsible for the propagation (or inhibition) of the coagulation 
cascade, leading to the formation of fibrin. Procoagulant factors can diffuse through 
the blood stream to other factors, triggering activation of the next step in coagu-
lation. At the same time, convective transport removes unbound factors, diluting 
the concentration of procoagulants in the area. As mentioned previously, coagula-
tion proceeds when the local concentration of procoagulant factors exceeds that of 
anticoagulants. 
In addition to transporting the coagulation factors, mass transfer is responsible 
for bringing platelets in contact with foreign surfaces and for removing activated 
platelets from the area. At normal flow rates, convective transport is the main force 
responsible for movement of platelets. Blood cells tend to be interspersed randomly in 
4 The complement system is responsible for the inflammatory response to pathogens and foreign 
materials [121, 151] 
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the blood stream, with a slightly higher concentration of red blood cells in the centre. 
However, at increasing Re numbers, the red blood cells align with the motion of flow 
and platelets are pushed to the outside [156, 154]. Diffusion becomes significant 
in platelet transport to the foreign surface, especially in the boundary layer, where 
convective velocity is zero [157]. On arrival at the surface, platelets are subject to 
one of the main forces associated with thrombosis: shear stress. 
2.3.2 Shear stress 
Shear stress is the force per unit area that one layer of fluid exerts on another layer; 
it is considered to be the most important force affecting thrombosis [158]. Several 
studies have been performed to assess the impact of shear stress on platelet activation 
and aggregation. These have revealed a complex involvement between shear and 
thrombus formation. 
Shear stress may lyse platelets or induce haernolysis (rupture of red blood cells), 
releasing chemicals into the blood stream that promote coagulation [159, 160, 161, 
162]. Additionally, wall shear stress greater than 40 N/rn2 has been shown to rup-
ture the endothelial lining [163], which can trigger the entire coagulation cascade. 
Haemolysis has generally been accepted to occur at turbulent shear stresses above 
400 N/rn2 [164], but more recently, Grigioni et al calculated that the threshold limit 
should be at least 600 N/rn2 [165]. Platelets appear to be more susceptible to lysis 
than erythrocytes [145]; platelet lysis has been associated with shear stress above 
250 N/rn2 [158]. Yet, it has also been shown that the duration of exposure time to 
the shear stress is as important as the magnitude of stress applied [162, 160, 166]; 
therefore any calculation of the damage potential associated with shear stress should 
also account for the exposure time. 
Cell rupture is not the only contribution of shear to coagulation. Several studies 
have shown that shear stress can act as an agonist itself, activating platelets and 
inducing thrombus formation [167, 168, 169]. As mentioned in Section 2.1.1, shear 
stress also governs the mechanism by which platelets adhere to each other. At low 
shear rates, the platelets are held together by fibrinogen, whereas at higher shear 
rates, aggregation is mediated by vWF. 
Yet, while higher shear rates promote coagulation in some circumstances, in others 
it has been shown to inhibit it. Turitto et al found that increased shear inhibits the 
production of fibrin [157], and Petschek noted a lack of platelet aggregation at the 
highest shear rates tested in a stagnation point flow chamber [92]. Clearly, the effects 
of shear on thrombus development are complicated. 




Thrombosis is also known to occur in regions of stasis, where there is very little shear 
[157, 170]. Stasis may occur in pockets of relatively 'dead' fluid or where stagnant 
recirculation zones develop downstream of flow obstacles. In heart valves, the regions 
of stasis have been identified as those having low downstream velocities [170, 65, 171]. 
In these cases, it appears that mass transfer mediates clot development. Activated 
platelets are held in the area for longer, causing the subsequent activation of ad-
ditional platelets, and providing the opportunity for them to adhere to the foreign 
surface and to each other. Coagulation factors are also allowed to accumulate, gen-
erating significant amounts of fibrin. Erythrocytes are trapped in the fibrin networks 
formed in stagnant zones, leading to the typical red thrombi associated with stasis 
[91]. 
2.3.4 Turbulence 
While stasis occurs at very low flow rates, turbulence may develop at high flow rates. 
Yet it, too, has been shown to promote thrombus development [153]. Turbulence has 
been described as 'a state of continuous instability' [172], characterised by unpre-
dictable flows. In fact, the flow field may be described statistically, if not explicitly, 
around a particular object. In the case of artificial heart valves, turbulence generally 
develops downstream of an obstacle or a sudden expansion. Both cases are associated 
with regions of flow instability and shed vortices. 
The effects of turbulence on thrombosis are confounding. High stresses exist in 
the regions of flow instability, which may lyse and activate cells, but the recirculating 
eddies are associated with low shear and increased residence time [153, 173]. Turbu-
lent mixing may promote thrombus development by causing more platelet collisions, 
increasing the chances for them to stick to surfaces and to each other [174]. In the 
vortices, platelet aggregates may accumulate and coagulation factors may have a 
chance to reach a concentration level adequate for promoting fibrin formation. Thus, 
multiple aspects of turbulence are conducive to thrombus formation. 
2.3.5 Flow studies with blood 
Several tests have been developed to assess the effect of various flow parameters on 
thrombus development. Particular attention has been focused on correlating stasis, 
turbulence, and shear stress with extent of coagulation. While a majority of mod-
ern studies focus solely on platelet activation and aggregation, several earlier works 
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Figure 2.7: The stagnation point flow chamber used by Petschek, showing streamlines 
of flow in the blood [92]. A darkfleld microscope was used for continuous monitoring 
of clot development. 
considered the effects of flow on whole blood coagulation. Some of the flow studies 
relating to general thrombus formation will be presented here, while those studies 
relating specifically to heart valves will be addressed in the next chapter. 
Stagnation point flow 
The impact of stagnation point flow on thrombus formation was first considered 
by Petschek in 1968 [175]. He performed ex vivo experiments in which the carotid 
artery of a dog was connected straight to a flow chamber, as shown in Figure 2.7. 
The blood impinged upon a microscope cover slip and then spread radially across 
the flow chamber into a reservoir and out an exit port. Flow out of the exit port was 
controlled by a flow regulator. This technique allowed for the direct observation of 
the stages of thrombus formation via a darkfleld microscope. It benefited from the 
use of virgin blood, since only the blood in the centre of the artery actually contacted 
the cover slip, so this blood was not previously activated before impingement. 
The use of the stagnation point flow chamber allowed for the effects of shear 
and stasis on thrombosis to be assessed. At the centre of the blood impingement 
region, a stagnation point exists where the velocity components are zero. The radial 
CHAPTER 2. THROMBOSIS 	 31 
velocity components then increase with distance from the stagnation point, and the 
vertical velocity components increase with depth below the stagnation point. For a 
given point in the chamber, the magnitude of the radial velocity, u is given by the 
following equation 
U,. = /3rz 	 (2.1) 
where r is the radial distance, z is the vertical depth, and /3 is a constant related to 
the shear rate in the chamber and determined by the width of the tubing and the 
height between the coverslip and the flow stage. 
Seven different flow chambers were tested, with the flow parameter 0 ranging 
from 1.9 - 200 (mm sec) -1 [92], the latter corresponding to flow conditions in the 
aorta. Thrombus formation on the cover slip was very dependent on the flow param-
eter. In all cases a protein layer first deposited, which was followed by the deposition 
of a platelet monolayer. With low flow parameters, corresponding to low shear, this 
was followed by deposition of a white cell circle whose diameter was shear limited. 
This was normally followed by the development of an azimuthally symmetric throm-
bus. At the higher flow parameters, however, the white cell circle did not deposit, 
and frequently no platelet aggregation was detected even after 3 hours of experimen-
tal time. When thrombi did form, they developed as wedge-shaped clots directed 
away from the stagnation point; with most of these wedge-shaped thrombi, a sur-
face imperfection was visible at the head of the clot. These results indicated that 
low shear rates favour thrombus development, while high shear rates may impede 
platelet aggregation. 
The stagnation point flow chamber has since been used by other investigators 
to further characterise the stages of thrombi development [77, 176]. Advances in 
microscopy and analysis techniques have allowed for further delineation of the mech-
anism of platelet adhesion and aggregation in stagnation point flow. Further details 
of this work are given in Section 4.1. 
Hiadovec's net experiment 
Hiadovec and Riha investigated thrombus formation on a net in an in vitro flow loop 
[177]. A schematic diagram of their flow system, including the location of the net 
is shown in Figure 2.8. Blood, platelet rich plasma (PRP), or platelet poor plasma 
(PPP) was recirculated at 55 ml/min through a nylon net of 0.25 mm mesh and the 
pressure upstream of the net was monitored. 
In all cases, a thrombus developed on the downstream side of the net and was 
found to form in three stages: an initial lag phase which was accompanied by no 
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Figure 2.8: Schematic of Hiadovec's net experiment, showing a) the setup of the 
recirculating flow system and b) the attachment of the net and location of thrombus 
formation [177]. 
pressure change, a flocculation phase in which there was a gradual pressure increase, 
and then the final clotting phase which was accompanied by a sharp increase in 
pressure. The pressure curves for the three test fluids are shown in Figure 2.9. PRP 
and whole blood exhibited similar clotting profiles, although the lag phase was shorter 
in the whole blood. This may be due to the interaction of other blood components, 
which could enhance platelet mixing and subsequent flocculation. For the PPP, the 
lag phase was even longer, and there was an extremely short period of flocculation; 
a bulk clot formed almost instantaneously after approximately 55 seconds. 
The clot that fofned was similar to the white thrombus found in regions of high 
flow in vivo. Fibrin and erythrocytes were both found trapped in the thrombus 
adjacent to the nylon mesh, aligned in the direction of flow. The results of this 
test were significant in that thrombus consistently formed on the downstream side of 
the net, rather than on the upstream, or sieving side. Even though the blood and 
plasma were recirculating, and thus presumably in a hypercoagulable state, thrombus 
formation only occurred where the fluid dynamic conditions were favourable. This 
occurred in the turbulent wake generated downstream of the mesh. 




Figure 2.9: Pressure curves with blood and plasma in Hiadovec's net experiment 
[177]. A-B: the lag phase. B-C: the flocculation phase. >C: the clotting phase 
Flow past bodies of revolution 
Vorhauer [178, 179] studied clot formation on bodies of revolution placed in the 
descending aortas of dogs. The test bodies used in his work are shown in Figure 2.10. 
The objects were situated upstream of cylinders that collected any clot forming in 
the object wake. Two different sets of experiments were run to assess the impact of 
turbulence and stasis on thrombus formation, with 108 observations made in each 
set. In the first set of experiments, the objects were aligned as shown in Figure 2.10a 
and left in the dog for 45 minutes. After that time, the objects were removed and the 
adherent thrombi were weighed. In the second set of experiments, the objects were 
mounted as shown in Figure 2.10b and left in the dog for only 20 minutes, to minimise 
clot formation on the objects themselves. At the end of the test, only thrombi in the 
collection cylinder were weighed. This set of experiments was intended to measure 
thrombosis due only to turbulence whereas the first set incorporated both thrombosis 
and stasis. 
In the first set of experiments, the quantity of clot was found to depend on 
the degree of turbulence and the size of the recirculation zone downstream of the 
test body, with the long teardrop generating the least thrombi. Since this object 
was streamlined, it would have introduced the least turbulence and recirculation 
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Figure 2.10: Bodies of revolution used in Vorhauer's work [178]. Flow is from left to 
right, a) Arrangement for the 45-minute tests, incorporating turbulence and stagna-
tion. b) Arrangement for the 20-minute tests, incorporating only turbulence. 
to the blood. In the second set of experiments, the teardrop again appeared less 
thrombogenic, but the relationship between turbulence and thrombus formation in 
the other objects was unclear. Further, it was found that more thrombi adhered in 
the cylinder without a test object attached than with one present for all but one 
of the test bodies. This indicated that turbulence may actually reduce thrombus 
formation, possibly by eliminating the boundary layer that allows clotting factors 
and platelets to accumulate. 
Viscometry 
Most of the work correlating platelet response with shear stress has been performed in 
rotational viscometers, such as the cone-plate viscometer [180, 166] and the Couette 
viscometer [181, 162]. Pictures of each type are shown in Figure 2.11. 
The cone-plate viscometer was used by both Belval et al [180] and Zhang et 





(a) cone-plate viscometer 	 (b) Couette viscometer 
Figure 2.11: Types of viscometers used in shear stress studies of blood, a) In the 
cone-plate viscometer, the plate is stationary while the cone rotates at a rate W. 
Shear stress is proportional to w and the angle 0 between the cone and plate [158]. 
b) In the Couette viscometer, an inner cylinder rotates within a stationary outer 
cylinder, with a fixed gap between the two. In the diagram, the numbers correspond 
to the following: 1-driving shaft of rotating cylinder. 2-outlet. 3-inlet. 4-Couette 
slit between cylinders. 5-carbon gasket. 6-thermostatic block, containing the outer 
cylinder [181]. 
al [166] to determine the importance of shear stress magnitude and duration on 
platelet aggregation. Belval et al subjected PRP to shear rates  ranging from 1000 to 
10,000 s and measured the resultant platelet aggregation. Samples were withdrawn 
through a port in the stationary cylinder to assess platelet count at different time 
intervals, and platelet aggregation was calculated from the drop in single platelet 
count over time. 10 seconds was found to be adequate to induce platelet aggregation 
for shear rates greater than 2000 s_i.  However, for lower shear rates, no aggregation 
occurred even after one minute of exposure time. For shear rates between 2000 
and 5000 s_i,  disaggregation was possible, whereas for higher shear rates, stable 
aggregation occurred. These results were useful for demonstrating the existence of 
threshold shear values, but they were limited by the fact that the lowest exposure 
time tested was 10 seconds, which was still longer than most platelet exposure times 
in vivo [162]. 
The work by Zhang et al addressed platelet response to a constant shear stress 
over a wider timescale—from 2.5 seconds to 120 seconds. Their work included both 
5Shear stress is the product of shear rate and viscosity. 
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PRP and whole blood, and they assessed both platelet aggregation, based on a di-
minishing count of single platelets, and platelet activation, based on expression of 
P-selectin, at a shear stress of 10 N/rn 2 . Whole blood was found to show an ag-
gregatory response faster than PRP, initially aggregating at 5 seconds and reaching 
a maximum stable value after 10 seconds. PRP initially aggregated at 10 seconds 
but did not reach a maximum until 40 seconds. Platelet activation took longer for 
both, although again, whole blood showed a faster response than PRP; blood was ini-
tially activated in 20 seconds, whereas 40 seconds passed before PRP activation. Both 
reached maximum values after 80 seconds. These results demonstrate the importance 
of exposure time in shear stress assessment, and they indicate that additional blood 
elements contribute to shear-induced platelet activation and aggregation. Therefore, 
shear stress studies of PRP alone should be carefully assessed for extrapolation to in 
vivo behaviour. 
The use of the Couette viscometer allowed for the study of shear stresses on a 
more physiologically relevant time scale than the cone-plate viscometer did. Fluid 
passed around the rotating cylinder and then back out of the exit port in as little as 
7 ms [181]. Wurzinger et al studied heparanized PRP exposed to shear stress ranging 
from 57 N/rn2 to 255 N/rn2 and exposure times from 7 to 700 ms [181, 162]. They 
found that even exposure to shear as low as 57 N/rn2 for 700 ms was sufficient to 
induce platelet shape change. With a higher shear stress of 108 N/m2 , 30% of the 
platelets were actually damaged after 700 ms of exposure time. This showed that 
even relatively low amounts of shear under physiological loading times may damage 
platelets. 
Flow through a model steriosis 
Several groups have investigated blood flow through a model stenosis [182, 183, 184]. 
A stenosis is a sudden narrowing of the flow, which results in accelerated velocities 
through the stenosis throat and a sharp pressure drop downstream. This pressure 
gradient generates flow separation near the downstream edge of the stenosis, which 
may result in the production of recirculating vortices. Similar effects are found with 
heart valves; accelerated jet flow occurs in the orifices of the valves, and flow sepa-
ration is generated around valve occluders [185]. A diagram of a model stenosis is 
shown in Figure 2.12. 
Karino et al [182] discovered that there is a critical Reynolds number needed 
to create vortices downstream of the stenosis, and this number is affected by the 
constriction/expansion shape. Sharper downstream edges induce recirculation at 





Figure 2.12: Flow through a model stenosis [182]. The recirculation zones can be 
seen downstream of the throat, and the reattachment points are indicated by vertical 
arrows downstream of the vortices. 
lower Re than rounded downstream edges. Three characteristics of the vortex were 
noted: 
It is a region of stagnant flow—Small cells migrate out after long residence times, 
while large aggregates are trapped indefinitely. 
It is a region of shear flow—Increased collisions result in spontaneous platelet 
aggregation. 
In is a region of disturbed flow—Convective transport of cells to the wall is 
enchanced, resulting in platelet adhesion at the reattachment point. 
Similar results were noted by Bluestein [186] and Schoephoerster [184]. Bluestein 
et al [187] analysed flow through a stenosis model with Re ranging from 300-3600 
and found that, in all cases, a turbulent jet was produced in the throat of the steno-
sis. This led to axisymmetric recirculating vortices downstream of the throat. This 
analysis was correlated with the study by Schoephoerster et al, and it was found 
that platelet deposition was dependent on the wall shear stress along the stenosis, 
with deposition higher in areas of flow recirculation and reattachment. These results 
demonstrate the significance of both mass transfer and shear in thrombus develop-
ment. 
Chapter 3 
Assessment of Heart Valves 
The International Standards Organisation has recently established guidelines for 
haemocompatibility testing of biomaterials in ISO 10993-4 [188]. The guidelines 
outline the tests that must be performed on materials in order be used in vivo; most 
governments, including those in Europe and the U.S.A., require adherence to these 
guidelines for certification of biological materials [54, 189]. Under ISO 10993-4, heart 
valves are required to undergo both thrombogenicity and haemolysis testing. The 
thrombosis tests involve valve implantation in an animal followed by autopsy of the 
device, autopsy of distal organs, identification of flow reduction, identification of per-
cent occlusion, and scanning electron microscopy of the thrombi. SEM is used to 
identify platelet adhesion and aggregation, platelet and leukocyte morphology, and 
fibrin deposition. In addition, the guidelines recommend invasive, non-invasive and 
in vitro hydrodynamic studies with dynamic similitude. The importance of modeling 
in situ valve function in these tests is noted. 
3.1 Animal testing 
Animal testing is currently the only accepted method for assessing heart valve throm-
bogenicity prior to clinical trial. It is generally believed that the animal can simulate 
the activation and dynamics of clotting better than any in vitro test; yet the ISO 
guidelines recognise that variations in species reactivity exist and advise caution if 
only one species is used for assessment [188]. The variability in reactivity was demon-
strated in a study recently conducted by Goodman [190]. Four different materials 
were tested in sheep, pigs, and human. Subsequent autopsy revealed that platelet 
spreading was dependent on both material and species. The pig and human responses 
were similar for pyrolytic carbon, silicone rubber, and formvar but not for polyethy- 
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lene. Sheep blood was far less active overall. The discovery in discrepancies between 
animal blood clotting and human blood clotting is not a new one. Grabowski et al 
[191] also identified differences between human and animal clotting that were depen-
dent on both species and material. With many materials, canine blood was found 
to be the most similar to human in terms of reactivity, but this similarity was not 
present in all materials tested. Thus, the assumption that animal testing is inherently 
the best model for thrombogenicity assessment is a fallacy. 
The limitations of animal testing became more obvious and more relevant with 
the Medtronic ParallelTM  valve. Medtronic performed a thorough preclinical trial 
of this valve, satisfying all FDA requirements. This included testing the valve in 
the requisite number of weanling sheep for thrombogenicity assessment [62]. No 
sheep developed any thromboemboli, and this was taken as a positive indication for 
proceeding to clinical trial. Unfortunately, in humans, the Parallel valve suffered 
from an unusually high incidence of thrombosis and was voluntarily removed from 
the market by the manufacturer. Subsequent analysis indicated that weanling sheep 
were particularly inappropriate for thrombogenicity studies; in a previous fracture 
test with a different valve known to cause thrombosis, the sheep had not developed 
thromboemboli either, even though they were not subjected to anticoagulation [62]. 
This illustrated the need for alternative methods for precinical valve assessment. 
3.2 Fluid Dynamic Assessment of Heart Valves 
3.2.1 Hydrodynamic testing 
General assessment of heart valve function has been accomplished with in vitro hydro-
dynamic studies. These studies involve mock circulation loops in which the test valves 
are subjected to various pulsatile flow rates and pulse frequencies, corresponding to 
different levels of cardiac output [192, 193]. Various measures of valve performance 
are then obtained, including pressure differential across the valve, regurgitation (or 
insufficiency), energy loss, and effective orifice areas. All of these provide indications 
of how hard the heart needs to work to pump fluid through the valve. Fisher and 
Wheatley [192] determined the pressure differential, energy loss, and regurgitation of 
ten different prosthetic heart valves in an aortic model, including four of the valve 
types studied in the current work. Of those four, the Björk-Shiley spherical disc 
valve had the highest energy losses, while the St. Jude Medical and the Björk-Shiley 
Monostrut were found to be similar. The Omniscience valve was intermediate be-
tween the others. Heiliger et at [193] compared the performances of the St. Jude 
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Medical and Duromedics bileafiet valves in the mitral position of a mock circulation 
loop. They found that the reflux volume and insufficiency were always higher in the 
St. Jude Medical valve, but for larger valves, the effective orifice area was higher as 
well. This indicated that smaller Duromedics valves were hydrodynamically superior, 
but in larger valves the choice of valves would depend on the patient. 
3.2.2 Flow visualisation 
Detailed information about the flow structures around the valve may be obtained from 
visualisation studies through transparent models of heart chambers. Various tracers 
may be used to identify the flow features, including dye and reflective particles [194, 
195]. In these studies, the focus has generally been on identifying flow structures for 
comparison with other data [196, 195]. Fluid dynamically scaled models have proved 
particularly useful for obtaining detailed observations of flow features. Knoch et al 
[197] visualised flow through four tilting disc and two bileaflet valves in a 3:1 scaled 
model of the human aorta. The valves were all tested in steady flow, representing the 
flow at peak systole. Flow separation was found to occur with all valves except for 
the Omniscience valve. However, the Omniscience valve did generate vortices that 
fluctuated along the boundary of the jet of flow through the valve, as did the other 
tilting disc valves. All of the tilting disc valves were associated with asymmetric 
regions of stagnant zones and turbulent mixing. The bileaflet valves generated a jet 
of fluid through the centre of the leaflets and turbulent mixing was found in the wake 
of the two leaflets. Any of these features may correlate with thrombosis. 
After thrombosis of the Parallel valve was proven to be associated with the pivot 
design, a 5:1 scaled model of the valve was produced by Medtronic to allow for 
detailed observation of the retrograde flow in the hinge region. A schematic of the 
hinge region, and one of the flow features identified, is shown in Figure 3.1. Healy 
et al [194] established flow similarity between the model and the normal heart valve 
by circulating a fluid with five times the viscosity of blood through the valve; this 
produced the same Reynolds number and pressure coefficient that would have existed 
in vivo. It was suspected that leakage flow conditions contributed to the thrombogenic 
nature of the pivot, so the valve was tested with liquid flowing against it, causing 
the leaflets to be closed. Dye was then injected directly into the hinge region to 
observe the flow patterns around the pivot. This study identified regions of stasis 
near the tip of the pivot peg and downstream between the leaflets and adjacent to 
the housing. Additionally, it illustrated the presence of a complex helical structure 
at the hinge inflow channel, which is shown in the diagram. The authors suspected 











Figure 3.1: A model of the Medtronic Parallel valve's hinge. The dashed lines indicate 
the path of dye across the hinge during retrograde flow, with the leaflets closed. A 
complex helical flow structure is evident in the inflow tract [194]. 
that this structure could have damaged blood elements and then held them in the 
hinge area, leading to thrombosis. 
3.2.3 Velocimetry studies 
Complex aspects of flow, including velocity profiles and shear stress distribution, 
have been identified with velocimetry studies. The two main techniques used in 
velocimetry studies are hot film anemometry and laser doppler anemometry (LDA). 
With hot film anemometry, a heated probe is placed in the flow that senses cooling 
by convective currents [83]. The heat flux can be used to calculate the local velocity 
and hence shear stress values. LDA involves the use of coherent laser beams to 
illuminate a point in the flow that has been seeded with reflective particles [185, 1871. 
An interference, or 'fringe', pattern is created at the point where the laser beams 
intersect, and particles passing through the fringe generate a Doppler shift in the 
light frequency. The magnitude of the shift is proportional to the particle velocity 
[198]. With modern LDA, 3 laser beams are used to generate a two-dimensional flow 
field [199], so that two components of velocity and one component of the Reynolds 
shear stress are measured directly. 
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Tillmann et al [83] used hot film anemometry to measure the wall shear stresses of 
aortic valves during pulsatile flow. The valves tested included the Bjork-Shiley, Starr-
Edwards, and Lillehei-Kaster (a predecessor to the Omniscience) valves. Because 
hot film anemometry involves the use of physical probes in the flow, measurements 
can only be made at the location of the probes. However, the advantage of this 
technique is that the probes can be inserted anywhere, so measurements are not 
limited by optics. In Tillmann's experiments, the values were obtained at the valve 
sewing rings. Wall shear stress measurements during systole indicated that the Starr-
Edwards valve was capable of causing sublethal damage to erythrocytes. On the other 
hand, the wall shear stresses generated by the tilting disc valves during systole were 
only slightly above the physiological range. However, during diastole, a significant 
leakage flow through the Björk-Shiley valve generated significantly higher shear stress 
values than the other valves at any point in the cardiac cycle; these were in the range 
suspected to cause haemolysis. This indicated that design of the Bjork-Shiley valve 
was suboptimal; wall shear stress during diastole could be associated with thrombosis. 
LDA has become a common tool in the assessment of prosthetic heart valves, as 
it involves noninvasive flow monitoring. A figure of a flow system set up for use with 
LDA is shown in Figure 3.2. The sample must be seeded with neutrally buoyant, 
reflective particles that are large enough to scatter light but small enough so that 
they follow the flow without interfering with it. Three laser beams pass through 
the sample at different angles, illuminating a small volume of flow (a few millimetres 
long) in the sample at a time. A receiver measures the doppler frequency shift induced 
by the seed particles, which allows the local velocity at the intersection of the laser 
beams to be determined [201]. Because LDA measures one small section at a time, a 
method must be in place for moving the beams through the flow to obtain an entire 
fiowfield. The flow system shown in Figure 3.2 was placed on a crossbeam connected 
to a stepper motor, and moved in discreet steps in the horizontal plane, while the 
laser transmitter and receiver remained stationary [200]. 
LDA has frequently been used to compare multiple valves in terms of generated 
shear stress, regurgitant characteristics, and developing flow structures [185, 170, 
202, 81]. In these studies, shear stress values have been measured directly, while flow 
features including turbulent jets and flow separations were deduced from the velocity 
components of the flow field gathered in successive experiments. In general, tilting 
disc valves were found to have better regurgitant characteristics than bileaflet valves 
[170], but they were also associated with larger flow separations downstream of the 
disc and higher levels of turbulent shear stress [202]. The use of bioprostheses did 
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Figure 3.2: Flow setup for laser doppler anemometry (LDA) study. The sample spot 
can be seen in the middle where the laser beams intersect [200]. 
not eliminate turbulence, but for these valves, the turbulent zones were confined to 
the bulk fluid rather than the vicinity of the valve [185]. All valves tested created 
regions of elevated turbulent shear stresses and regions of stasis, both of which have 
been associated with thrombosis in vivo [170, 185, 81]. 
The use of LDA as an important forensics tool was demonstrated after the failure 
of the Parallel valve [200, 64]. Zimmer et al mounted the valve in the mitral position 
of the system shown in Figure 3.2 and obtained values of Reynolds shear stress and 
mean velocity profiles in the vicinity of the valve. They found that four leakage jets 
developed near the hinges that generated excessive turbulent shear stresses. The 
shear stress values were correlated with threshold levels for platelet and erythrocyte 
damage to generate a Blood Damage Index (BDI) for the Parallel valve. It was 
found to be ten times higher than the BDI for the St. Jude valve, which is generally 
accepted at the bileaflet standard. 
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One of the limitations with LDA is that it is an optical tool; the laser beams need 
to be able to pass through the sample and out the other side without being blocked in 
order to generate data. Historically this meant that flow inside and immediately ad-
jacent to the valve could not be observed. Recently, this problem has been eliminated 
by the production of transparent replicas of the valves to allow analysis within the 
plane of the valve itself [203, 64, 65]. After the failure of the Parallel valve, it became 
desirable to observe the flow in the hinge region of bileaflet valves. Using transparent 
valve models, the microflow fields in the CarhoMedics [203], St. Jude Regent [64], 
and Medtronic Parallel [65] hinges have been analysed. The Parallel valve hinge was 
found to have regions of stasis near the leaflet peg combined with a highly turbulent 
vortex in the inflow channel that persisted throughout the cardiac cycle. The St. 
Jude hinge also developed a recirculating zone in the inflow channel during forward 
flow, accompanied by areas of flow separation, but these were abolished with leakage 
flow during valve closure. Flow structures in the CarboMedics hinge were also found 
to be washed out during regurgitation, but the turbulent shear stresses associated 
with the leakage flow were higher than those developed during leakage flow through 
the St. Jude hinge. This indicated that the St. Jude hinge design was superior to 
those of the other valves. 
3.3 Milk as a Blood Analogue 
While the velocimetry studies are invaluable for identifying flow features of heart 
valves that may lead to clotting, they suffer from three significant deficiencies: they 
cannot confirm that a particular flow structure will lead to clotting, they do not 
mimic the dynamic flow environment generated by a growing clot, and they are 
focused on one small volume of flow at a time, which means previous knowledge of 
where to focus the study is necessary. In the case of the Parallel valve, this knowledge, 
unfortunately, came from the failures in clinical trial. While, in hindsight, the hinge 
area seems to be an evident location for focusing LDA studies, no one suspected this 
to be excessively thrombogenic prior to the Parallel failures. How could one decide 
where to focus velocimetry on novel valve types in the future? One potential option 
would be to subject the valve to an in vitro clotting test first. 
In vitro clotting tests involve the use of either anticoagulated blood or a blood 
analogue fluid. In fact, since it has been shown that animal blood reacts differently 
to human blood [191, 190] and anticoagulated human blood behaves differently in 
vitro than it does in vivo [204], it could be said that all in vitro thrombogenicity 
CHAPTER 3. ASSESSMENT OF HEART VALVES 	 45 
tests involve the use of analogue fluids. In determining whether a fluid is a suitable 
analogue, several factors must be considered. These include the ability of the fluid 
to coagulate in a similar fashion to in vivo blood, the ability of the fluid to adhere to 
foreign surfaces, and a similarity in the rheology of clotting. Additionally, the ana-
logue fluid should be readily available, fairly inexpensive, and easy to handle. There 
is one alternative biological fluid that satisfies the latter requirements and naturally 
coagulates: milk. Extensive work has been performed at Edinburgh University to 
determine whether milk could also satisfy the other requirements of a blood analogue 
fluid. 
Similarities between milk and blood have long been noted [205]. For a brief period 
in the 1800s, the use of milk was even attempted in blood transfusions [206]. Jollès 
outlined structural similarities between the clotting processes of milk and blood in 
1975 [70]. Both reactions involve the specific proteolysis of a soluble macropeptide 
to form insoluble strands and soluble glycopeptides [70, 207]. The strands then 
polymerise in the presence of calcium to form a reinforced gel matrix [70, 208, 209]. In 
blood, fibrin strands bind platelets and other blood cells together to form a thrombus; 
in milk, para-/c-casein binds micelles together, trapping fat globules in the matrix to 
form milk curd [210, 211]. 
3.3.1 Milk chemistry 
Milk is a biological fluid that may be viewed as a colloid, consisting primarily of 
fat globules (3.7%), protein (3.5%), and lactose (4.9%) suspended in an aqueous 
serum [212]. The fat globules vary in size from 0.1 to 15 microns, representing the 
largest particles in milk [213]. They are hydrophobic but contain an outer membrane 
that prevents the globules from coalescing, allowing them to stay suspended in the 
milk. The stability of the milk suspension is generally short-lived, shown by the fact 
that fresh, untreated milk left out at room temperature will separate into two layers 
within a day. Homogenisation of the milk, which reduces the size distribution of the 
fat globules, improves this stability. 
Protein is the part of the milk that is involved in enzymatic coagulation. The 
primary protein in milk is casein, and it is found in four main forms: ai, as2, 01 
and ic-casein [209]. The majority of the casein is organised into roughly spherical 
particles called micelles, which range from 40-300 nm in diameter [213]. A picture 
of a casein micelle obtained from electron microscopy is shown in Figure 3.3a with a 
proposed model for the micelle in Figure 3.3b. In addition to the caseins, the micelles 
contain colloidal calcium phosphate (CCP), which aids in micelle stability. The a, 
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Figure 3.3: Structure of a casein micelle. a) Image of micelle obtained from transmis-
sion electron microscopy (TEM). The areas of lower electron density on the periph-
ery of the micelle correspond to the 'hairy layer' [214]. b) A proposed schematic for 
the casein micelle, showing hydrophobic interactions, and electrostatic bonding with 
CCP. The bars represent hydrophobic sections, while the lines represent hydrophilic 
components [215, 216] 
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a82, and 3-caseins constitute the core of the micelle. They are largely hydrophobic 
but also contain multiple negatively-charged phosphoserine residues [209]; these form 
electrostatic bonds with the CCP, helping to hold the micelle core together [216]. ,c-
casein contains a hydrophobic section that is attached to the micelle core and a highly 
hydrophilic carbohydrate tail that extends into the plasma as a 'hair' [217, 213]; this 
'hairy' hydrophilic layer stabilises the micelle in the aqueous medium' [219]. 
3.3.2 Enzymatic clotting of milk 
There are two means by which micelles are prevented from flocculating under normal 
conditions: charge repulsion and steric hindrance [220, 2161. The hairy layer on the ic-
caseins and the phosphoserine groups on the other caseins both have strong negative 
charges that help keep the micelles apart. In addition, the hairy layer is subject to 
Brownian motion. This increases the hydraulic radius of the micelles, minimising the 
distance to which two micelles can approach one another [212]. Coagulation can occur 
when steric hindrance and charge repulsion are reduced; this is largely accomplished 
by cutting of the 'hairs'. 
Milk coagulation proceeds in two steps, although they overlap in normal condi-
tions: the proteolysis of r,-casein and the subsequent aggregation of casein micelles. 
This is illustrated below, along with the final stage of the blood coagulation cascade 
for comparison [70]: 
thrombin 
	
Blood: fibrinogen 	 fibrin monomer +fibrinopeptides 
(soluble) 
,, [ 	2+1 
Fibrin gel Ftatelets and WBC 
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thrombus 
ctiymosln 
Milk: K-casein 	para-K-casein + glycopepbdes 
(soluble) 
2+ 
Curd gel Fat globules and 
(insoluble) micelles trapped in 
matrix to fam cheese 
It can be seen that both reactions involve specific proteolysis of substrates, followed 
by aggregation that is enhanced in the presence of calcium ions. Proteolysis of milk 
involves the cleavage of the hydrophilic 'hairy layer' of r,-casein by the enzyme chy-
mosin, originally called rennin. Chymosin is a soluble protein found in the fourth 
'Other caseins are known to reside on the surface as well but do not appear to contribute to the 
outer 'hairy layer' [218j. 
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stomach of an unweaned calf [70, 221]. It specifically cleaves the Phe-Met bond on 
r.-casein, leaving hydrophobic para-!c-casein attached to the micelle core [213, 212] 
and releasing a large soluble macropeptide into the milk serum. In recent years al-
ternatives to chymosin have been developed that are capable of similar proteolysis 
[221, 222]; the general term for these proteases is rennet 2 [212]. 
After the macropeptide is cleaved from the r.-casein, the net negative charge is 
lowered and steric hindrance is reduced at the point of cleavage [216]. However, 
the negative charge associated with the phosphoserine groups of the other caseins 
is still present; this is where CaCl2 impacts aggregation. The Ca 2+  ions bind to 
the phosphoserine groups on the micelle surface, neutralising the negative charge 
[220], and allowing rapid coagulation to proceed. Adjacent micelles may then be 
held together by a combination of salt bridges, hydrophobic interactions, and van der 
Waals forces [216, 213]. In this manner, CaC12 reduces clotting time and increases 
curd firmness [219]. 
Extensive work has been performed to assess the kinetics of the renneting reac-
tion. It is currently accepted that the enzymatic cleavage is first order with respect 
to concentration and time [216, 213, 223, 224]. However, fitting an equation to the 
whole renneting reaction is much more complex [212, 224, 2251. This is due to the 
fact that flocculation is such a complicated event. Whether or not two micelles will 
adhere depends on the local removal of both electrostatic and steric repulsion. When 
hydrolysis of one hair occurs, the electrostatic charge at that point is reduced but 
steric hindrance still exists due to the presence of the adjacent hairs. Only when a 
large proportion of hairs has been reduced will steric hindrance be eliminated. Floc-
culation then requires that two micelles with minimal steric hindrance collide to form 
adhesive bonds. If proteolysis and micelle motion are random, the chances for such 
collisions to take place are initially low. However, the randomness of the enzymatic 
cleavage is debatable, especially at low values of pH [213]. Since the enzyme moves 
from one place to another while the micelle remains comparatively stationary, prote-
olysis is diffusion-limited and 'sticky patches' may be created. These sticky patches 
could then result in successful collisions earlier than would be implied by random 
collisions. The potential for van der Waals attractions and calcium bridging between 
micelles further complicates the matter, as does the influence of the coagulating en-
vironment. Temperature, pH, and fluid dynamics have all been shown to impact 
coagulation [226, 227, 228]. 
'One of these rennets is derived from the fungus Rhizomucor miehei; this rennet is used in the 
current research. 
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Figure 3.4: The time course of milk coagulation, as observed with turbidity instru-
ments [212] 
The two main techniques that have been used to observe the kinetics of milk 
coagulation are viscometry and turbidity. After hydrolysis of the #c-casein, attractions 
between micelles increase and hence the viscosity increases [229]. The change in 
viscosity with time can be used to monitor coagulation. Similarly, as flocs develop 
in an aqueous medium, more light is absorbed, and the turbidity increases. A graph 
showing the turbidity change with time is shown in Figure 3.4. From this graph, 
it can be seen that there are three phases of milk coagulation: a lag phase with 
no detectable coagulation, a phase with rapid turbidity increase while flocculation 
occurs, and a stabilising phase when most of the micelles have coagulated [212]. 
The lag phase represents the amount of time that must pass before the micelles 
are sufficiently hydrolysed for aggregation to be favoured. The length of this time 
has proven fairly controversial: Dalgleish suggested that at least 90% of the micelles 
need to be hydrolysed before flocculation can begin [230], van Hooydonk and Walstra 
calculated a minimum value of 65% [223], and results by Peri et al indicated that 
aggregation begins as soon as rennet is added to milk [231]. While it is clear that 
the lag phase does exist, there is disagreement as to the exact reasons why. 
One important distinction must be made in comparing the reported coagulation 
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times of milk and blood; while the blood coagulation time is generally taken as the 
time that the blood stops flowing [232], the rennet coagulation time (RCT) normally 
refers to the time that the first flocs are visible in the liquid [212]. For the remainder 
of this thesis, however, the coagulation time will refer, in both cases, to the time that 
it takes for the solid clot to form. 
3.3.3 Effects of fluid mechanics on milk gelation 
Compared to blood, relatively little has been published concerning the effects of fluid 
mechanics on milk gelation. Presumably, this is because fluid mechanical influences 
do not represent catastrophic problems to cheese manufacturing; cheese is generally 
formed in large vats with gentle agitation, so that only the outer periphery is subject 
to any significant shear forces. In cases where stirring (introducing turbulence) or 
shearing has been seen to affect the final structure, the information has likely been 
kept proprietary for commercial reasons. However, the general effects of flow on clot 
development have been noted: if milk coagulates in a stagnant environment, a soft gel 
forms, but if milk clots while constantly moving, large particles develop [233]. It has 
also been recognised that many of the methods for measuring viscosity, which involve 
shearing the fluid, alter the structure they are trying to measure [234]. Unfortunately, 
the mechanisms by which these alterations occur have not received much attention. 
Most of the coagulation tests with milk are nondestructive, allowing coagulation to 
occur without any external mechanical influences [216]. 
However, there has been one recent, scientific study of the impact of shear stress 
on milk coagulation. Konuklar and Gunasekaran [228] tested milk in a double-gap 
couette viscometer, similar to the one shown in Figure 2.11b but with no inlet or exit 
ports. The sample remained inside the viscometer throughout the test, exposed to a 
constant shear stress. Their results are shown in Figure 3.5. Interestingly, at very low 
shear stress ( :5 0.01 Pa), the lag phase normally observed in coagulation was abol-
ished; however, the final coagulum was less viscous. It was suspected that this was 
due to hydrodynamic forces increasing capture efficiency prior to hydrolysis; thus the 
initial rate of coagulation was higher but the final coagulum was not packed together 
as tightly. For moderate levels of shear stress, coagulation prior to hydrolysis was 
minimised, but the collision frequency of hydrolysed particles increased. Thus, above 
the minimum threshold, the lag time was observed but it decreased with increasing 
shear stress. A maximum shear stress threshold for shear-induced aggregation was 
observed at 0.5 Pa. Below this threshold value, the application of continuous steady 
shear stress (CSSS) was actually found to enhance coagulation; the ultimate viscosity 
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Figure 3.5: The influence of shear stress on the rennet-induced coagulation of milk 
[228] 
of the final curd that developed with CSSS was an order of magnitude higher than 
the viscosity of the curd formed in the presence of intermittent shearing. It was 
suspected that this corresponded to denser packing and more alignment induced by 
moderate shear stress. The ability of shear stress to enhance platelet aggregation 
within a range of shear stress values has also been noted [157]. Both are governed by 
the interaction of capture efficiency and particle collisions [104]. 
3.3.4 Adhesion of milk protein to foreign surfaces 
Capture efficiency and particle collisions also affect milk adhesion to foreign surfaces. 
As noted by Berridge and Scurlock [235], deposition is most significant when renneted 
milk flows past a surface just prior to coagulating. They studied the impact of 18 
different materials on this adhesion. Their results showed that the composition of the 
surface was more important than the surface charge, as has also been established with 
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faces, adhesion also occurred on hydrophilic surfaces, likely due to ionic bonding. The 
presence of CaC12 was shown to enhance binding to cellulose, which supported the 
theory that electrostatic interactions occur between casein micelles and hydrophilic 
surfaces. An interesting result was also obtained with a section of bovine aorta: the 
deposition rate on the aorta was very high, with adhesion occurring preferentially on 
the cut edges—the location where platelets are designed to adhere in vivo. 
3.4 Development of the Milk Test 
The use of renneted milk in the assessment of heart valves was first proposed by 
Lewis and MacLeod in 1983 [69]. They recognised that a blood analogue fluid for 
thrombogenicity assessment should be capable of coagulating under controlled con-
ditions, and they hypothesised that the similarities in the clotting reactions between 
milk and blood made milk a suitable candidate. It was not suggested that milk could 
be used to mimic the activation of coagulation, but rather that a milk test could be 
used to simulate the fluid mechanics of clot formation, thus indicating where a clot 
is likely to develop. 
Studies have indicated that the mere presence of a mechanical heart valve causes 
blood to be in an activated, or hypercoagulable, state [236, 237, 238]. This may be 
due to the fact that no truly inert biomaterial has yet been developed; as discussed in 
Section 2.2, the commonly used pyrolytic carbon is still capable of inducing extensive 
platelet activation. Basmadjian et al have calculated that it would take more than 
an 8-fold reduction in biomaterial thrombogenicity to prevent the activation of the 
coagulation cascade [150]. Then, even if that were possible, the presence of shear 
stress in the vicinity of the valve could still trigger platelet activation. As mentioned 
in Section 2.3, even exposure of low shear for the duration of milliseconds induces 
platelet shape change, potentially leading to activation and coagulation if the other 
fluid mechanical factors are favourable. Since the task of preventing activation of the 
coagulation process seems improbable in the foreseeable future, it is still desirable 
to determine where activation of blood will lead to clot formation. In the presence 
of both a thrombogenic material and activated blood, thrombus development is con-
trolled by fluid mechanics. Thus, a test which models fluid mechanically-induced 
clotting is justifiable. 
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3.4.1 Flow studies comparing milk and blood coagulation 
While the similarity in clotting reactions demonstrated the potential for using milk 
as a blood analogue, it was necessary to confirm that renneted milk would clot in a 
similar fashion to blood under typical physiological flow conditions in order to confirm 
its suitability for modeling thrombosis. To confirm this, Lewis decided to replicate 
three tests conducted elsewhere with blood: the Lee-White test, stagnation point 
flow, and Hiadovec's net experiment. Subsequently, Vorhauer's work with bodies of 
revolution was also replicated with renneted milk by Christy [73]. 
Lee-White test 
The first, and most basic, test used for comparing milk and blood clotting was the 
Lee-White test [72]. This test consisted of inverting a stoppered test tube filled with 
1 mL of blood every 30 seconds until the blood clotted. The end clotting time was 
noted, and the tube was then left to settle for observation of syneresis [232]. Lewis 
repeated this test with milk, but with 1% rennet and 1% saturated aqueous calcium 
chloride added at the start of the test to initiate the clotting reaction. Both milk 
and blood were found to have a very sharp endpoint where the fluid stopped flowing. 
Then the clot eventually pulled away from the test tube walls, leaving a solid gel 
and a liquid layer [232, 72]. This test has been used clinically to identify coagulation 
disorders of the blood [239], and in the laboratory, it has served as an adequate 
test to determine the coagulation time of milk in the presence of different rennet 
concentrations. 
Stagnation point flow 
Lewis's next step was the replication of Petschek's stagnation point flow experiment 
with milk [72]. Details of Petschek's work were given in Section 2.3.5. Lewis used 
three different test chambers, representing low, medium, and high shear environ-
ments. The relevant chamber dimensions and flow parameters are listed in Table 3.1. 
The test chambers were made of perspex, with a glass coverslip held on top by a metal 
ring. The experimental setup used by Lewis is shown in Figure 3.6. In an attempt to 
minimise clotting prior to the test chamber and to maximise mixing of reagents, two 
inlet streams of milk were used, each delivered at 66.65 mL/hr by Meltec infusion 
pumps. The streams were recombined immediately upstream of the test chamber, 
giving a total inflow rate of 133 mL/hr, which approximated Petschek's flow rate of 
2 mL/min. Calf rennet was added to one milk stream and saturated aqueous cal- 




Figure 3.6: The experimental setup used by Lewis in his stagnation point flow ex-
periments [72] 
cium chloride was added to the other stream, each pumped at 1.33 mL/hr. The milk 
syringes were held in a thermostatically-controlled oven, although the significance of 
this seems questionable given the length and diameter of tubing between the oven 
and flow stage. Since the flowstage itself was not heated, the clotting likely occurred 
close to room temperature. 
The medium shear chamber provided the best results, and Lewis was able to ob-
serve the stages of clot deposition with a Zeiss photomicroscope. Lewis interpreted 
his results to show that milk deposited in a similar fashion to blood: 
Formation of an initial protein layer 
Deposition of a monolayer of small particles 
Deposition of larger particles 
Formation of a symmetric clot or wedge clot 
Entrance hole Cover slip Flow paramater 3, 
diameter, mm height, mm 	(mm-sec) 1 
low 	 2.9 	 1.9 	 1.9 
medium 	2.5 0.31 17 
high 	 1.6 	 0.2 	 157 
Table 3.1: Dimensions of the stagnation point flow chambers used by Lewis [72] 
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However, this interpretation of Lewis's results is somewhat misleading. The first 
stage is not truly a step in the clotting process. While proteins from the whey likely 
deposit as soon as they contact the glass surface, the para-k-casein micelles are ca-
pable of adhering directly to the surface as well [213]. This differs from blood, where 
a protein layer acts as a substrate for subsequent platelet adhesion. While it seems 
likely that smaller casein fractions would initially deposit, followed by subsequent 
deposition of larger aggregates, Lewis's published results do not confirm a sequential 
deposition, as they were taken from different runs and in different stagnation cham-
bers. However, the similarities in appearances of the final clot structures are relevant 
and significant. Both milk and blood demonstrated the ability to form symmetric 
clots about the stagnation point in an appropriately sheared environment, and both 
generated similar wedge-shaped clots in the presence of surface imperfections. 
Lewis found that clot formation was affected by shear, as Petschek had discovered 
with blood. In the low shear chamber, clot was found to be adherent to the test 
chamber, rather than the glass coverslip. Given the height between the stage and 
the coverslip, it seems likely that the milk arriving at the cover slip did not have the 
force required to adhere at the flow rate tested. Again, little deposition was found 
on the coverslip in the high shear chamber, but in this chamber, adhesion was likely 
prevented by excessive shear forces. The ability of high shear to prevent clotting was 
also noted by Petschek with blood [175], although he did not note a lack of adhesion in 
the low shear chamber. However, since the viscosity of blood is approximately three 
times higher than that of milk, the force with which blood would have impinged upon 
the coverslip would have been higher than that of milk at the same velocity and stage 
height; the shear stress in the chamber would have been proportionately higher as 
well. A comparison between the two fluids should have accounted for the difference 
in viscosity; the phenomenon noted by Lewis might have been observed with blood 
at lower flowrates. 
A subsequent analysis by Lewis et al indicated that clot development in the 
stagnation point flow chamber was dependent on a complex interaction between mass 
transfer and shear stress, with neither one correlating independently with particle 
deposition [240]. The fact that this interaction was able to lead to the growth of a 
similar clot in both milk and blood provided justification, on a microscopic level, for 
pursuing the use of milk as a blood analogue fluid. 
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Hiadovec's net experiment 
A macroscopic comparison of milk and blood clot formation was provided by repli-
cating Hiadovec's net experiment [177, 72], which was described in Section 2.3.5. 
For the milk experiment, clotting was initiated with the introduction of rennet and 
CaC12 to volumetric concentrations of 1%. Flow continued at 75 mL/min until a 
pressure increase of 30 mmHg was detected. Lewis tested multiple variables in this 
system, including the effects of mesh size and temperature on clotting. The results 
obtained with these experiments showed remarkable similarities to Hladovec's work 
with blood. 
For both fluids, clot formed on the downstream side of the net and clotting time 
was independent of the mesh size. This was significant because it showed that the clot 
developed due to fluid mechanical factors, specifically regions of stasis and turbulence 
created downstream of the net. It has been speculated that the milk test merely works 
because large aggregates in the flow get caught in flow-impeding structures. However, 
if this was the case, then milk clot would have occurred upstream of the net due to 
filtering, and there would have been a sharper rise in pressure with a finer net. 
Renneted milk also exhibited the stages of clotting shown by blood and illustrated 
in Figure 2.9. There was a phase with constant pressure and no visible aggregates, 
followed by a gradual increase in pressure with some visible flocculation, and finally 
a sharp pressure rise when a bulk clot formed downstream of the net. The tem-
poral scale of this curve was affected by temperature for both milk and blood; the 
clotting time decreased with increasing temperature. The remarkable similarities 
between milk and blood in this experiment were considered sufficient to justify the 
development of a milk test for artificial heart valves. 
Lewis used the net setup to assess the impact of testing parameters on clot for-
mation. He found that clotting time was significantly dependent on temperature, 
indicating the need for tight temperature control in the milk test. Calcium chloride 
had a less significant impact, with the clotting time relatively unaffected for con-
centrations between 0.8 and 2 %. However, for lower or higher concentrations, the 
clotting time began to increase rapidly. Lewis's results indicated that clotting time 
decreased significantly with rennet concentrations up to 2 %, but then the clotting 
time began to increase again slightly for concentrations greater than 3 %. How-
ever, this was likely due to experimental error. It has been shown elsewhere that 
the renneting reaction is a first order reaction [241], so coagulation time should be 
proportional to the inverse of rennet concentration, approaching an asymptotic value 
at high concentrations. 
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Flow around bodies of revolution 
Christy subsequently performed additional tests to compare the fluid dynamics of 
milk and blood clotting [73]. Initially, he developed a flow chamber for mimick-
ing Vorhauer's experiments involving flow around solid bodies of revolution (Sec-
tion 2.3.5). Christy tested the same objects as Vorhaeur under conditions of both 
steady and pulsatile flow [73]. He did find preferential clotting occurring in the wake 
of the objects, as Vorhauer had, but there was also additional clot formed at the 
upstream face. That clot was of a different nature, however, and it was hypothesised 
that it may have been due to bubbles on the object surface or to trapped clot formed 
further upstream. Only the downstream clot was considered in ranking the objects. 
The results obtained in pulsatile milk flow were the opposite of those obtained 
with blood. However, due to the compliant nature of the canine aorta and damping 
effects of the relatively large test objects, the flow in Vorhauer's tests may actually 
have approximated steady flow [73]. In steady flow the object ranking with milk was 
similar to that with blood, with the only exception being the teardrop. This had 
the second-highest amount of clot in Christy's experiments but the least amount in 
Vorhauer's. Christy suggested that the shapes may not have been identical, with the 
one used in the milk test causing boundary layer separation not seen in the blood. 
Another possible explanation for the discrepancy was that Vorhauer's test objects 
occluded almost half of the aorta whereas Christy's objects were only about 1/10 
the diameter of his test chamber. This meant that the wall shear effects would 
have had a significant impact on Vorhauer's results but almost none on Christy's. 
Additionally, the Reynolds number and frequency parameter of the tests differed, 
possibly contributing to differences in flow [74]. Despite the differences in results, 
Christy's work provided other useful information about the milk clotting process. 
One important finding was that the results with steady flow were markedly differ-
ent from the results with pulsatile flow [73]; this clearly shows the importance of using 
a pulsatile system in thrombogenicity tests. Christy used dye injections to depict the 
flow patterns around the objects, and this showed that the residence time and size of 
downstream vortices differed for the two flow regimes [242], as shown in Figure 3.7. 
In steady flow, trapped vortices, or regions of stasis, continued throughout the test 
and were associated with clotting. In pulsatile flow, some of these vortices were con-
tinuously washed away and clotting did not occur. Christy attempted to correlate 
the fluid residence time with weight of clot formed, but found that there was not a 
clear comparison. Stasis appeared to be a requirement for clot deposition, but it was 
not the only factor involved. Other mechanical forces, including mass transfer and 
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Figure 3.7: Depiction of the movement of dye in the wakes of test objects during a) 
steady flow, and b) the two phases of pulsatile flow [73]. (Photo arrangement taken 
from [75]) 
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shear, were suspected to combine with stasis in the development of clot. 
A modified Lee-White test 
Christy also assessed the influence of mass transfer using a modified version of the 
Lee-White tests. Test tubes were filled with milk, rennet, and CaC12 and inverted 
every 30 seconds, as with the regular Lee-White tests, but for a period of 30 seconds, 
the test tubes were shaken vigorously. The starting time of this agitation was varied 
to determine if it influenced clot development. Christy then noted the time that the 
first particles were visible in the test tube, the time for complete coagulation, and 
the nature of the final clot formed. 
In all cases, agitation did not affect the onset of flocculation, when the first parti-
cles were observed, and it generally did not affect the time of coagulation. The only 
incident where the coagulation time increased was when the shaking had occurred 
immediately prior to the normal coagulation time; once the sample was left to set-
tle, coagulation finished. However, agitation did have an impact on clot structure, 
and most significantly, this impact was highly dependent on the stage in clotting at 
which it occurred. When the sample was agitated prior to the onset of flocculation, 
no influence on the final clot structure was observed; after syneresis, a smooth plug of 
clot pulled away from the whey in the test tube, as with the normal Lee-White tests. 
However, if agitation occurred at the onset of flocculation, the clot demonstrated 
very strong adhesion to the test tube wall and only a small portion pulled away with 
syneresis. The part that pulled away was of a looser, spongier nature than the normal 
clots. Lastly, if agitation occurred in the latter stages of clotting, the clot still pulled 
away from the wall after syneresis, but it formed a loose, spongy plug. These results 
demonstrated the sensitivity of milk coagulation to agitation. If the milk experienced 
significant agitation, due to turbulence for example, at the appropriate stage of co-
agulation, then a much more adhesive milk clot would develop. These results have 
significant implications for milk testing of heart valves, and will be discussed further 
in Section 8.1. 
3.4.2 Milk testing of heart valves 
After confirming the ability of renneted milk to clot in a similar manner to blood on 
both a microscopic and macroscopic scale, Lewis pursued the testing of prosthetic 
heart valves. Lewis devised an apparatus in which milk was deaerated and heated 
to 40 °C prior to entering a perspex model of the left side of the human heart. 
The testing system used by Lewis is shown in Figure 3.8. Immediately upstream of 
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Figure 3.8: The experimental setup used by Lewis in the testing of heart valves [72] 
the test chamber, the milk stream was split in half. Calf rennet was added to one 
stream, and CaC12 was added to the other stream. Those streams were split again and 
then recombined inside the heart chamber to promote mixing. The heart chamber 
consisted of two circular, axisymmetric sections, the inner diameters of which were 
chosen to give the equivalent cross-sectional area of the approaches to the mitral 
and aortic valves in the human heart. A diaphragm was installed between the two 
sections, with water on the back side of the diaphragm driven by a pulsatile pump, 
to pull milk through the heart valves in the chamber. Lewis tested six different heart 
valves, including two models of the Starr-Edwards caged ball valve, the Bjork-Shiley 
Standard valve, and three versions of a valve developed at Edinburgh. As only the 
Starr-Edwards and Bjork-Shiley valves have been used commercially, results with 
those valves will be discussed here [72]. 
All valves were tested in both the mitral and aortic positions for one hour at 
either 2 or 3 L/min with 1 % vol saturated aqueous CaC12 and 1 % vol rennet. 
This gave a clotting time of approximately 45 seconds, so that bulk clotting occurred 
downstream of the test chamber in the drain. Results of two tests are shown in 
Figure 3.9. In the aortic position, clotting on the Starr-Edwards valves was most 
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Figure 3.9: Milk clot deposition in Lewis's experiments. Both were tested in the 
aortic position for one hour at 40 °C and 2 L/min [72]. 
prominent at the apex of the struts and the inflow orifice, with no clot developing 
on the ball. The largest clots on the Björk-Shiley valve were found on the struts up-
and downstream, although there was frequently a generalised clot found covering the 
disc as well. This clotting compared favourably to reported thrombus development in 
vivo. In the mitral position, clot occurred in similar locations on the Starr-Edwards 
valves, although normally to a lesser extent. However, the Björk-Shiley valve was 
only subject to a generalised light coating both up- and downstream. 
Lewis attributed the difference in clotting between the two test positions to stages 
in clot development. He suggested that the clot on the Björk-Shiley valve in the 
mitral position was the conditioning protein layer hypothesised to be the first stage 
in milk clot formation. However, in light of recent work with the test chamber, 
it now seems more probable that the mitral position did not adequately replicate 
thrombus formation. This may either have been due to the shape of the chamber 
or to the short coagulation time of the milk prior to encountering the mitral valve. 
As Christy's work with the modified Lee-White tests demonstrated, agitation prior 
to flocculation had no impact on the resultant clot. Valves in the mitral position 
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of Lewis's chamber were exposed to milk in the early stages of clotting, potentially 
before turbulence would have influenced clot development. Thus, while the nature of 
clot on the Björk-Shiley valve in the mitral position did reflect exposure to an early 
stage in the clotting cycle, it may not have represented a prerequisite conditioning 
stage for subsequent clot development. Support for this theory is supplied by the fact 
that the discs of the tilting disc valves were often free from clot in the aortic position, 
whereas a thin coating of clot could be seen on all of the discs in the mitral position. 
If the mitral and aortic positions represented sequential stages in clot development, 
then any clot observed in the mitral position should have been observed in the aortic 
position as well. 
The main problem that Lewis reported encountering with his apparatus was tem-
perature control. However, a review of his results indicates that deaeration may have 
hen poor we!!. The appernre of clot on many of the valves is consistent with 
clot subsequently observed by Marosek in the presence of bubbles [74]. Both tem-
perature control and deaeration were improved by subsequent researchers of the milk 
test [73, 74, 75]. 
Additional valve assessment has been performed in a straight-walled, cylindrical 
chamber by Christy [73] and Keggen et al [76]. Christy tested a Bjork-Shiley valve 
five times in a long test section, with a residence time of 21 seconds upstream of 
the valve. The test conditions were similar to those used by Lewis, but each valve 
was tested for only 35 minutes. This was deemed an acceptable time to generate 
reproducible results. Results from one run are shown in Figure 3.10. Clot on the 
upstream side of the valve was either found in the minor orifice or around the struts. 
Downstream, a large bulk clot formed over the entire valve. 
Keggen et al tested three different valves in their cylindrical chamber: the Björk-
Shiley Monostrut, the CarboMedics bileaflet, and the Wessex Medical porcine bio-
prosthesis. The location of milk clot on all three valves was found to be comparable 
to that of thrombus formation. Clot on the Monostrut valve was associated with the 
struts; clot on the CarboMedics valve was associated with the hinges; and, clot on 
the bioprosthesis was observed on the outlow surface of the cusps. The agreement 
between milk and blood clotting with these additional valve types further confirmed 
the potential of renneted milk as a blood analogue in thrombogenicity assessment. 
3.4.3 Ultrasonic monitoring of milk clot development 
One flaw in the milk test has been the lack of visual monitoring until the very end 
of the test, after the equipment is dismantled. This means that the stages of clot 
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Figure 3.10: Milk clot deposition on the Björk-Shiley valve in Christy's experiments. 
Both were tested with 15 gallons of milk at 37 °C and 2 L/min [73]. 
deposition cannot be observed, so correlations of the final clot structure with local 
fluid dynamics are still largely conjectural. Additionally, the risk exists that clot 
could impinge upon the valve from another part of the chamber during dismantling, 
or that a clot could break free prior to the end of a test, leaving little trace of its 
previous attachment. In an attempt to remedy that, Marosek [74] and Curtis [75] 
have developed a noninvasive procedure for monitoring milk clot formation via the 
use of ultrasound. 
For simplicity, the ultrasound procedure was developed in a straight-walled cham-
ber, initially using the same objects Christy had tested in replicas of Vorhauer's ex-
periments. Marosek found that it was possible to observe the test object throughout 
the milk run, but excessive attenuation, reflection, and refraction of the ultrasound 
beam made it difficult to quantify the developing clot on the test object; the resolu-
tion around the test object was not sufficient. It was possible to detect artefacts in 
the flow, however, and these could subsequently be correlated with clot deposition. 
In particular, Marosek observed excessive bubbles in the flow, which correlated with 
the presence of craters in the clot on the upstream face of the test objects. This is 
shown in Figure 3.11. 
Marosek also discovered that it was possible to quantify the growth of wall clot, 
and this was pursued to determine whether any differences were found between clot 
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(a) 
Figure 3.11: Correlation of ultrasound image with clot deposition on the teardrop-
shaped test body. Flow was from left to right in (a) and bubbles can be seen on the 
left side of the image. These correspond to craters visible in the clot in (b) [74]. 
development in steady and pulsatile flow. These results are depicted in Figure 3.12. 
In both cases, a lag period was seen before the wall clot developed, but the lag period 
was longer with pulsatile than with steady flow. The wall clot then developed faster 
and reached a thicker final value in steady flow. This was attributed to the presence of 
higher shear stresses and a transient boundary layer in pulsatile flow; the shear may 
have inhibited clot adhesion, and the transient boundary layer would have resulted 
in less reactive milk micelles remaining in the vicinity of the test chamber wall. In 
both flow profiles, there were cases where the wall clot broke off after 28 minutes. 
This confirmed the importance of coupling real-time monitoring with the milk test, 
and implied a practical limit for the duration of subsequent milk tests. 
Curtis's work addressed some of the problems encountered by Marosek. Deaera-
tion was improved with the addition of raschig rings to the degassing column upstream 
of the header vessel and by incorporating both inlet and outlet baffles in the header 










Figure 3.12: Growth of wall clot immediately upstream of the test body during steady 
(S) and pulsatile (P) flow, as monitored with ultrasound [741. Instances where clot 
broke off are indicated by the sudden drop in wall thickness, around 29 minutes in 
pulsatile flow and 34 minutes in steady flow. 
vessel. Further details of the deaeration unit are provided in Section 5.1. Curtis 
also increased the volume of milk that flowed through the system before the reagents 
were turned on, allowing more of the entrained bubbles to escape. It appeared that 
residual water in the milk enhanced bubble formation, but the quantity of bubbles 
decreased as pure milk flowed through the system. With the use of ultrasound, the 
bubbles in the flow could be monitored, allowing the operator to decide when to turn 
on the reagents. Not only did this reduce the artefacts in clotting caused by bubbles 
in the system, it also improved the imaging of test objects by reducing attenuation 
of the ultrasound beam. 
The ultrasound image was further improved by machining a flat window onto the 
cylindrical test chamber wall. This allowed the entire ultrasound probe to contact 
the chamber. In Marosek's work, the probe was only touching the test section at 
one line of contact. Although ultrasound gel was used to allow transmission of waves 
outside of the line of contact, the incident angles of those waves differed from those 
through the flat section. This modification improved resolution of the sample image, 
allowing Curtis to observe clot growth on test objects. As the ultimate goal of the use 
of ultrasound was to monitor clotting of heart valves, Curtis pursued testing with a 
fixed disc and monoleaflet valves, rather than the bodies of revolution that had been 
tested earlier. 
The valves were tested in both steady and pulsatile flow, normally for 11 min-
utes. A result with one valve is displayed in Figure 3.13, showing the clot on the 
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Figure 3.13: Clot growth on the Edinburgh valve in steady flow, with utrasonic 
monitoring. The clotted valve is shown mounted in place at the top, with the corre-
sponding ultrasound image below [75]. 
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downstream side of the leaflet. Clot growth was not detectable by ultrasound in 
the pulsatile runs, even with the testing time increased to 25 minutes. According to 
the manufacturer, the limits for axial resolution and lateral resolution of the ultra-
sound probe were 0.31 mm and 1 mm, meaning that objects smaller than that were 
indistinguishable from one another. The growth of clot in Curtis's chamber during 
pulsatile flow never exceeded 1 mm, and hence could not be resolved with the existing 
ultrasound system. 
Ultrasound has been used successfully to provide noninvasive, real-time monitor-
ing of milk clot development. Unfortunately, thus far it has only been applied to a 
straight-walled cylindrical test chamber. Recent attempts to use it with Lewis's heart 
chamber have been unsuccessful due to the thickness and curvature of the chamber 
walls; the ultrasound beams were distorted to such an extent that visualisation of 
the valves was not possible. However, it is hoped that the introduction of a flexible 
chamber surrounded by water will minimise distortions in the ultrasound beam, mak-
ing ultrasonic monitoring of clot development in a physiological chamber possible in 
the future. 
Chapter 4 
Stagnation Point Flow 
Stagnation point flow was one of the techniques considered by Lewis [721 in his initial 
defense of renneted milk as an analogue for blood. As mentioned in Section 3.4.1, 
Lewis replicated the experiments conducted by Petschek et al and found similarities 
in the stages of clot formation for milk and whole blood. While these similarities were 
significant in justifying the use of milk as a blood analogue, they did not answer the 
question as to why milk and blood clotting were similar on a microscopic scale. Since 
the time of Petschek's work, the effects of stagnant flow have been observed separately 
on platelet coagulation [80, 77] and fibrin coagulation [79], both of which contribute 
to thrombus formation. It was desired to revisit the stagnation point flow work 
with renneted milk to determine whether similarities could be found between milk 
clotting and that of either fibrin or platelet coagulation. Improvements in microscopy 
techniques since Lewis conducted his experiments made it possible to obtain better 
images of the coagulation process throughout the course of the run. It was hoped that 
these improvements would lead to a quantitative assessment of milk clot deposition, 
as has been done elsewhere with platelets [80]. 
4.1 Background 
An artificial heart valve introduces an obstacle to the normal circulatory flow, which 
generates regions of both flow separation and recirculation. Both of these are asso-
ciated with stagnation points. When flow passes over a leaflet, for example, it must 
separate around the leaflet edges, recombining downstream. At both edges of the 
leaflet, there is a point where the velocity is zero, which is referred to as the stagna-
tion point [172]. This is illustrated in Figure 4.1. Several researchers have considered 
the effects of stagnation point flow on thrombus formation. 
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Figure 4.1: Illustration of stagnation points (S) at the edges of a heart valve leaflet. 
Arrows indicate direction of flow along streamlines. 
4.1.1 Fluid mechanics in the stagnation point flow chamber 
Stagnation point flow involves the transport of fluid perpendicularly to a stagna-
tion plate, where flow is then directed radially outward. The use of a narrow inflow 
tube allows for laminar flow of very low Reynolds number to be observed with rela-
tively high velocity components. Due to the symmetric nature of the flow, the fluid 
mechanics around the stagnation point are easily delineated. 
The main parameters that govern the flow regime in a stagnation point flow 
chamber are the diameter of the inflow tube, the distance between the tube and 
the stagnation plate, and the flowrate of the fluid inside the tube. Streamlines of 
stagnation point flow are shown in Figure 4.2. The stagnation point occurs on the 
plate at the centre of the flow, where the velocity components are zero. The velocity 
component normal to the wall is at a maximum along the streamline adjacent to the 
stagnation point and then decreases to a minimum just downstream of R 0 [243, 80]. 
On the other hand, the velocity parallel to the wall, and thus the wall shear rate, 
increases from zero at the stagnation point to a maximum value near R 0 , and then 
gradually drops off again. Thus stagnation point flow allows for the observation of 
effects of both convection (due to the normal velocity components) and shear rate 
(due to the parallel velocity components) on particle deposition. 
4.1.2 Flow studies with blood 
The effects of stagnation point flow on blood were first observed by Petschek in 
1968. As discussed in Section 3.4.1, Petschek performed an ex vivo experiment with 
whole blood from the carotid artery of a dog. Darkfleld microscopy was used to 
monitor thrombus growth over time, and two distinct types of clots were observed: 
symmetric white cell circles around the stagnation point and wedge-shaped thrombi 
at imperfections distant to the stagnation point [175]. Further details of Petschek's 
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Figure 4.2: Schematic of stagnation point flow. R0 is the radius of the inflow tube, 
d is the diameter of the tube, h is the height between the tube and the stagnation 
plate, and S is the stagnation point on the coverslip [77]. 
work are included in Section 3.4.1. 
Tippe carried out further experiments with stagnation point flow to quantitatively 
assess platelet deposition from platelet rich plasma (PRP) [77]. The chamber was 
similar to the one used by Petschek, consisting of an inflow tube (0.6 mm diameter) 
held at a fixed distance (either 0.2 or 0.6 mm) from a stagnation plate. A darkfleld 
microscope was used to monitor platelet deposition; microphotographs were taken at 
distinct points in the clotting cycle, and light reflected from the adhering platelets was 
focused onto a photomultiplier, generating an output voltage dependent on the re-
flected light intensity. This voltage was then plotted as a function of time, generating 
growth curves for platelet deposition under conditions dominated by adhesion only, 
aggregation only, or both adhesion and aggregation. At the end of the experiments 
additional pictures of adherent platelets were taken with a scanning electron micro-
scope (SEM). A growth curve of deposition due to both adhesion and aggregation is 
shown in Figure 4.3 along with the corresponding darkfleld photographs. 
Tippe's group showed that it was possible to quantitatively assess platelet de-
position in terms of adhesion and aggregation parameters. Initial deposition was 
primarily governed by the adhesion of new platelets to the stagnation plate, while 
subsequent deposition was dominated by aggregation. The SEM photographs re-  - 
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Figure 4.3: Adhesion and aggregation of platelets in stagnation point flow. The curve 
indicates the number of platelets, Pd adhering to the coverslip as a function of time, 
which was proportional to the light intensity (in volts) scattered by the platelets in 
the darkfield microscope. The corresponding microphotographs at three time periods 
are shown above. Streak-like alignment in the direction of flow is visible in the latter 
photographs. The bar corresponds to 100 microns [77] 
vealed that platelets were randomly aligned near the stagnation point but showed 
streak shaped alignment near the outer edge of the microthrombus, in line with the 
direction of flow. 
Affeld [243] and C. Reininger [80] have further extended Tippe's work to correlate 
platelet distribution densities with wall shear rate and velocity components. They 
found that platelet density was related to distance from the stagnation point, with 
few platelets adherent in the centre or at the periphery. The thrombi looked similar 
to the white cell circles observed previously by Petschek. The maximum density in 
both cases occurred at a radial distance of approximately 0.61t0, where R was the 
radius of the inflow tube. This was upstream of the maximum shear rate, leading 
Affeld to conclude that there was a critical shear rate for platelet adhesion. 
There is no published work on fibrin deposition in a stagnation point flow cham- 
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Figure 4.4: T-brancing model used by Reininger et al to observe fibrin deposition in 
niches of stagnant flow [79]. S is the stagnation point, R is the reattachment point, 
and the shaded area represents fibrin clot formation at the lowest flowrate. The arrow 
indicates the direction of the main flow through the model. 
her, but work has been done on fibrin deposition in niches of stagnant flow in a 
branching model [79]. Large arteries in the vasculature constantly branch off into 
smaller arteries and arterioles which deliver blood to various parts of the body. Each 
time one of these smaller arteries branches off, stagnant zones are created opposite the 
branching point, which may be associated with thrombus deposition. A T-branching 
flow model, shown in Figure 4.4, was designed to simulate this branching, in order to 
correlate the flow environment with the resultant fibrin clot. A fibrinogen solution 
was perfused through the main tube inlet, with the bulk flow continuing through this 
tube; secondary flow passed out of the daughter tube, simulating branching of flow 
into a smaller artery. With laminar flow, two stationary, counter-rotating vortices 
formed in the main tube opposite the daughter tube; a stagnation point formed at the 
upstream boundaries of the vortices, with the reattachment point downstream. Clot 
that formed between the stagnation point and the reattachment point was affected 
by flowrate: the largest clot formed at the smallest laminar flowrate, and transition 
to turbulence prevented clot formation. While this might indicate that fibrin coag-
ulation occurred preferentially at low shear rates, two factors suggested otherwise: 
first, there was no difference in the lag time to clot formation for different flow rates, 
indicating that the initial clot deposition was not governed by shear. Second, as the 
clot at the lowest flowrate grew, occluding the tube, the shear rate increased by a 
factor of 100-fold but fibrin continued to deposit. The authors attributed differences 
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in clot growth around the stagnation zone to the influence of friction forces between 
the counter-rotating vortices and the developing clot; at lower flowrates these were 
sufficient to decelerate the vortices and support additional clot growth. Thus, larger 
fibrin clots were associated with slower regions of recirculation. 
The results of clot formation near the niches of stagnant flow were distinctly 
different from those with wall-parallel flow. In the T-branching experiments, fibrin 
deposited along the wall outside of the recirculation vortices but did not form large 
clots. Rather, strands of fibrin deposited that were oriented in the direction of flow. 
This type of fibrin clotting is likely to be more similar to that observed in continuous 
steady shear stress experiments, where shear has been shown to impact fibrin coag-
ulation. In an experiment by Tippe and Muller [77], increasing the shear rate from 
0 to 500 resulted in a marked increase in fibrin coagulation. This was attributed 
to an increase in fibrin breakages, increasing reaction sites for polymerizaton. 
4.1.3 In situ observation of milk coagulation 
In situ monitoring of milk coagulation is very difficult because of the opacity of the 
sample. The use of traditional light microscopy is inadequate due to reflection, ab-
sorption, and scattering of light by the thick sample in the flow chamber. Alternative 
methods for monitoring coagulation include measurements of turbidity [225], viscos-
ity [229, 228], or near-infrared (NIR) reflectance [244, 245], but these do not allow 
for the direct observation of gelation on a microscopic level. More recently, electron 
microscopy has become a powerful tool for observing the structures of the milk com-
ponents [214], but this requires dehydration and fixation and does not allow for in 
situ monitoring of the coagulation reaction. For the purpose of this work, a technique 
for directly monitoring the protein behaviour was desired. 
The intial observation method considered was darkfleld microscopy, as this has 
been used elsewhere to observe coagulation of a dilute milk solution [246], as well 
as in Petschek's work with blood [175] and Reininger's work with platelets [247]. In 
darkfleld microscopy, images are formed by the reflection of light off of particles in a 
sample, rather than by the transmission of light through the sample. A basic form 
of darkfleld microscopy was attempted using a powerful, focused light source and 
an Olympus SZ6045 trinocular microscope. A schematic of this type of 'darkfleld 
microscope' is shown in Figure 4.5. While this did allow enhanced observation of 
macroscopic clot formation, resolution at high magnification was limited. 
True darkfleld microscopy allows for higher resolution, but involves a more compli-
cated apparatus. An opaque disc is placed between the light source and the condenser 
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Figure 4.5: Low magnification darkfield microscopy [248] 
lens of a microscope, blocking most of the incident lightwaves. Only light scattered 
from the sample then passes through to the objective, generating an image of bright 
particles against a dark background. However, this requires the sample to be placed 
at a specific height relative to the incident light beams. For normal samples, a slide 
is simply placed on the microscope stage [246]. However, this was not possible with 
the stagnation point flow chamber used for the current work. In order for the sam-
ple to have been at the precise distance between the light beams and the objective, 
the flow chamber would have needed to be incorporated into the microscope stage. 
Subsequent discussion with A. Reininger confirmed that darkfleld microscopy with 
platelets had involved similar modifications to a compound microscope [249]. As the 
cost of such work was prohibitive, an alternative method was sought. 
Confocal laser scanning microscopy (CLSM) has been used successfully by Mellema 
et al [250] and Auty et al [251] to observe the rennet-induced coagulation of milk 
in a stagnant system. For Auty's work, approximately 75 ILI of milk was treated 
with chymosin, stained with Nile Blue, and then placed in a sample well 1 mm 
deep. A coverslip sealed the milk inside the well, and then CLSM was used to moni-
tor the timecourse of clotting, focused approximately 20-30 Am below the coverslip. 
A helium-neon laser excited the Nile Blue fluorophores at 633 nm, identifying the 
proteins. Figure 4.6 shows the sequence of images obtained by Auty et al for the 
rennet-induced coagulation of milk. Since we were hoping to obtain similar results, 
CLSM seemed like a promising technique to pursue further. 
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Figure 4.6: CLSM sequence of rennet-induced coagulation of milk in a stagnant 
system [251]. The bright spots are protein. Numbers indicate the time elapsed since 
rennet addition. Bar = 25 microns. 
4.1.4 Confocal laser scanning microscopy 
The first commercial confocal laser scanning microscope was produced in 1987, and 
since that time, CLSM has become an invaluable tool in biological, physical, and 
material science applications [252]. The primary advantages of CLSM are the elimi-
nation of out-of-focus blur, the opportunity for non-invasive sub-surface imaging, and 
the ability to obtain an in situ time-series of three-dimensional images [252, 250]. 
CLSM involves the illumination and detection of one point in a fluorescently-
stained specimen. Figure 4.7 illustrates the basic optics involved in CLSM. A laser 
beam is emitted through a source pinhole, which directs the light to a dichroic mirror. 
The beams of light leaving the mirror are focused through the lens of a microscope 
objective into the sample. Fluorophores in the stained sample are excited by the light 
and then emit light beams back through the objective. The objective lens then focuses 
the emitted light through a detector pinhole to a photomultiplier, which transmits a 
signal to a computer to generate an image of the sample point. The key to confocal 
microscopy is that the source pinhole and detector pinhole are aligned so that only 
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Figure 4.7: Basic optics of CLSM. Solid line represents light from the sample plane. 
Dotted line represents light from below the plane, and dashed line represents light 
from above the plane. [253] 







Figure 4.8: Illumination of a CLSM sample point, with an indication of the resolving 
power of the objective [254]. ox, Oy, and 8z are the minimum distances that two 
points must be separated from one another in order to be distinguishable. Oz may 
also be referred to as the vertical resolution (VR) of the objective. 
lightwaves from one plane in the sample are fully detected by the photomultiplier. 
Light beams from planes above or below that plane are defocused by the objective 
lens and do not pass through the detector pinhole [252, 253]. 
The size of the resolvable sample spot illuminated by the CLSM is dependent 
on the objective used. Each objective has a characteristic numerical aperture (NA) 
which relates to the angle of the conical beam of light emerging from the objective 
opening. This is illustrated in Figure 4.8. The angle of light emerging from the 
objective is 2cr. NA is then equal to n (sino), where n = refractive index of the 
medium between the sample and the objective [255]. The size of the sample spot 
that can be resolved by the objective is given by Ox, Oy, and Oz [254]. As c, and 
hence NA, increases, the working distance (WD) of the objective decreases, so it 
must be placed closer to the sample. However, the size of the resolvable sample spot 
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(8x, 8y, and öz) also decreases due to the increase in photon density in the smaller 
cone of light. This results in a smaller field of view (FOV) but it also means that 
points closer together can be distinguished from one another. The condensed field of 
view with higher resolution allows for higher magnification of the sample. 
Because only one spot in a sample specimen is illuminated at a time, CLSM 
requires scanning of the sample to obtain a complete image. The light beam is 
moved in a regular x-y pattern across the sample, and the photomultiplier signals are 
used to generate a square sample image point-by-point [252]. Frequently, a three-
dimensional image is further acquired by subsequent scanning of the adjacent planes, 
but for the present work, 2-dimensional scanning was deemed sufficient. 
The application of CLSM to a high velocity flow system is difficult due to the fact 
that each image must be scanned, requiring a finite acquisition time. However, since 
we were actually interested in observation of the layer that adheres to the coverslip, 
and hence is not moving, it seemed that CLSM could be an appropriate technique 
for monitoring coagulation in the stagnation point flow chamber. In fact, identifying 
adhering proteins should have been facilitated by the fact that they would remain 
fixed from one frame to the next. 
A CLSM system was available for use in the Physics Department, but it was not 
equipped with the same lasers used by Auty et al for their work with renneted milk. 
This meant that a different tracer had to be considered for protein monitoring. Auty's 
group had looked at the suitablility of additional fluorescent probes for identifying 
fats and proteins in dairy products [256] and reported the use of Rhodamine B for 
labeling protein in cheese with green (568 nm) excitation. The system available 
at Edinburgh had the option of green excitation at 543 nm, which was within the 
working range for Rhodamine B, so this was selected for the CLSM work. 
4.2 Materials and Methods 
Homogenized lowfat milk' was purchased on the day of each experiment and premixed 
with a fluorescent tracer. As mentioned in the previous section, Rhodamine B 2 was 
selected as the appropriate tracer for protein labeling and the milk was made up to 
a concentration of 0.01 g dye/L. 1% vol saturated aqueous calcium chloride was then 
added to the dyed milk, and a 50 ml syringe was filled with the milk solution. A 
separate syringe was filled with rennet, made up to 10% vol Fromase (DSM Food 
'Robert Wiseman Dairies, UK 
2 Sigma Aldrich Chemical Company, Old Brick Yard, New Road, Gillingham, Dorset, FP8 4XT 
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Specialties) in distilled water. There was concern that adding the dye, or pre-mixing 
the milk and calcium chloride, could have affected clotting, but modified Lee-White 
tests showed no difference between clotting of the pre-mixed, dyed milk and clotting 
of regular milk with calcium chloride added at the same time as rennet. All tests 
were run at ambient temperature, which gave a Lee-White clotting time of 2 minutes. 
4.2.1 The stagnation point flow chamber 
Figure 4.9 is a schematic drawing of the flow chamber used for this work, which was 
based on the stagnation point flow chamber used by Reininger et al for the study of 
platelet adhesion and aggregation [80]. It consisted of two inlet ports for milk and 
rennet, and one exit port for the waste milk to leave the system. The chamber was 
initially designed for use with a light microscope, so the chamber height was kept to a 
minimum by having all of the flow ports on the sides of the chamber. This meant that 
the milk inlet stream was subject to a 90° bend inside the chamber in order to flow 
perpendiculary toward the coverslip. As this would have created a stagnation point, 
possibly inducing coagulation, it was necessary to add the rennet to the milk stream 
downstream of the bend. This had the added benefit of minimizing proteolysis prior 
to impingement on the coverslip. A 19-gauge needle delivered the rennet into the 
milk stream inside the chamber. 
The renneted milk stream flowed toward the coverslip through a bore of 0.6 mm 
diameter. After impinging upon the coverslip, flow passed radially outward across 
the flow stage and into a canal, where it then exited via the exit port. The outer 
diameter of the flow stage was 9 mm, and the height (h) between it and the coverslip 
was 0.6 mm. A metal ring held the coverslip in place against an 0-Ring, creating a 
single-pass, sealed flow system. 
4.2.2 Confocal laser scanning microscope 
Continuous monitoring of the system was provided by a Nikon PCM 2000 Personal 
Confocal Microscope System, which was connected to a personal computer for image 
capture. A picture of the apparatus used is shown in Figure 4.10. This system 
was equipped with both a helium-neon (He/Ne) and an argon-ion laser, capable of 
emitting light at 543 nm (green) or 488 nm (blue), respectively. The flow chamber was 
inverted and placed on the microscope stand, with the center of the test chamber lined 
up with the center of the objective. Three different objectives were used to observe 
the clot formed in each run, providing different magnifications of clot structure. The 
specifications of these objectives are listed in Table 4.1. The He/Ne laser with 543 nm 
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Figure 4.9: The stagnation point flow chamber 
Objective NA WD (mm) FOV (/Lm) 	VR*  (gm) 
4x 0.2 15.7 1300 x 1300 36 
20x 0.75 1.0 260 x 260 	2.5 
60x 1.20 0.22 86.7 x 86.7 1 
Table 4.1: Objectives used with the CLSM. NA =Numerical Aperture. WD=Working 
Distance. FOV=Field of View. \TR=Vertical Resolution (8z) 
*Values  obtained from Alan Monk at Nikon Instruments 
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Figure 4.10: The Nikon PCM 2000 Personal Confocal Microscope System 
excitation was used to excite the Rhodamine B fluorophores, identifying the proteins. 
The laser beam passed through the objective into the sample and was then reflected 
by the fluorophores back to the objective to generate the sample image. With CLSM, 
only light from one plane in the sample is reflected sharply back to the objective at 
a time, so it is possible to focus on a particular sample depth by adjusting the height 
of the microscope stage. For the purpose of this work, it was desired to focus on 
the fluid immediately adjacent to the coverslip. This was done by moving the stage 
away from the objective, and then slowly moving it toward the objective until the 
first reflectance was detected. Fine adjustment of the stage was then performed to 
obtain the brightest image of the proteins adherent to the coverslip. 
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Flow Rate Inflow Velocity Reb 
(ml/hr) (mm/s) 
11 10.8 5.59 
16 15.7 8.13 
22 21.6 11.2 
33 32.4 16.8 
44 43.2 22.4 
49 48.1 24.9 
66 64.8 33.6 
Table 4.2: Flow rates used in the current work 
4.2.3 Testing protocol 
At the start of each run, the chamber was initially primed with the CaC12/milk 
solution. Once the chamber was full of milk, the milk syringe pump  was set to the 
desired flow rate. Video acquisition of the CLSM images was initiated and then the 
flow of rennet was started. For each run, the flow rate of rennet was adjusted to 
1% of the flow rate of milk. Rennet was delivered by continuous perfusion from a 
microsyringe pump 4 . The initial milk flow rate studied was 22 mL/hr, which was 
selected to give a similar Reynolds number to that used by Reininger's group of 11 
[80]. Assuming a milk viscosity of .0012 kg/ms and density of 1.035 g/cm 3 [257], 
the Reynolds number of milk flowing at 22 mL/hr through a 0.6 mm tube is 11.2. 
All of the flowrates observed in this study are listed in Table 4.2 along with their 
corresponding Reynolds numbers. 
For all except for the highest flowrate, rennet injection continued for 20 minutes. 
Milk injection continued after that time until all required still pictures were obtained. 
For the highest flowrate, the endpoint of clotting was not reached within the 20-
minute timeframe, so rennet addition continued until the milk syringe bottomed out. 
The endpoint of clotting was considered to be the time that the acquired image 
became constant between successive video frames. Once the image was constant, 
video acquisition was halted, and still pictures of the clot were obtained at each of 
the selected magnifications. 
3 Razel A-99 syringe pump 
4 Cole-Parmer 74900 series dual syringe pump 
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4.2.4 Mixing studies 
The results obtained in this work indicated that there may not have been uniform 
mixing of rennet and milk at the impingement point. To test this, dye injection was 
used with the flow chamber set up as described in Section 4.2. The inlet milk syringe 
was filled with tap water and the system was primed with water as with milk. The 
rennet syringe was filled with a saturated solution of potassium permanganate and 
attached to the rennet inflow port. The water and dye were then perfused through 
the system at the same flow rates used in the stagnation point flow milk experiments, 
and the migration of dye across the chamber stage was observed. 
After establishing the flow profiles of the two streams in the test chamber, which 
revealed no mixing, various methods for improving mixing were attempted. Tech-
niques were considered that would have a minimal impact on upstream clotting and 
that could readily be tested with the existing laboratory equipment. Dye injection 
was then used to assess the mixing induced by each technique. 
The first modification tested was simply moving the injection point. The rennet 
port in the test chamber was sealed with grease, and the needle at the end of the 
rennet injection line was inserted into the milk tubing upstream of the test chamber. 
The next modification considered was filling the milk port with glass ballatini, with 
the rennet injection needle still inserted upstream of the test chamber. Ballatini of 
1.5 mm diameter were used, which allowed them to fill the milk port but not move 
into the impingement bore. The final technique considered was splitting the main 
flow stream into two equal parts, one entering via the milk port and the other via 
the rennet port. The flow rate of each of these streams was 12.7 ml/hr. Dye was 
injected via the injection needle into the stream entering the rennet port, immediately 
upstream of the test chamber. 
4.3 Results 
4.3.1 Light microscopy work 
Macroscopic observation of clot development was possible with the stereomicroscope, 
and is depicted in Figure 4.11a. In each test, a flow channel formed that had a 
different clotting pattern than the clot over the rest of the chamber. The flow channel 
started over the stagnation point and extended across the flow stage to the outlet 
canal. The clot over the flow channel was speckled and disconnected, while the clot 
over the rest of the chamber was of a continuous, striated nature. Magnification of 
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(b) 6.3x magnification 
Figure 4.11: Milk clot deposition at 10 ml/hr, as viewed with a light microscope. 
The arrow indicates the direction of flow through the flow channel. a) bar = 1000 
microns. b) bar = 300 microns 
the clot with the light microscope was attempted, but resolution was not significantly 
improved. This is shown in Figure 4.1 1b. 
4.3.2 CLSM results 
Continuous monitoring of protein adhesion during clot formation was possible using 
confocal laser scanning microscopy. Observation with low magnification provided a 
macroscopic picture of the coagulation process, allowing the clotting time of the sam-
ple to be assessed. Only a small section of the chamber could be observed under high 
magnification, but the vertical resolution, and hence sample image thickness, was 
only 1 micron at this magnification, allowing for the layer of clot immediately adja-
cent to the coverslip to be monitored. Since the width of depositing aggregates was 
larger than 1 micron, it was possible to observe individual aggregates adhering to the 
coverslip over time. Figure 4.12 shows the stages of clot formation under low magni-
fication. Clot first started outside of the flow channel, and eventually moved inwards 
until ultimately adhesion was seen over the flow channel itself. Higher magnification 
showed the stages of clot formation over the flow channel. Protein first deposited 
near the impingement point, with subsequent strands depositing downstream of the 
first strands. This is shown in Figure 4.13. 
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Figure 4.12: Milk clot development at 33 ml/hr, as viewed with CLSM. The stagna- 
tion point is in the centre of the photographs. 4x manific.ation. Bar = 200 microns. 
Figure 4.13: Time sequence of protein adhesion over the flow channel at 33 ml/hr, 
as viewed with CLSM. The stagnation point was below and to the left of the pho-
tographs. Flow was directed from the stagnation point toward the upper left side of 
the images. 60x magnification. Bar = 10 microns. 
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Figure 4.14: CLSM image of protein 
deposition over the flow channel at 22 
ml/hr. 60x magnification. Bar = 10 mi-
crons 
Figure 4.15: CLSM image of protein de-
position outside the flow channel at 22 
ml/hr. 60x magnification. Bar = 10 mi-
crons 
There were distinct differences in the type of clot found over the different sections 
of the test chamber. Over the flow channel, there were patchy strands of clot, aligned 
in the direction of flow for most of the flowrates tested. (Figure 4.14). Outside of the 
flow channel, the strands were much smaller and evenly distributed; this is shown in 
Figure 4.15. 
The flow channel formed at all of the flowrates tested, and had an outer and inner 
boundary as seen in Figure 4.11. Dismantling of the flow chamber revealed that these 
actually corresponded to walls of clot along the edges of the flow channel that built 
up between the flow stage and the coverslip. Upon dismantling, these clots remained 
firmly attached to the coverslip. The width of the flow channel was then measured 
with a micrometer and found to be approximately 0.8 mm, independent of flow-rate. 
The shear stress over the flow channel was approximated by assuming that the 
flow channel was a straight duct through the chamber with a width (w) of 0.8 mm 
and height (h) of 0.6 mm (the distance between the coverslip and flow stage). A 
sketch of such a duct is shown in Figure 4.16. The forces acting on a section Ax are 
P 1 and P2 over the cross sectional area of each end of the duct, and the shear stress 
r along the perimeter of the duct. Balancing these forces and rearranging gives the 






Figure 4.16: Dimensions for fluid in a duct, with laminar flow from left to right 
following equation for shear stress along the wall of the duct: 
P1 - P2 	Area 
T = 	
(4.1) 
Ax * Perimeter  
To simplify solving the equation for a rectangular duct, the hydraulic radius (HR) of 
the duct was calculated: 
Area 	hw 
(HR) = Perimeter = 2h + 2w 	
(4.2) 
Since the flow was laminar, Poiseuille flow was assumed in the duct. This meant the 
velocity profile was parabolic, with a maximum at the centre of the duct, and zero 
velocity at the walls. The flowrate, Q, was then equal to f VdA. For a circular duct, 
this can be integrated and rearranged to obtain the pressure drop per unit length [7]: 
P1 - P2 - 128Q 	
(4.3) 
Ax - 7r(D6rc ) 4 
Since D=4HR [7], equations 4.1 and 4.3 can be combined to obtain a formula for 
the wall shear stress: 
Q[L 
- 27r(H)q) 3  
The shear rate was then equal to T1/1. These values are listed in Table 4.3. 
The nature of clot over the flow channel also varied with flowrate. Protein ad-
hesion over the flow channel at different flowrates is shown at low and high magnifi-
cations in Figures 4.17 and 4.18, respectively. At the lowest flowrates, the protein 
aggregates were larger and more randomly distributed. As the flowrate increased, the 
aggregates that adhered to the coverslip were smaller, more densely packed together, 
5 
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(d) 33 ml/hr 
It 
(b) 	16 	fill ./ hr 
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Figure 4.17: Milk clot deposition over the flow channel under low (4x) magnification. 
The stagnation points were below the centres of the photographs. Arrows indicate 




(c) 22 ud /llr 
CHAPTER 4. STAGNATION POINT FLOW  
8 9 




(') -1.1 111 ill- 	 ( f) 49 ml/hr 
Figure 4.18: Milk clot deposition over the flow channel under high (60x) magnifica-
tion. The photographs correspond to magnified sections of the flow channels shown 
in Figure 4.17. Arrows indicate the direction of flow in the flow channels. 
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Flow Rate Shear Stress Shear Rate 
(ml/hr) 	(N/rn2 ) 	(s_i) 
11 0.116 97 
16 0.168 140 
22 0.232 193 
33 0.348 290 
38 0.400 333 
44 0.463 386 
49 0.516 430 
66 0.695 579 
Table 4.3: Calculated values for shear stress and shear rate in the stagnation point 
flow chamber 
and were aligned in the direction of the flow. However, at the highest flowrate (66 
ml/hr), the clot never adhered over the central portion of the flow channel through-
out the duration of the run. To determine whether this was due to shear, the rennet 
concentration was doubled to reduce the clotting time and the milk was tested again 
at 66 ml/hr. Again, no clot was detected over the central portion of the flow chamber 
throughout the course of the run, indicating that there was a maximum shear rate 
above which clotting would not adhere. 
Flowrate also had an impact on clotting time over the flow channel, as shown in 
Figure 4.19. For the purpose of this work, clotting time was considered to be the 
time when attachment to the coverslip was completed. As mentioned in Section 4.2.3 
this was the point at which the video images became constant from one frame to 
the next. Clotting time increased with higher flow rates, appearing to reach an 
asymptotic value above which adhesion was no longer possible. 
4.3.3 Mixing studies 
Dye injection with the initial chamber setup revealed that the rennet had not been 
mixing properly into the milk stream. A distinct jet of dye started at the stagnation 
point and flowed across the stage and into the canal. This is shown in Figure 4.20a. 
Close inspection of the fluid inside the chamber revealed that the dye emerged from 
the rennet injection tube and travelled along the wall of the inlet port toward the 
stagnation point, ultimately emerging as a coloured jet moving across the flowstage 
in the direction of the rennet injection tube. This was in the opposite direction that 
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Figure 4.19: Influence of flow rate on the time of clot formation over the flow channel 
the flow channel generally formed with the coagulating milk. 
Moving the dye injection point further upstream of the test chamber improved 
mixing slightly, with better mixing the further away the injection point was. Moving 
the injection point also changed the direction of the path of dye across the flow stage. 
In these cases, the dye entered the chamber through the normal milk inlet port instead 
of the rennet injection tube, and it emerged across the flow stage directly over this 
port. Introducing ballatini immediately downstream of the dye injection point further 
improved mixing, as shown in Figure 4.20b. However, the improvement was still very 
slight, with less than 25% of the water mixing with the dye. 
Splitting the streams resulted in the biggest improvement, as shown in Fig-
ure 4.20c, but it still resulted in less than half of the water stream mixing with 
the dye. The direction of the dye path in this case was the same as that in the 
original configuration; the dye had entered through the rennet injection tube, and 
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(a) original configuration 	 (b) ballatini 	 (c) split stream 
Figure 4.20: Flow of dye across the stagnation point flow chamber stage in mixing 
studies. Dashed area represents jet of dye. The inlets for the water and dye streams 
are indicated on each image. 
4.4 Discussion 
The milk clot did not form symmetrically around the stagnation point, as had been 
reported for blood clots, but this was due to insufficient mixing of the rennet. The 
dye injection work revealed that the rennet was initially only moving across one small 
area of the stage, as shown in Figure 4.20a. In that area, the rennet concentration 
would have been significangly higher than 1%, inducing rapid local milk coagulation, 
and blocking flow where the clot formed. The rennet would have then been directed 
to either side of that clot, causing it to grow larger. In this way, a bulk clot grew 
up between the coverslip and the flow stage in most of the test chamber, until only 
a small path was left for the milk and rennet to flow through. Attempts to improve 
mixing with available equipment were not successful, so analysis of the flow in this 
narrow channel was pursued instead. 
Because the clot had not formed in the same manner as those in Tippe's and 
Reininger's work, it was not possible to replicate their quantitative analyses of clot 
deposition around the stagnation point. However, the present work did provide alter-
native information regarding the influence of shear stress on clot development, which 
can be interpreted for comparison with blood clotting. 
Protein adhesion outside of the narrow flow channel was significantly different to 
protein adhesion over the flow channel. In the bulk clot, protein adhesion to the coy-
erslip would have occurred under minimal shear, and was likely governed by diffusion. 
Very small aggregates formed, which were homogeneously distributed without any 
orientation to flow. In contrast, over the flow channel, where convection would have 
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had a much higher impact on aggregation and deposition, larger aggregates deposited, 
which were generally aligned in the direction of flow. However, there seemed to be 
both a minimum and maximum shear stress determing the extent of that alignment. 
Below a shear stress of 0.232 N/rn2 , there was little alignment in the direction of flow, 
with aggregate width (transverse to flow) and length (aligned with flow) nearly equal. 
However, above 0.516 N/rn2 , no detectable adhesion occurred. Between 0.232 N/rn2 
and 0.516 N/rn2 , protein aggregates aligned in the direction of flow, with aggregates 
longer than they were wide. 
A limiting shear stress affecting milk coagulation has also been noted by Konuklar 
and Gunasekaran [228]. Studying milk in a rheorneter, they found that continuous 
steady shear stress above 0.5 N/rn 2 inhibited the formation of milk coagulum. Con-
sidering the fact that the shear stress values in the present work are fairly rough 
estimates based on the assumption of a rectangular duct for the flow channel, this is 
in surprising agreement with the present results, in which milk clot did not adhere 
to the coverslip at a shear stress of 0.695 N/rn2 , even when the rennet concentration 
was doubled. 
The influence of shear stress on clotting time in this experiment does not correlate 
directly with the work by Konukiar and Gunasekaran. In their work, they found that, 
for moderate shear stress, clotting occurred faster as shear stress increased (refer to 
Section 3.3.3). However, there is one critical difference between their work and the 
work presented here; their fluid was not flowing across the viscometer. Thus, in their 
experiments, the exposure time of the bulk fluid to rennet was independent of shear 
stress. In the stagnation point flow experiment, this was not the case. The higher 
shear stresses resulted from faster flow rates, which meant that the milk impinging 
upon the stagnation plate had been exposed to rennet for less time. It was not possible 
to separate the effects of hydrolysis and shear stress in this experiment. Thus, the 
increasing flow rates resulted in higher collision frequencies (due to higher shear 
stress) but lower capture efficiencies (less hydrolysed #c-casein available for binding). 
At low shear, more micelles were ready to adhere to the surface, but they did so in a 
random arrangement. At higher shear rates, less micelles were available for adhesion 
but those that did were arranged in an increasingly ordered fashion. 
As mentioned in Section 4.1.2, Affeld also attributed the pattern of platelet de-
position around the stagnation point to a critical shear rate. Immediately over the 
stagnation point, where the shear rate was zero, very few platelets adhered to the 
coverslip. Platelet concentration then increased to a maximum around 0.6 R0 , where 
the shear stress, r was 0.7rmax . Platelets did still adhere at the calculated maxi- 
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mum shear, however, so the existence of a maximum shear stress preventing further 
platelet adhesion was not confirmed with the stagnation point flow work. However, 
earlier viscometry work by Belval et al [180] identified both minimal and maximal 
shear rates limiting platelet aggregation. 
Shear stress alone does not account for the pattern of platelet deposition observed 
by Tippe, Affeld, and Reininger. In those cases, platelet concentration was highest 
upstream of Tmax and then dropped down to zero at downstream levels of r that had 
previously supported platelet deposition. Clearly, other aspects of the flow field must 
impact coagulation as well. Convection and diffusion likely combine with shear stress 
to determine the extent of deposition [176]. A similar combination of forces has been 
suspected to impact milk protein gelation as well [240]. 
The influence of flow on platelet alignment was also noted by both Tippe and 
Reininger. In areas of lower shear, near the stagnation point, the platelet deposition 
demonstrated random arrangement. This is similar to the milk clot alignment at the 
two lowest flowrates. At higher shear, near 0.6R0, the platelets showed streaklike 
arrangement in the direction of the flow. This would be similar to the alignment 
of the milk clot at the higher flowrates. Affeld also confirmed that the milk clot 
alignment resembled that of platelet alignment [258]. 
The milk protein deposition was not similar to that of fibrin deposition near a 
stagnant zone, since the growth of the fibrin clot did not positively correlate with 
shear stress, and there was no difference between the lag time prior to fibrin clot 
formation for different flowrates, as there was with milk. However, Reininger did 
note that there was a different type of fibrin formation in wall-parallel flow. This was 
affected by shear, and may have been similar to the milk protein deposition. 
When one considers milk coagulation on a microscopic structural level, it seems 
plausible that it is more similar to platelet adhesion and aggregation than to fib-
rin gelation. Platelets normally circulate in the plasma as discoid structures with a 
slight negative charge and will not adhere to one another. However, when platelets 
are activated, they undergo a conformational change, becoming 'spiny spheres' that 
can attach to non-endothelial surfaces and to each other. Similarly, milk proteins 
are organised into spherical micelles which normally have hydrophilic r,-casein 'tails' 
extending into the milk serum [217] that provide electrostatic repulsion between mi-
celles. When rennet is added to milk, these 'tails' are cut, and the micelles can adhere 
to one another. Similar to platelets, hydrolysed milk micelles have been described 
as 'sticky spheres'. They are then prone to adhere to charged surfaces, as well as to 
each other [88]. The aggregation of both platelets and casein has been described by 
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Smoluchowski kinetics [180, 225]. 
Fluid mechanic effects have a clear impact on the microscopic development of 
both blood and milk clots. While it appears that casein micelles are more similar 
to platelets in their adhesion and aggregation, additional comparisons are desired. 
Unfortunately, obtaining true stagnation point flow results with homogeneously dis-
persed rennet appears difficult; most methods that would improve mixing would also 
be likely to induce coagulation. However, if a satisfactory mixing technique could be 
developed, replication of this experiment would be beneficial. Alternatively, it should 
be relatively easy to replicate the experiment of fibrin in a branching flow with milk. 
Since the technique of ultrasonic monitoring of milk coagulation has already been 
established at this institute, it should be possible to monitor the growth of milk clot 
on the walls of a tube in the region of stagnant flow. Such an experiment might pro-
vide a definitive comparison between fibrin deposition and milk coagulation. Lastly, 
SEM photographs of milk protein adhesion and aggregation under different degrees 
of shear stress would be interesting. While the present work has clearly shown that 
the type of milk clot formed is dependent on shear, it would be beneficial to actually 
view this on a micellar level. 
Chapter 5 
Experimental Equipment and 
Reagents 
A flow diagram for the milk rig used in this work is shown in Figure 5.1 It is similar 
to the one originally designed by Lewis [72], but with improved temperature and flow 
control [73] as well as better deaeration [75]. The rig can essentially be split into two 
sections: the milk preparation section and the testing section. 
5.1 Milk Preparation Section 
The main purposes of the milk preparation section were to bring the milk up to the 
testing temperature and remove most of the entrained gases from the milk. Milk 
was provided in 5-gallon containers, and each of these containers was connected to 
the system via a hose attached to a 3-way valve. The existing rig facilitated the 
attachment of three milk containers to the system at the same time. This allowed 
easy changeover from one container to the next without interrupting flow in the 
system. A 25-litre water reservoir was also attached to the system via a 3-way valve, 
allowing flow to be switched to water at the beginning and end of a run. The reservoir 
was intermittently filled with water from the mains supply. 
A parallel plate heat exchanger was used to heat the milk to the test temperature. 
Water circulating in channels parallel to those of the milk was heated to the user-
defined setpoint temperature by a 3-phase 6kW heater (Eltron Ltd). The heater was 
driven by a 91e Eurotherm controller connected to a thermocouple in the milk outlet 
stream and operating on a negative feedback loop. There was also an additional ther-
mocouple immediately upstream of the test section, for monitoring the downstream 
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temperature in the system. 
Flow from the heat exchanger was directed to the deaeration unit, with the de-
livery lines insulated to minimise heat losses in the system. The entrance to the 
deaeration unit contained a shower head, which dispersed the flow into the column. 
The column itself was full of raschig rings, designed to provide maximum surface 
area so that the milk would form a thin film with minimum diffusion thickness for 
air dissolution. The top of the deaeration unit was also attached to a vacuum line, 
with a simple vacuum induced by flowing mains water through the water jet ejector. 
A vacuum of 0.2 bar was found to give a satisfactory holdup of liquid (approximately 
8 cm) in contact with the raschig rings. The level of fluid inside the deaeration unit 
was maintained via a level control column adjacent to the unit. This column con-
tained three level-sensing probes: one positioned at the minimum height, one at the 
maximum height, and one common. These probes were connected to an actuator 
valve downstream of the heat exchanger. The actuator valve opened when the liquid 
level dropped below the minimum height, and it closed when the level was above the 
maximum height. There was also a bypass valve in parallel with the actuator valve, 
to allow a stream of steady liquid into the system, minimising fluctuations in flow. 
Flow was pumped out of the deaeration unit via a Watson-Marlow peristaltic 
pump (Model 603U). With the upstream vacuum at 0.2 bar, the maximum pumping 
capacity was 3 L/min. The peristaltic pump directed flow to a thermally insulated 
stainless steel header vessel, where fluid was stored prior to being pumped into the 
test section. The purpose of the header vessel was to maintain constant pressure 
upstream of the test chamber. Deaeration in the header vessel was achieved with the 
incorporation of an inlet baffle, against which the flow from the pulsatile pump was 
directed, and a cylindrical outlet baffle at the bottom of the tank. A schematic of 
the vessel is shown in Figure 5.2. A level controller attached to the header tank was 
set to maintain approximately 5 litres of milk in the vessel by adjusting the pumping 
speed of the peristaltic pump. 
5.2 Test Section with Rigid Heart Chamber 
The flow diagram displayed in Figure 5.1 shows the test section configured for the 
rigid heart chamber. Downstream of the header vessel, flow was split into two separate 
streams. Rennet was injected into one stream, and aqueous calcium chloride was 
injected into the other stream. These two streams were then split again prior to 
entering the test chamber. 
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Figure 5.2: Cross-section of the header vessel, showing the baffle arrangement for 
deaeration [75] 
The rigid test chamber used in this work was the same one used by Lewis [72]; it 
consisted of a rigid, Perspex model of the left side of the human heart and is shown 
in Figure 5.3. The mitral section was designed by Lewis and Macleod [72, 69] based 
on the hydraulic radii of the left atrium and left ventricle of an average adult. The 
aortic section was based on a design by Wieting [195], with an ellipsoidal section 
downstream of the valve for modeling the sinuses of Valsalva. Scaled drawings of the 
wetted perimeter of the test chamber are shown in Figure 5.4. Flow was directed into 
the test chamber via four distinct inlets in the model left atrium, representing blood 
return from the pulmonary arteries. This facilitated mixing of the milk streams in 
the heart chamber, promoting coagulation. Pulsatile flow through the chamber was 
accomplished by the use of a diaphragm at the bottom of the left ventricle. Water on 
the reverse side of the diaphragm was displaced by a piston-driven pulsatile pump, 
causing the space behind the diaphragm to expand and collapse, moving fluid through 
the valves. The pump is described in more detail in Section 5.6. The outlet from the 
aortic section of the test chamber was positioned 1 metre above the header tank to 
create sufficient back pressure to close the mitral valve during systole. 
5.3 Test Section with Flexible Heart Chamber 
Flow through the system with the flexible heart chamber had to be modified slightly. 
The reagent streams were not split into four separate streams as they were for the rigid 
WA 
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Figure 5.3: The rigid heart chamber 
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Figure 5.4: Wetted perimeter of the rigid heart chamber 
CHAPTER 5. EXPERIMENTAL EQUIPMENT AND REAGENTS 	101 
heart chamber. Instead, the calcium chloride and rennet streams were immediately 
recombined and delivered to the test chamber by 12.5 mm ID tubing. This meant that 
the length of that tubing determined the length of time that the clotting reaction 
had proceeded prior to entering the chamber. It was adjusted so that the bulk 
residence time of fluid entering the mitral valve was approximately halfway between 
the residence times at the mitral and aortic positions of the rigid heart chamber. A 
tubing length of 3 metres was found to be satisfactory, giving a bulk residence time 
of 22.5 seconds at the mitral valve. The effect of tubing length is discussed further 
in Section 6.3.1. 
The addition of this tubing increased the resistance in the system upstream of 
the mitral valve, preventing it from closing during systole. To remedy that, a latex 
balloon was inserted into the flow by a T-piece connected immediately upstream of 
the reagent injection points. Insertion of the compliance prior to the rennet injection 
point was necessary so that no coagulating milk was allowed to stagnate inside the 
balloon. 
The flexible chamber was based on part of the pulse duplicator system in the 
cardiovascular engineering department at the Helmholtz Institute, Aachen, Germany 
[83]. Figure 5.5 shows the flexible ventricular chamber with the straight-walled aortic 
chamber mounted on top. The ventricular conduit' was made of silicone, and its 
shape was based on physiological data. The ventricle was sealed inside a Perspex 
housing filled with water, the mitral valve was mounted at the inlet to the ventricle, 
and the aortic valve was mounted at the exit. The angle between the two valves 
was 120°. Two hoses on one wall of the housing were connected to the piston-driven 
pulsatile pump, forcing water in and out of the housing. This caused the ventricle to 
expand and contract, opening and closing the valves, and forcing fluid through the 
system. 
Two different aortic chambers were tested with the flexible ventricular chamber. 
Schematic diagrams of both are shown in Figure 5.6. The straight-walled aortic 
chamber (5.6a) was made in our workshop; it consisted of a Perspex tube attached to 
a flange for mounting to the ventricular housing. The aortic valve was mounted inside 
the flange. The other aortic chamber (5.6b) was made of glass and contained models 
of the sinuses of Valsalva. Three axisymmetrical semicircular sinuses protruded from 
the chamber immediately downstream of the aortic valve. The maximum width of 
each sinus, as measured from the opposite chamber wall, was 40 mm. In the true 
'Physiological ventricular and aortic conduits were both manufactured by Christoph Schmitz, 
Institute for Biomedical Technologies, Aachen University of Technology 
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Figure 5.5: Flexible test chamber used in the current work, with the straight-walled 
aortic section mounted on top 
aorta, one sinus is actually smaller than the other two and they are not perfectly 
spherical [1], but this model was deemed adequate for determining whether sinuses 
had any significant impact on in vitro coagulation. This chamber had a similar flange 
attached for mounting the aortic valve. 
5.4 Valve Mounting 
Due to variations in design between the rigid and flexible heart chambers, the valves 
had to be mounted differently depending on which chamber they were to be tested in. 
For the rigid chamber, all valves were placed in a silicone mould (Silastic RTV 9161), 
50 mm diameter, 7 mm thick. This mould was then mounted in the chamber, sealing 
the valve in place. For valves with sewing ring attached, the mould encapsulated the 
ring, so that all valves had a similar mounting when placed inside the test chamber. 
A picture of a valve mounted in the silicone mould is shown in Figure 5.7a. 
The design of the flexible chamber resulted in a much smaller outer diameter 





(a) straight-walled 	 (b) sinuses of Valsalva 
Figure 5.6: Schematic diagrams of the aortic chambers used in the current work. 
(Drawing not to scale) 
available for inserting the test valves, so the silicone mould had to be removed from 
the valves. In addition, any sewing rings were removed from the valves as well. The 
valves were then fitted into a PVC mounting with external diameter 31 mm and 
height of 7.5 mm. A valve in its housing is shown in Figure 5.7b. 
5.5 Injection Pumps 
Rennet and calcium chloride were injected into the system by dosing pumps. For most 
of the work, both pumps were Liquid Metronics Series Al metering pumps, capable of 
delivering 15-100 strokes/mm, with stroke volumes of 0-0.63 ml. The settings on the 
pumps were no longer accurate, so the pumps had to be calibrated with a measuring 
cylinder and stopwatch. Near the end of the work, the calcium chloride pump failed. 
It was replaced by a ProMinent gamma/L solenoid pump (Model 1005), capable of 
delivering 18-180 strokes/mm, with stroke volumes of 0-0.45 ml, depending on the 
downstream pressure 2 . A stroke length of 36 % was found adequate to deliver 20 
ml/min. 
2 Since the delivery volume of the Prominent pump depends on hack pressure, this had to be 
calibrated while online in the milk rig. Volumetric displacement in the CaCl 2 reservoir was noted 
with time, and the stroke length on the pump was suitably adjusted. 
(b) Flexible chamber (a) Rigid chamber 
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Figure 5.7: Bjork-Shiley valve mounted for use in the a) rigid heart chamber and b) 
flexible heart chamber 
5.6 Pulsatile Pump 
A picture of the pulsatile pump used for the current work is shown in Figure 5.8. It 
was a piston pump, driven by a 200 W stepper motor, and manufactured in brass. The 
piston motion followed a sinusoidal waveform controlled by adjusting the frequency 
and amplitude of the power supply to the pump. For all of this work, the frequency 
was set to 70 strokes/mm. Adjusting the amplitude changed the stroke length of 
the pump, and had to be determined for each experiment. Since the static head of 
liquid (determined by the height of the outlet tubing to the drain) and the flow rate 
remained constant throughout all of the experiments, but the pressure drops in the 
chamber were dependent on the valves being tested, the dynamic pressure needed to 
drive the fluid at 2 L/min varied slightly from one test to another. The amplitude 
was adjusted until the desired flow rate was achieved. 
5.7 Milk and Reagents 
Fresh, unpasteurised milk was obtained from the Edinburgh University farm  on the 
day of each test. If two tests were run in a single day, two of the containers of milk 
were stored in a refrigerator until the afternoon run began. 
3 Bush Farm, Roslin, Midlothian EH2I 7AG, UK 
Figure 5.8: The piston-driven pulsatile pump 
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A bulk solution of saturated calcium chloride was made up in advance by dissolv-
ing flakes of CaC12 4 (77%) in warm water until a solid layer of CaC12 was found to 
precipitate out on cooling. Additional flakes of CaCl2 were occasionally added to the 
solution to maintain saturation. Previous work by Marosek [74] demonstrated the 
importance of using saturated aqueous calcium chloride in each of the runs. He had 
inadvertantly used a significantly lower concentration and did not obtain adequate 
clotting around his test objects. 
The rennet used for the present work was Fromase 220 XL, a microbial rennet 
purchased from DSM Food Specialties 5 . Lewis's original work with the rigid heart 
chamber had involved the use of Bannerman's animal rennet, derived from the fourth 
stomach of an unweaned calf. However, since that time, obtaining animal rennet 
has become increasingly difficult. Curtis thus conducted an extensive test to find a 
suitable replacement for the animal rennet [75]. She performed modified Lee-White 
tests on 5 types of commercially-available rennets to assess their influence on clot 
development and adhesion over time. Fromase was found to be most similar to 
4 Kemira Chemicals OY, P.O. Box 330, Fin-00101 Helsinki, Finland 
5 DSM Food Specialties, 15 rue des Comtesses, B.P. 239, 59472 Seclin Cedex, France 
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Bannerman's rennet, so this was chosen for her work, as well as the work presented 
here. 
The Fromase was made up to its desired clotting strength the morning of each 
test by adding the necessary volume of rennet to a 1 L volumetric flask, and making 
the remainder up with distilled water. Further details of the rennet concentrations 
used are included in Sections 6.2.1 and 6.3.1. 
Chapter 6 
Experimental Methods 
6.1 General Testing Protocol 
Prior to each test with milk, the system was first brought up to steady-state with 
water. A vacuum was established in the system by opening the water- jet ejector 
valve, which was attached to the mains water. This initiated the flow of water from 
the reservoir tank through the heat exchanger and into the deaeration unit. The 
peristaltic pump was then turned on to pump the water into the header vessel. The 
water-jet ejector valve was readjusted until a steady vacuum of 0.2 bar was reached; 
this was found to give a satisfactory level inside the deaeration unit, while allowing 
the peristaltic pump to function steadily. The setpoint for the level inside the header 
vessel was set to 60, which actually gave a steady-state level of approximately 70% 
inside the vessel. Once this level was reached, the pulsatile pump was switched on, 
directing flow through the test chamber and out to the drain. After flow was estab-
lished in the system, the heat exchanger was switched on. The setpoint temperature 
for the heat exchanger was set to 38°C, which resulted in a temperature of 37°C 
immediately upstream of the test chamber. 
The flow rate used for all runs was 2 L/min, with a pulse rate of 70 bpm. This 
rate was chosen for consistency with previous work done by Lewis with the heart 
chamber [72]. The flow rate in the system was affected by 3 factors: the outlet 
height of the drain tube, the test valves in the test chamber, and the power setting 
on the pulsatile pump controller. The outlet height and the test valves established 
the downstream pressure in the system, while the amplitude setting on the pulsatile 
pump controller determined the driving force used to pump the fluid through the 
valves and against the head of liquid in the outlet drain. The outlet drain height was 
maintained constant at 1 metre above the fluid in the header vessel. This provided 
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sufficient head to close the mitral valve during systole. The power setting on the 
pulsatile pump controller had to be adjusted for each test until the desired flow rate 
was reached. The flow rate was determined by volumetric measurement: a stopwatch 
was used to measure the time it took to collect 1 L of water in a graduated cylinder. A 
time of 30±0.3 s was considered satisfactory for all runs, resulting in a rate of 2±0.02 
L/min. After the system had reached steady-state at a flow rate of 2 L/min and 
a downstream temperature of 37°C, flow was switched from water to milk. At this 
time, it was also necessary to open the drain water valve, allowing copious amounts 
of water to flush away the milk and prevent bulk clotting in the drain. 
Milk was pumped through the system for 5 minutes to displace the water that 
had been used for achieving steady-state before starting the dosing pumps. After 
that time, the calcium chloride and rennet pumps were both switched on. The stroke 
rate and stroke length of each pump had previously been adjusted to give a flowrate 
of 20 mL/min at 70 strokes/mm, representing 1% of the milk flow rate. Calcium 
chloride and rennet injection continued for the desired length of the test. After that 
time, the injection pumps were switched off and flow was then switched back from 
milk to water. Water was flushed through the system for an additional 5 minutes to 
halt the clotting process. After this time, the remaining pumps and heat exchanger 
were turned off. 
At the end of each test, the test chambers were carefully dismantled and the 
valves removed for observation. The nature and location of clots on the valves, as 
well as any on the test chamber in the vicinity of the valves, were noted. All valves 
were photographed using a Nikon F3 SLR camera. 
6.2 Rigid Test Chamber 
6.2.1 Rennet concentration 
As discussed in Section 5.7, the rennet used in the current work was different from 
that used by Lewis [72]. However, for comparison with his work, it was desired to 
use the same clotting time in these experiments. Lewis had reported a bulk clotting 
time of approximately 45 s, as determined by Lee-White tests. This clotting time was 
chosen because it resulted in bulk clotting occurring downstream of the test chamber, 
in the drain, though significant clot formation was still induced on the test valves. 
A 10% vol/vol dilution of Fromase in distilled water resulted in a similar Lee-White 
clotting time, so this concentration was used for all of the experiments in the rigid 
test chamber. 
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Heart Valve Diameter(mm) 
Ball and cage valves 
Starr-Edwards cloth-covered 19.8 
Starr-Edwards silastic ball 19.1 
Tilting disc valves 
Bjork-Shiley Standard 24.0 
Bjork-Shiley Monostrut 22.0 




St. Jude Medical 22.4 
CarboMedics 20.5 
Edwards-Duromedics 24.5 
Medtronic Parallel 23.7 
Table 6.1: Heart valves tested in the rigid heart chamber 
6.2.2 Heart valves tested 
The purpose of testing in the rigid heart chamber was to further confirm the ability 
of renneted milk to form localised clots on all types of commercial heart valves. To 
this end, eleven different commercial heart valves were tested, and they are listed 
in Table 6.1. It was decided that the inner valve diameter, through which the fluid 
passed, was the most critical for comparison purposes. These were measured with a 
micrometer and are also listed in Table 6.1. It should be noted that these are not 
the same as the tissue annulus diameters reported by valve manufacturers. All valves 
except for the Omniscience were able to be placed in either the mitral or the aortic 
position of the chamber for testing. Unfortunately, the downstream outer diameter 
of the Omniscience valve was too large to fit in the aortic section, so this valve could 
only be tested in the mitral position. All valves were then tested at least 3 times in 
each possible position. 
In addition to the commercial valves, a prototype lycra trileaflet valve 1 was avail-
able for testing. The inner diameter of this valve was 22 mm. The trileafiet valve did 
not appear to be opening properly at the normal flow condition of 2 L/min in the 
'AorTech International plc 
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rigid heart chamber, so it was tested at 3 L/min instead. 
6.2.3 30 minute runs 
The initial runs with the rigid test chamber were performed to assess the end-stage 
clotting of the commercial heart valves. Lewis had used 120 L of milk in his work, 
but this was deemed costly and excessive if a significant number of experiments were 
to be run, as was the case with the current work. In addition, Marosek's work 
with ultrasound showed that there was an increased risk of clots dislodging after 30 
minutes. Since it was desired to have a maximum amount of clotting with minimal 
risk of dislodging, 30 minutes was chosen as the length of time for the end-stage 
clotting tests. This meant that the rennet and calcium chloride pumps were left on 
for 30 minutes during each run, thus exposing the valves to 60 L of renneted milk. 
6.2.4 5 minute runs 
The rigid test chamber was also used to determine if differences in clot initiation could 
be discerned between a valve of excessive thrombogenic potential and a standard 
valve. The Medtronic Parallel valve had been prone to an unusually high incidence 
of thrombosis in clinical trials and removed from the market. On the other hand, 
the St. Jude Medical valve, while still prone to thrombosis, is considered to have an 
acceptable level of clot formation and is currently the mechanical valve standard. To 
assess whether the milk test could differentiate between their clotting potentials, both 
valves were tested for merely 5 minutes in the aortic position of the test chamber, 
with a Björk Shiley Standard valve mounted in the mitral position. Previous work 
at this institute with ultrasonic monitoring of coagulation showed that a lag phase of 
approximately 5 minutes existed before clot began to build up on the walls of the test 
chamber [74, 751. It was suspected that a similar lag phase would exist before clot 
developed on the valves themselves, so the shortened run time of 5 minutes should 
have provided results near the onset of clotting. Both bileaflet valves were tested 5 
times under the 5-minute test conditions. 
6.3 Flexible Test Chamber 
The flexible chamber was used to determine what effect test conditions, including 
chamber design and coagulation time, had on in vitro clotting. Since several variables 
were to be observed with this work, it was desired to be able to run two tests in a 
single day. Due to transport limitations, only 4 5-gallon containers of milk could 
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be obtained for each day, thus limiting each test to 10 gallons of milk. Most of the 
tests in the flexible test chamber were therefore run for 20 minutes, exposing the 
valves to 40 L of renneted milk. A few experiments were run for the full 30 minutes 
to determine whether the time difference had a significant impact on the final clot 
formation. 
6.3.1 Effect of clotting time 
Following experiments with the rigid heart chamber, it was suspected that the phase 
of the clotting reaction that the heart valves were exposed to had a significant impact 
on clot formation. As mentioned in Section 3.3, the milk clotting reaction contains 
a lag phase, a flocculation phase, and a bulk clotting phase. There are three means 
of changing the coagulation phase in the region of the valve: by changing the length 
of tubing between the rennet injection point and the test chamber, by varying the 
rennet concentration, or by changing the flow rate of the milk. It was desired to use 
a constant flow rate to maintain the same Reynolds number in the system, so the 
latter option was not considered. Changing the tube length results in a change in 
the valve exposure time, but the clotting profile remains the same. With a change 
in rennet concentration, the valve exposure time remains the same but the clotting 
time shortens as concentration increases. For the initial setup of the system, tubing 
length was varied until an adequate clot formed on the valve. However, once the 
system was working adequately, it was easier and more practical to vary the rennet 
concentration for subsequent work. The impact of clotting time was thus assessed by 
testing at 4 different rennet concentrations: 5, 7.5, 10, and 12% vol/vol. 
6.3.2 Effect of valve orientation 
The shape of the rigid heart chamber, particularly the sections immediately adjacent 
to the test valves, was axisymmetric, so valve orientation was essentially irrelevent. 
However, in the flexible heart chamber, this was not the case. The silicone ventricle 
was designed to resemble the human heart, so the chamber was asymmetrical. In 
vitro testing of the St. Jude valve in a similar chamber at another laboratory revealed 
that valve orientation impacts the development of vortices, which may affect clotting 
[84]. Clotting has also been impacted by valve orientation in situ; the Omniscience 
mitral valve was found to be significantly more thrombogenic when mounted in the 
posterior orientation than in the anterior orientation [259]. It was therefore desired 
to test whether orientation of valves in the flexible chamber had an impact on clot 
formation. To test this, the bileaflet valves and the tilting disc valves were each 
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(a) Tilting disc in 'central' orientation 
	(b) Bileafiet in 'perpendicular' orientation 
Figure 6.1: Orientation of valves in flexible heart chamber 
tested in two different orientations in both the mitral and the aortic positions. For 
the tilting disc valves, the orientations were at a 1800  angle to one another, with the 
main flow (major orifice) either directed toward the centre of the chamber or toward 
the outside of the chamber. The central orientations are shown in Figure 6.1a. 
The different orientations tested for the bileafiet valves were at 900  to each other, 
since the valves are symmetric over 180° . The orientations for these valves are 
referred to as parallel or perpendicular. Valves in the perpendicular orientation are 
shown in Figure 6.1b, where the leaflets, when open, are perpendicular to the section 
of the chamber shown in the diagram. 
6.3.3 Effect of sinuses of Valsalva 
The native human aorta has three pseudo-spherical cavities immediately downstream 
of the aortic valve, referred to as the sinuses of Valsalva. However, there is a lack of 
consistency among researchers as to whether or not to include these sinuses in mock 
circulatory loops. The aortic section in the original rigid test chamber consisted of 
an elliptical cavity immediately upstream of the aortic valve [72]. While some other 
groups still use elliptical sinus models [260, 261] or straight-wall aortas [193, 262], 
a growing number of institutes have begun to model the three separate sinuses of 
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Valsalva [83, 187, 263]. A recent study by Morsi et al. demonstrated the potential 
importance of the three separate sinuses [264]. In their study with an annular valve, 
they found that the elliptical model produced lower shear stresses and created a more 
uniform axial velocity distribution than the other potential aortic models. 
To determine whether the sinuses of Valsalva have an impact on clotting in the 
aortic section, two different aortic chambers were used. One consisted of a straight-
walled cylindrical tube, and the other contained the sinuses of Valsalva moulded in 
glass. The Bjork-Shiley Standard, St. Jude, and Parallel valves were tested in both 
chambers to assess whether the sinuses had an impact on in vitro clot formation. 
Additionally, as it had been discovered that the trileaflet valve did not work properly 
in the rigid heart chamber, it was desired to test this valve again in the sinus chamber. 
Unfortunately one of the leaflets of the original trileaflet valve tore the first time it 
was mounted in the sinus chamber, so an alternative prototype 2 of similar design and 
flexibility was tested instead. 
6.3.4 Effect of valve size 
The final variable considered was the effect of valve size on clotting. It was sus-
pected that the interaction of chamber walls with the valves had an impact on clot 
formation, and the nature of this interaction would be affected by the ratio of valve 
diameter to chamber diameter. This theory seemed to be justified by Christy's work; 
discrepancies between clot formation on his objects and those on Vorhauer's test 
bodies were largely attributed to a difference in the percentage of area obstructed. 
(See Section 3.4.1). We had two St. Jude valves of significantly different diameters 
(22.4 mm and 18.5 mm), so these were tested in the heart chamber to determine if 
any difference in clotting pattern resulted. 
6.4 Cleaning Procedure 
Careful cleaning of the test rig was necessary after each run to prevent any milk clots 
from carrying over to the next run. With the test chamber disassembled, macroscopic 
clots were removed from the inside of the chamber with a soft brush. Similar clots 
were removed from the valves by hand. The test chamber was then reassembled with 
the valves in place. Flow through the system was restarted with water, according 
to the initialisation procedure described in Section 6.1, but with the heat exchanger 
setpoint adjusted to 50°C. Once this temperature was reached, the flow was again 
'leaflets 48% estane, frame coated with estane 
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stopped and the system was divided into two sections: the upstream part, which had 
not been exposed to rennet, and the downstream part, which had. 
The outlet hose from the peristaltic pump was removed from the header vessel 
and connected to a tube flowing into the water reservoir tank. Approximately 100 
g of sodium hydroxide were added to the water reservoir tank, and the peristaltic 
pump was switched back on. This pumped caustic through the upstream system. 
The outlet hose from the test chamber was disconnected from the drain and 
attached to the inlet of the header vessel. Approximately 50 g of the enzymatic 
cleaner Tergazyme were added to the header vessel, and the pulsatile pump was 
switched back on, pumping the detergent through the renneted section. 
The sections were left cleaning separately for at least 2 hours. After that time, the 
caustic solution was drained via one of the milk reservoir valves, and the Tergazyme 
was pumped down the drain. The system was then returned to its normal operating 
configuration and clean water was pumped through for at least one hour. The ap-
propriateness of this cleaning procedure was confirmed by similarities in clotting of 
valves on their first trial and clotting in subsequent runs in the system. 
6.5 Dye Injection Experiments 
The residence time of fluid inside the test chambers was determined by dye injection. 
A syringe filled with 0.2 ml of a saturated potassium permanganate solution was 
attached to the flow system at the rennet injection point. Once the system had 
achieved steady-state at normal test conditions, the dye was quickly injected into the 
flowstream. This generated a pulse of dye that could be followed through the test 
chamber. Because the time of interest was the residence time of the coagulating milk 
at each valve, the times were determined differently for the two test chambers. For the 
rigid test chamber, the initial time was taken as the point that the dye first entered the 
mitral chamber. This is where the renneted milk stream would have combined with 
the calcium chloride stream, essentially initiating coagulation. 3 For the flexible test 
chamber, the rennet and calcium chloride streams were mixed together immediately 
downstream of the injection points, so the initial time was taken as the time at which 
the syringe was emptied. 
Previous researchers have judged the residence time of dye in the chamber visually, 
but it was desired to develop a more objective method for determining the residence 
31n fact, the renneted milk stream would have undergone some proteolysis before this point, but 
since the secondary stage of coagulation is dependent on C a2+, this was considered an acceptable 
starting point for the appreciable coagulation time in the rigid test chamber. 
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time in the current work. A Panasonic digital video camera (model NVDS28) was 
used to record the path of dye through the test chamber. ImagePro Express 4.5 
software was then used to obtain a data file of the hue and saturation values near 
a given valve over time. This data was then plotted in Excel, generating profiles 
of colour decay inside the test chamber over time. The hue profile illustrates the 
presence of any dye in the chamber, while the saturation profile depicts the decline 
in the intensity of dye over time. For the purposes of this work, the bulk residence 
time, when most of the dye had passed through the chamber, was chosen to be the 
time at which the saturation had dropped to 25% of its peak value. 
The dye injection method was used to determine the residence time of fluid in 
the vicinity of the Starr-Edwards metal ball, Björk-Shiley Standard, and St. Jude 
Medical valves in both the mitral and aortic positions of the rigid heart chamber. 
The purpose of this was to determine whether the residence times in the chamber 
were independent of the type of valve being tested. This would justify the practice 
of testing valves in both positions at the same time. For this work, a Björk Shiley 
Standard valve was used as the control valve: if a valve was tested in the mitral 
position, a Björk Shiley Standard valve was mounted in the aortic position and vice 
versa4 . 
The results of dye injection with the rigid heart chamber were subsequently used 
to commission the flexible heart chamber. It was desired to have a residence time in 
the flexible chamber that was approximately midway between those of the residence 
times in the mitral and aortic test positions of the rigid chamber. The residence 
time in the flexible system could easily be adjusted by changing the length of tubing 
between the rennet injection point and the test chamber, and then using the dye 
injection technique to confirm that the desired residence time was obtained. 
4Two Bjork-Shiley Standard valves of similar size were available to facilitate this. 
Chapter 7 
Results of Milk Clotting on 
Heart Valves 
7.1 Tests in the Rigid Heart Chamber 
All of the valves were tested for 30 minutes in the rigid heart chamber to simulate 
end-stage clot formation. This work was used to assess three factors: the ability of 
milk to clot on all valve types, the reproducibility of the milk test, and the accuracy 
of the milk test in modeling thrombus formation. 
Milk clot did adhere to all of the valves tested, indicating that there is potential for 
its use with all valve types. Frequently, two different types of clot were found on the 
valves: a smooth clot of fairly uniform morphology that could be easily removed, and 
a coarser clot of heterogenous composition that seemed denser and more adherent. 
Even when the coarser clot broke off, it generally left fragments behind that were 
still attached to the valve. The two different types of clot are shown in Figure 7.1. 
The smoother clot formed in the boundary layer on the leaflets of the tilting disc 
and bileafiet valves, and was similar to boundary layer clot found on the walls of 
the chambers. This clot was not considered to be representative of in situ thrombus 
formation. On the other hand, formation of the coarser clot appeared to be due to the 
localised fluid mechanics and formed in specific, reproducible locations on different 
valves. This 'localised clotting' was identified for comparison to reported thrombus 
formation. 
116 
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Figure 7.1: Different types of milk clot formation on heart valves. The coarser, 
'localised', clot can be seen around the struts of the valve, while the smoother clot is 
present as a film on the disc. 
7.1.1 Reproducibility in the rigid heart chamber 
Clot formation on the tilting disc and ball and cage valves was highly reproducible, 
with the main clot forming on the fixed occluding mechanisms. Any variability in 
clot formation on the tilting disc valve appeared to depend on whether or not the disc 
had continued to rotate throughout a run. In cases where it did rotate, clot formation 
in the centre of the disc was generally more prominent, while the outer edge of the 
disc was wiped free. Clot formation on the upstream side of the Björk-Shiley valve 
is shown in Figure 7.2. 
Localised clot formation on the bileaflet valves was slightly more varied. While it 
was confined to only two general locations (around the hinges or the outer edge of the 
downstream leaflets), it did not form in both locations in all tests. The reproducibility 
of clotting on a CarboMedics valve is shown in Figure 7.3. Despite the variability 
between tests, however, the hinges and the leaflet edges can still clearly be identified 
as the sites of localised clotting. 
7.1.2 Caged ball valves 
Two types of caged ball valves were tested: the Starr-Edwards sila.stic ball with 
bare struts and the Starr-Edwards metal ball with cloth-covered struts; milk-clotting 
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Figure 7.2: Reproducibility of clotting on the Bjork-Shiley valve in the rigid heart 
chamber. All valves were tested in the aortic position of the rigid heart chamber at 
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Figure 7.3: Reproducibility of clotting on bileaflet valves. A CarhoMedics valve was 
tested four times in the aortic position of the rigid heart chamber at 2 L/min for 30 
mm. Downstream side is shown. 
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results are shown in Figure 7.4. Localised clotting on the caged ball valves was seen 
in both the mitral and aortic positions, although it was much more extensive in the 
aortic position. For both valves, clot occurred on the struts, with a thickened clot 
at the apex, often extending downstream of the valve. Frequently, there was also a 
thinner clot on the lower part of the struts, at the intersection of the strut and the 
silastic mould. 
Milk clot never formed on the silastic ball in pulsatile tests, but there were two 
occasions where a patchy clot was found adherent to the metal ball. To confirm 
that the lack of milk clot on the silastic ball was due to fluid mechanics rather than 
material compatibility, the silastic ball valve was also tested under steady flow. In 
that case, thick clot was found adherent to the downstream side of the ball. This 
indicated that milk clot would adhere to the silastic ball given the appropriate flow 
conditions. Since there are no reported incidents of thrombus formation on the metal 
balls in situ, it seemed likely that this patchy clot was peculiar to this test. The 
valve tested was an explant, and the metal no longer appeared uniform throughout. 
It may have been subjected to damage over the years of residing in a laboratory, 
leaving part of it more susceptible to clot adhesion. In Lewis's orginal work with the 
same valve, no observations of clot forming on the ball were reported [72]. 
Explanted Starr-Edwards valves are shown in Figure 7.5 for comparison with 
the milk-tested valves. Thrombus can clearly be seen on the struts of both valves. 
Other studies have noted similar thrombus formation, both at the intersection of 
strut and valve housing and at the downstream apex [265, 266]. Thrombi have not 
been reported as extending downstream of the struts to the extent that the milk clot 
did, but this could be due to the compliant nature of a true heart. As the heart walls 
contract, clot could break free, forming emboli in the valve recipient. There was one 
case where a similar phenomenon was noted with the milk test on a Starr-Edwards 
valve, even in the absence of compliance. No bulk clot was found on the valve after 
removing it from the test chamber, but patches of strongly adherent clot were found 
on the struts, indicating that clot had been there previously but broke off prior to 
the end of the test. 
7.1.3 Tilting disc valves 
Five different tilting disc valves were tested: the Bjork-Shiley Standard, Björk-Shiley 
Monostrut, Medtronic Hall, Ultracor, and Omniscience valves. All of these valves 
have free-floating discs, restrained by and pivoting around projections extending from 
the orifice ring. For the first four, the main clotting occurred downstream, primarily 
(b) silastic ball, aortic position 
(c) niet al ball, !nitIal position 
	
(d) metal ball, aortic position 
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Figure 7.4: Milk clot on Starr-Edwards ball and cage valves in the rigid heart cham-
ber. Valves were tested at 2 L/min for 30 mm. Clot is visible on the base and apex 
of the struts. 
611i,  
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(a) silastic bail 
	
(b) irietal ball 
Figure 7.5: Blood clot on Starr-Edwards ball and cage valves [72] 
on valve struts. However, the Ultracor valve, which has a large strut extending into 
the main flow orifice, also had a significant clot upstream. 
The Björk-Shiley valves 
The Bjork-Shiley Standard and the Bjork-Shiley Monostrut valve are very similar in 
design and consequently behaved similarly in the milk test. Photos of milk clot on 
the Standard valve are shown in Figure 7.6, while Figure 7.7 contains the Monostrut 
results. There was little localised clotting in the mitral position. For both valves, a 
light clot formed upstream on the struts and centre of the disc, but the downstream 
side of the valves was covered in a nondiscriminate smooth clot that provided little in-
dication of thrombogenicity. However, results in the aortic position were considerably 
different. 
In the aortic position, localised clotting was found on both the up- and down-
stream sides of the valves. The thickest clot was on the struts. On the Standard 
valve, this often extended into the minor orifice region and out to the downstream 
pivot points. Additionally, a thinner clot frequently formed on the disc itself. The 
amount of clot present on the disc seemed to depend on whether or not the disc 
continued to rotate throughout the test. If the disc did rotate, there tended to be 
clot up- and downstream on the centre of the disc, but none on the outer edge of 
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Figure 7.6: Milk clot on Bjork-Shiley Standard valve in the rigid heart chamber. 
Valves were tested at 2 L/min for 30 mm. 




(b) mitral position, downstream 
Figure 7.7: Milk clot on Björk-Shiley Monostrut valve in the rigid heart chamber. 
Valves were tested at 2 L/min for 30 mm. 
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Figure 7.8: Thrombus on explanted Bjork-Shiley valves [72], for comparison with 
Figures 7.6c and d. 
the disc, which would have been constantly wiped by the struts. However, if the disc 
stopped rotating, then there tended to be a covering over the entire disc. There were 
no cases where the Bjork-Shiley Monostrut valve appeared to have stopped rotating; 
in all instances, the clot on the disc was confined to the disc centre. 
Several papers have discussed thrombus formation on the Björk-Shiley Standard 
valve [267, 268, 269, 40, 270]. In most cases, the valve had clotted completely by the 
time thrombus was detected, but there are some photos which show the thrombus 
at its early stages, providing an indication of clot origin [268, 269]. Thrombus was 
typically found on the struts both up- and downstream, extending to varying degrees 
into the minor orifice. There is also evidence of thrombus forming at the downstream 
pivot points [268]. Figure 7.8 shows two explanted valves with thrombus evident 
in the minor orifice region, for comparison with the Björk-Shiley valves tested with 
milk. Thrombus can be seen attached to the struts, as well as at the downstream 
pivot points. 
The Medtronic Hall valve 
The Medtronic Hall valve differs from the other tilting disc valves in that the main 
strut actually extends through the centre of the disc. It is an S-shaped strut, and the 
disc is free to rotate around it. An additional strut on the downstream side of the 
CHAPTER 7. RESULTS 	 126 
valve prevents the disc from escaping. Two further retaining mechanisms are present 
on the upstream side of the valve, fixing the pivoting axis of the disc. 
Figure 7.9 shows milk clot on the Medtronic Hall valve. Again, little localised 
clotting occurred in the mitral position; a thin clot was seen on the upstream centre 
of the disc, which was not wiped free during the test. Downstream, a thin coating 
formed on the struts, with a small clot connecting the two. The tests in the aortic 
position provided more definitive results. Upstream, milk clot was found on the two 
side projections and at the base of the centre strut. There was also a thin clot that 
formed on the disc itself. Downstream, a significant amount of clot formed on the 
two struts, with a concentration of clot in the space between them. Clot also formed 
at both of the downstream pivot points, often connecting to the clot formed between 
the struts in the centre. This is illustrated in Figure 7.9d. 
Figure 7.10 shows thrombi on the Medtronic-Hall valve for comparison with milk 
clotting. Distinct similarities can be seen in the locations of clotting, both up- and 
downstream. Upstream, thrombi formed on the retaining mechanisms and the base 
of the strut [272], the same locations where milk clot formed in the current work. 
Downstream, thrombi extended from the pivot points toward the centre of the disc, 
attaching downstream of the disc hole [271]. This clotting pattern was also observed 
when the Medtronic Hall valve was tested with milk. Although no thrombus is visible 
on the downstream strut in Figure 7.10b, it seems probable that blood clot would 
also develop there in vivo, as it did on the struts of other tilting disc valves that 
extended into the minor orifice. 
The Ultracor valve 
Figure 7.11 shows milk clot on the Ultracor valve. As mentioned previously, the 
Ultracor valve has a large strut upstream that extends into the flow; downstream 
there are merely two retaining projections that hold the disc in place. The disc on 
the Ultracor valve did not appear to be rotating in the rigid heart chamber, and 
this had a significant impact on clot formation. Although minimal clot formed in 
the mitral position, the aerofoil pattern on the downstream side of the disc clearly 
indicated that the disc was merely opening and closing about a fixed axis, allowing 
a significant boundary layer to develop. Had the disc been rotating, this clotting 
pattern should not have developed since the pivot points on the disc would have been 
constantly changing. In the aortic position, this resulted in extensive clot forming 
downstream along the outer edges of the disc, as shown in Figure 7.11d. Extensive 
clot was also found upstream on the region where the struts contacted the disc. 




mitral position, upstream 
	
(b) mitral position, ilowust real ii 
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Figure 7.9: Milk clot on Medtronic Hall valve in the rigid heart chamber. Valves 
were tested at 2 L/min for 30 mill. 





(b) downstream [271] 
Figure 7.10: Thrombus on explanted Medtronic Hall, for comparison with Fig-
ures 7.9c and d. 
There is little detailed information in the literature regarding performance of the 
Ultracor valve, although incidents of thrombosis have been reported [273, 274]. In 
one case it was even noted that a thrombus caused the disc to stick. It was not 
possible to determine whether a lack of disc rotation was the cause of thrombosis in 
that case, so it is unknown if this phenomena occurs in situ or was an artefact of 
the testing conditions. The contractile nature of the human heart would create more 
crossflow around the valve, which could aid in rotation. However, the milk clotting 
results still would indicate that disc rotation is a potential area of concern with the 
Ultracor valve. 
The Omniscience valve 
The Omniscience valve differs from the other tilting disc valves in that it does not 
have any struts extending into the flow. Instead, there are two retaining projections 
both up and downstream holding the disc in place. As mentioned in Section 6.1, the 
Omniscience valve available was too big to be tested in the aortic position of the rigid 
heart chamber, so it was only tested in the mitral position. The results of these tests 
are shown in Figure 7.12. A smooth clot formed on the disc itself, as was seen on the 
other valves in the mitral position. A coarser clot was found around the projections, 
both up- and downstream. 
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(d) aortic position, downstream 
Figure 7.11: Milk clot on the Ultracor valve in the rigid heart chamber. Valves were 
tested at 2 L/min for 30 mm. 
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The projections of the Omniscience valve have also been associated with thrombus 
formation in situ [275, 276]. Figure 7.13 shows up- and downstream views of an 
explanted Omniscience valve for comparison with the milk clot. The most extensive 
thrombus formation has been seen around the downstream pivot housing, as shown 
in the picture. 
7.1.4 Bileafiet valves 
Four bileaflet valves were tested: St. Jude Medical, CarboMedics, Edwards-Duromedics, 
and Medtronic Parallel. The first three have all passed clinical trials and been used 
in patients'. The Parallel valve, however, was subject to an unusually high number 
of cases of thrombosis in clinical trial and voluntarily removed from the market. It 
was desired to discover whether the milk test could distinguish between the clotting 
potentials of the 'successful' valves and the Parallel valve. 
The St. Jude Medical valve 
Figure 7.14 shows milk clot on the St. Jude valve. No localised clotting was seen in 
the mitral position; smooth clot covered the hinge housing and the leaflets both up-
and downstream. A smooth clot was also seen on the leaflets and housing in the aortic 
position, but this was accompanied by a spongier, localised clot around the hinges. 
Generally, this localised clot was seen upstream at the pivot points, and downstream 
between the leaflets. In one case, the downstream milk clot also extended to the 
downstream outer edge of one leaflet, significantly impairing leaflet motion. There 
were other cases where the clot behind the hinges decreased the leaflet opening angle 
before the test was completed. 
Thrombosis around the hinge mechanism of the St. Jude Medical valve is a 
commonly reported problem [277, 278, 2791. Figure 7.15 shows up- and downstream 
views of explanted St. Jude valves with thrombus visible at the hinges. Similar photos 
of thrombus formation can be found elsewhere [277, 280, 281]. It is also common for 
the thrombosed valve to show decreased leaflet motion, as was found with the milk 
clot. 
'The Edwards-Duromedics valve is no longer available due to incidents of leaflet escape, but it 
performed similar to the others in terms of thrombogenicity 
(a) upstream [275] 






Figure 7.12: Milk clot on the Omniscience valve in the mitral position. Valve was 
tested at 2 L/min for 30 mm. 
(b) downstream [27j 
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(b) mitral position, downstream 
(C) aurt me position, upstream 
	 (d) aortic position, downstream 
Figure 7.14: Milk clot on the St. Jude valve in the rigid heart chamber. Valves were 
tested at 2 L/min for 30 mm. 
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Figure 7.15: Blood clot on an explanted St. Jude Medical valve, for comparison with 
milk clotting. Clot is visible upstream at one pivot point and downstream between 
the leaflets. 
CarboMedics and Edwards- D uro medics valves 
The CarboMedics and Edwards- D uromedics valves performed nearly identically in 
the milk test. Results of these tests are shown in Figures 7.16 and 7.17. In the mitral 
position, both were covered with a thin, smooth clot upstream and a thicker, smooth 
clot downstream. No localised clotting was observed. In the aortic position, both 
valves had small clots upstream near the hinges and then large clots downstream 
on both sides behind the hinges'. Normally, an additional clot was found along the 
outer edge of one or both leaflets, as shown in Figures 7.16d and 7.17d. There was 
also one case where a very large thrombus built up behind the entire leaflet of the 
Duromedics valve, reducing leaflet motion. 
Thrombus occurring around the hinge mechanisms of both the CarboMedics and 
Edwards- Duromedicsvalves has been reported in the literature [278, 282, 283, 284]. 
Figure 7.18 shows thrombus formation both up- and downstream of the CarboMedics 
hinges, for comparison with the milk clot at the hinges of the CarboMedics and 
Duromedics valves. A similar thrombus was documented by Hirsch et al [282]. There 
has also been a reported case of a large thrombus developing behind one of the leaflets, 
interfering with leaflet motion [283], as happened in the milk test. 
'Frequently, this clot remained attached to the chamber walls. This will be discussed further in 
Section7. 1.7 
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Figure 7.16: Milk clot on the CarhoMedics valve in the rigid heart chamber. Valves 
were tested at 2 L/min for 30 mm. 
CHAPTER 7. RESULTS 
	
135 
(a) mitral position, upstream (b) mitral position, downstream 
 
71 
LL)1LIU posh AoU. UpU udi ii 
Figure 7.17: Milk clot on the Duromedics valve in the rigid heart chamber. Valves 
were tested at 2 L/min for 30 mm. 







Figure 7.18: Thrombus formation on the CarboMedics valve, for comparison with 
milk clotting. Clot is visible adjacent to the hinges both up- and downstream. Cour-
tesy Lawford 
Medtronic Parallel valve 
At first glance, the Medtronic Parallel valve performed similarly to the other bileaflet 
valves in the 30-minute tests. In the mitral position, only a thin coating of milk clot 
was observed over the entire valve, thickest downstream on the valve housing. In the 
aortic position, small clots were observed upstream at the hinge pockets with large 
clots downstream behind the hinges, between the leaflets. Photos of these results are 
shown in Figure 7.19. However, closer inspection of the clots on the valves revealed 
some differences. The downstream bulk clots on the other valves were able to be 
removed with little force, leaving no clot behind in the hinge pockets. The localised 
clots on the Parallel valve were much more adherent. In one case, when a large 
clot behind the leaflets was removed, the piece nearest the hinges actually broke off, 
remaining firmly attached to the valve. This is shown in Figure 7.20. The clot can 
clearly be seen adhering to the hinge pockets. In every other run, clot also remained 
inside the hinge pockets both up- and downstream after the bulk clots were removed. 
One run with the Parallel valve provided another interesting result. At the end 
of the run, one of the leaflets was found to be stuck open. Upon inspection, it 
was discovered that a clot extended from the hinge region to the downstream outer 
edge of the stuck leaflet. This is shown in Figure 7.21. The amount of clot present 
on this valve was less than that found in runs with other bileaflet valves (compare 
I)) Ii It ii position, do\VfltIIedTtt 
CHAPTER 7. RESULTS 
	
137 
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Figure 7.19: Milk clot on the Parallel valve in the rigid heart chamber. Valves were 








Figure 7.20: Clot adherent to the Parallel hinge mechanism in a 30-minute run. The 
bulk clot had been removed, leaving this section firmly attached to the hinge pockets. 
Figure 7.21: A stuck leaflet on the Parallel valve during a 30-minute milk run. a) 
showing stuck leaflet on the right side of the photo. b) milk clot behind the stuck 
leaflet. 
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Figures 7.16d and 7.17d), but it had a deleterious impact on leaflet function. Whereas 
the clot on the other valves merely reduced the leaflet opening angle, the clot on the 
Parallel valve retarded movement altogether. After the valve had been removed from 
the test chamber, it was noted that excessive manual force was required to move the 
stuck leaflet against the milk clot. Again, removal of the bulk clot revealed that it 
was firmly adherent to the Parallel hinge pocket. 
As mentioned previously, the Parallel valve was removed from the market due 
to a high incidence of thrombosis in clinical trial. In most cases, the thrombosed 
valves had clotted extensively, providing little indication of clot origin, but there was 
one instance where it was reported that thrombus could clearly be seen in the hinge 
pocket of one of the leaflets [63]. This compares favourably with the milk clot that 
consistently adhered to the Parallel hinge pockets. 
7.1.5 5-Minute runs with bileafiet valves 
Since the milk clots obtained with the bileaflet valves in the 30-minute runs appeared 
to be similar in gross appearance but different in origin, it was decided that a shorter 
test could provide more useful information for differentiating between the Parallel 
valve and the others. The St. Jude and the Parallel valve were retested for only 5 
minutes to allow closer observation of the valve hinge pockets in the early stages of 
clotting. 
In all of the 5-minute runs, the St. Jude valve was found to be free of macroscopic 
clot at the end of the test. There was no clot visible in the hinge pockets up- or down-
stream of the pivot. Results with the Parallel valve were significantly different. In all 
cases, small clots were found around the hinges, visible either immediately adjacent 
to the pivot or in the outflow tract. This is shown in Figure 7.22. Additionally, in 
one run a similar clot was found in the inflow tract. The clots around the pivots 
appeared to be in the hinge pockets between the leaflet and the valve housing. 
In the final 5-minute test of the Parallel valve, a slightly larger clot had developed 
in one of the downstream hinges. Although this clot was confined to the hinge pocket, 
it was actually sufficient to interfere with the motion of the adjacent leaflet, decreasing 
the opening angle of the valve. This illustrated the potentially catastrophic nature 
of clot formation in the Parallel hinge pockets. 




Figure 7.22: Milk clot present inside the hinge pocket of the Parallel valve after a 
5-minute run 
7.1.6 Flexible trileaflet valve 
A prototype trileaflet valve  was tested in the rigid heart chamber to determine 
whether the milk test could be used on this next generation of mechanical heart 
valves. This valve did not open fully in either position at 2 L/min, so it was tested 
at 3 L/min instead. At this flowrate, the leaflets still did not appear to open fully, 
but this was the highest flowrate possible with the current system so a preliminary 
attempt to assess milk clotting on the valve was made. The results of these tests are 
shown in Figure 7.23. In the mitral position patchy clots built up on the upstream 
side of the leaflets, with a big smooth clot on the outside. There was also a smooth 
clot upstream on the stents. In the aortic position, a large clot built up between 
the downstream leaflets and the wall of the aortic chamber, although this remained 
attached to the chamber when the valve was removed. There appeared to be a higher 
concentration of clot at the attachment point of the stent to the leaflet upstream, 
and one clot was found between two of the leaflets, as indicated by the arrow in 
Figure 7.23d. However, these results were highly variable and largely inconclusive. 
The fact that milk clot would adhere to both the flexible leaflets and the stents was 
promising, but the testing conditions in the rigid heart chamber were not adequate 
to assess the flexible trileaflet valve. This may have been due to the inability of the 
leaflets to open fully in that chamber. 
3 AorTech International plc. 
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7.1.7 Wall clot in the rigid heart chamber 
In addition to the clot that formed on the valves, clot was found adherent to all of 
the surfaces of the test chambers. This clot was generally smooth in nature, similar 
to the boundary layer clot shown on the disc in Figure 7.1. However, the clot on 
the aortic chamber walls immediately downstream of the valve was frequently similar 
to the coarse, localised clots found on the valves themselves. This clot was found 
in most runs, regardless of valve type, but the exact location and shape of the clot 
depended on the valve tested in the aortic position. The different wall clots observed 
are shown in Figure 7.24. The majority of the clot downstream of the caged-ball 
valve developed in the wake of the struts and remained attached to the valve after 
dismantling. The clot downstream of the tilting disc valves developed in the pivoting 
points of the valve, on both sides of the minor orifice, while the wall clot behind the 
bileafiet valves developed downstream of the hinges. There were also cases where 
these clots remained attached to the valves on dismantling. The clot that developed 
downstream of the trileaflet valve filled the entire space between the valve and the 
wall, indicating that the valve was barely opening for the majority of the run. In all 
cases, it appeared that the wall clot in the aortic chamber should be considered when 
assessing the clotting potential of the valves. 
7.2 Compliant Heart Chamber 
Clotting in the flexible heart chamber was slightly more variable than clotting in the 
rigid heart chamber, although the variation was normally in the extent of clot rather 
than the locations. It appeared that the valves in the flexible chamber were more 
sensitive to testing conditions, presumably due to the narrow spread of residence 
time of clotting fluid in the vicinity of the valves. There were also more cases of clot 
breaking free prior to the end of the test, in both the mitral and aortic positions. If 
the compliant chamber were to be used to assess valve thrombogenicity, a minimum 
of five runs would be advisable. However, for comparing similarities between different 
testing parameters, three runs were considered sufficient. 
7.2.1 Comparison of results with different test durations 
As mentioned in Section 6.3, the test duration was reduced to 20 minutes for the runs 
in the compliant heart chamber in order to accommodate two runs in a single day. 
To confirm that the shorter testing duration did not significantly impact the results, 
one run was performed for 30 minutes with the Björk-Shiley Standard valve in the 
(c) bileaflet valve 
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Figure 7.24: Clot adjacent to the rigid chamber wall downstream of the aortic valve 
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(a) 30 minutes 	 (b) 20 minutes 
Figure 7.25: Influence of experimental duration on final clot formation. Downstream 
view of Björk-Shiley Standard valve tested in the mitral position of the flexible heart 
chamber. Both valves were tested at 2 L/min. 
mitral position and the Duromedics valve in the aortic position. The clot formed 
in the 30 minute run was nearly identical to clot that could be formed in 20 minute 
runs. Figure 7.25 shows clot formed on the downstream side of the Björk-Shiley valve 
during the 30-minute run, for comparison with clot formed during a 20-minute run. 
Both the location and extent of clot are remarkably similar. Further justification for 
use of the 20-minute runs was provided by other tests, in which the extent of clot 
actually exceeded that formed in the 30-minute run. 
7.2.2 Influence of rennet concentration and test position 
The Starr-Edwards silastic ball valve, Björk-Shiley Standard valve, and St. Jude 
Medical valve were all tested in both the mitral and aortic positions of the compliant 
chamber at four different Fromase concentrations: 5%, 7.5%, 10%, and 12%. For 
comparison, only the two extremes of the tested concentrations will be documented 
here; localised clotting at the other two concentrations was very similar to that 
at 12%. The results for the Starr-Edwards valve are shown in Figure 7.26. The 
5% results for the Bjork-Shiley valve are in Figure 7.27 with the 12% results in 
'The rennet flow rate remained constant, representing 1% vol/vol of the total milk flow rate. 
Only the dilution of the stock Fromase was altered. 
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Figure 7.28. Lastly, the 5% St. Jude results are in Figure 7.29 with the 12% results 
in Figure 7.30. 
The clot formed on the valves with only 5% Fromase was significantly different 
from the clot formed at the other concentrations. In all cases, only smooth clot was 
found covering the valves at the lowest rennet concentration. No localised, coarse clot 
was found on the valves. For the Starr-Edwards valve, the smooth clot was confined to 
the same locations that localised clotting was found at higher rennet concentrations, 
but this correlation did not exist with the other valves. Smooth clot was consistently 
found on the discs and leaflets at the 5% concentration, whereas they were generally 
free from clot at higher concentrations. Conversely, the upstream strut of the Björk-
Shiley valve was relatively free from clot with 5% rennet but was the site of significant 
localised clotting at higher concentrations. In addition to these differences, the rennet 
concentration also appeared to influence clot adhesion. At the highest concentration, 
clots were more likely to break free from the valves, as well as the chamber wall, 
prior to the end of the test. This indicated that a concentration of 7.5% Fromase is 
ideal for use with the flexible heart chamber. However, for consistency with the work 
done in the rigid chamber, the majority of the remaining work was performed with 
a rennet concentration of 10%. 
Test position did not significantly affect clotting on the Starr-Edwards or Björk-
Shiley valves in the flexible chamber. In all cases, the struts were the primary location 
for clot adhesion, with the pivot point and the minor orifice of the Bjork-Shiley valve 
also subject to clotting. However, clot formation on the St. Jude valve (as well as 
the Duromedics and CarboMedics bileaflet valves) was significantly impacted by test 
position. The valve did not develop any localised clotting in the mitral position. In 
fact, at all of the higher rennet concentrations, the bileaflet valves normally appeared 
to be free from all clot in the mitral position at the end of the run; even the smooth 
clot found on the leaflets with 5% rennet was absent. However, in the aortic position, 
localised clotting occurred with rennet concentrations greater than 5%. Clot was 
found behind the hinges and on the outer edge of one or both leaflets, similar to the 
results in the aortic position of the rigid test chamber. 
It should be noted, however, that the Medtronic Parallel valve behaved differently 
from the other bileaflet valves. With 5% rennet, it was also subject to only a layer 
of smooth clot covering the valve, but at the three higher rennet concentrations, 
coarse 'localised' clot was consistently found in the downstream hinge pockets. The 
clot did not extend out to form a larger clot behind the hinges as it did in the aortic 
position, but the presence of the clot in the hinge pockets themselves was a significant 
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Figure 7.26: Milk clot on the Starr-Edwards silastic ball valve in flexible heart 
chamber with different rennet concentrations. The straight-walled aortic section was 
mounted on top. The results with 5% Fromase in the mitral position were identical 
to those in the aortic position. 
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(c) aortic, upstream  (d) aortic, downstream 
Figure 7.27: Milk clot on Björk-Shiley Standard valve in flexible heart chamber with 
5% Fromase. The straight-walled aortic section was mounted on top. 




(a) mitral, upstream 	 (b) mitral, downstream 
(c) aortic, upstream 	 (d) aurtie, do\ leti ealli 
Figure 7.28: Milk clot on Bjork-Shiley Standard valve in flexible heart chamber with 
12% Fromase. The straight-walled aortic section was mounted on top. 
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(a) mitral, upstream 
	 (b) mitral, downstream 
Figure 7.29: Milk clot on St. Jude Medical valve in flexible heart chamber with 5% 
Fromase. The straight-walled aortic section was mounted on top. 
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VP 
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Figure 7.30: Milk clot on St. Jude Medical valve in flexible heart chamber with 12% 
Fromase. The straight-walled aortic section was mounted on top. 
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difference from the other bileaflet valves. 
7.2.3 The Omniscience and Ultracor valves 
As the Omniscience valve could not be tested in the aortic section of the rigid chamber 
and the clot formation on the Ultracor valve was suspected of being influenced by 
the ventricular geometry of the rigid chamber, these valves were tested again in 
the mitral position of the compliant chamber. Results of these tests are shown in 
Figure 7.31. The Omniscience and Ultracor valves have small retainers downstream 
which maintain the disc in place. Clot on those retainers was extensive for both 
valves. The Omniscience valve also has small retainers present on the upstream side 
of the disc; these clotted but to a lesser extent than the downstream retainers. Clot 
around the upstream projections was primarily located between the projection and 
the disc. When the valve had been tested in the mitral position of the rigid test 
chamber, it had been suspected that the upstream clot could have merely been the 
result of clot around the edge of the disc being wiped free when the disc rotated. 
However, as Figure 7.31a shows, this clot developed even when no clot formed on 
the disc itself. The upstream test section was also inspected and no clot appeared to 
have broken free, indicating that the milk clot developed there during the course of 
the run. This clot, as well as the downstream clot, was very similar to thrombi found 
on the valve in vivo (Figure 7.13). 
The Ultracor valve clotted differently in the compliant chamber than it had in 
the rigid test chamber. In most cases, it appeared that the disc continued to rotate, 
as it was free from clot both up- and downstream. A large clot still developed in 
the upstream centre of the valve, where the struts contacted the disc, but this clot 
was attached to the struts rather than the disc. This site is a plausible location for 
thrombus formation in vivo. The clot on the downstream retainers was also different. 
In the rigid chamber, the clot extended the length of the valve and was attached to 
the disc. In the compliant chamber, the clot was only over the projections and not 
attached to the disc. Since the downstream retainers were similar to those found on 
the Omniscience valve, where the milk clot matches thrombus formation, the clotting 
pattern in the flexible chamber is likely to be found in vivo. 
7.2.4 Influence of flow rate on clot formation 
There were two instances where clot development in the flexible chamber was sig- 
nificantly affected by fluctuations in the flow rate. In one case, the flow rate was 
found to have accelerated during the run. It had been checked multiple times prior 
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(a) Omniscience, upstream 
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(c) Ultracor, upstream 	 (d) Ultracor, downstream 
Figure 7.31: Milk clot on the Omniscience and Ultracor valves in the mitral position 
of the flexible chamber. Valves were tested with 10% Fromase at 2 L/min for 20 mm. 
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a va1e  (t) mitral valve 
Figure 7.32: Influence of reduced flow on clot formation. The Björk-Shiley Standard 
valve (a) experienced extensive clotting in the aortic position, reducing the flow rate 
and generating a large clot on the St. Jude Medical valve (b) in the mitral position. 
Valves were tested with 10% Fromase for 20 minutes. 
to the test and found to be 2 L/min, but near the end of the run it became apparent 
that the milk reservoirs were being depleted faster than normal. At this point the 
flow rate was checked again and found to be closer to 3 L/min. The flow rate was 
subsequently decreased, but it appeared to be too late to impact clot formation; at 
the end of the run, no localised clotting was found, and the valves were covered in 
smooth clot similar to that observed in the runs with 5% Fromase. In another run, 
the opposite problem occurred. A Bjork-Shiley Standard valve in the aortic position 
suffered from extensive clotting during the test, severely blocking the outlet flow and 
reducing the flow rate in the system. Clot on this valve is shown in Figure 7.32a. The 
reduced flow rate resulted in an extensive, coarse clot developing on the downstream 
side of the St. Jude valve, which was mounted in the mitral position of the flexible 
chamber. Clot on this valve is shown in Figure 7.32b. However, this coarse clot did 
not appear to be localised to thrombogenic sites of the St. Jude valve; rather, it 
seemed to be part of a bulk clot behind the valve. A bulk clot was also found in the 
centre of the ventricular chamber itself. 
CHAPTER 7. RESULTS 
	
154 
7.2.5 Effect of orientation on clotting 
Orientation appeared to influence valve performance more than it impacted valve 
clotting. In the mitral position, the Omniscience valve only operated in the 'central' 
orientation (refer to Figure 6.1) with the existing test conditions. It would not close 
when the major orifice was directed toward the outside, or posterior, wall. For the 
other tilting disc valves, the pressure needed to close the valve in the 'outside' orien-
tation of the mitral position appeared to be higher than the pressure needed in the 
central position; this was indicated by the fact that the amplitude of the pulsatile 
pump had to be set higher than average to operate the system at 2 L/min. The 
bileaflet valve performance was also affected by orientation; with the perpendicular 
orientation in the mitral position, the bottom leaflet did not appear to be open-
ing fully, whereas in the parallel orientation, the full opening angle appeared to be 
achieved. 
Any differences in operation did not appear to affect clotting of the Bjork-Shiley 
Standard valve or the St. Jude Medical valve. Both were tested in both orientations 
in the mitral and aortic position of the flexible heart chamber with the straight-walled 
aortic section. Results for the different orientations are shown in Figure 7.33. Again, 
little difference was seen between the clotting of the Bjork-Shiley valve in the mitral 
and aortic positions. Additionally, clot formation in different orientations was similar; 
in all cases it was primarily found on the struts, at the downstream pivot points, and 
in the minor orifice. There were cases in the aortic position where a large bulk clot 
developed downstream of the valve, as shown in Figure 7.32, but this occurred in 
both orientations. The St. Jude valve did not clot in either orientation in the mitral 
position. In the aortic position, localised clotting was found behind the hinges, as 
well as at the outer edge of one or both leaflets. This clot was not seen in all runs, 
but its variance did not appear to depend on orientation, as it could be found in 
both. Thus, for the valves tested, orientation appeared to have minimal impact on 
clot formation in the flexible chamber with the straight-walled aortic section. 
7.2.6 Tests in chamber with sinuses of Valsalva 
Four valves were tested in the aortic section containing sinuses of Valsalva: the Björk-
Shiley Standard, St. Jude Medical, Medtronic Parallel, and trileaflet valves. For the 
first three, localised clotting occurred in the same locations as for the straight-walled 
aortic sections. However, with the sinuses present, the wall clot appeared to be more 
integrated with the downstream valve clot; it was difficult to separate the two. The 
clot adherent to the downstream strut of the Björk-Shiley valve extended out laterally 
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Figure 7.33: Effect of orientation on milk clot formation on the a-d) Björk-Shiley 
Standard valve and e-f) St. Jude Medical valve. Valves were tested in the flexible 
ventricular chamber with the straight-walled aortic section mounted on top. Test 
conditions: 2 L/min for 20 minutes with a-b) 10% Fromase and c-f) 12% Fromase 
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to the sinuses of the chamber, as did the clot downstream of the St. Jude hinge 
mechanism. This is shown in Figures 7.34a and b, respectively. The flexible trileaflet 
valve appeared to be opening more in the chamber with the sinuses of Valsalva than 
it had in the rigid heart chamber. However, it still never opened fully; there always 
appeared to he a 'pinch point' between adjacent leaflets at the downstream edge 
of the valve. The valve was also significantly smaller in diameter than the aortic 
chamber. This meant that the leaflets, when open, did not approach the walls of 
the sinuses, as a true aortic valve would do in situ. This appeared to affect clotting 
of the valve, which is shown in Figure 7.34c. Significant clot developed downstream 
between the valve and the chamber walls, the majority of which remained attached 
to the chamber. Clot appeared to have developed indiscriminitely on the upstream 
side of the valve. No localised clotting pattern could be confidently identified from 
these tests. 
7.2.7 Test results with chamber in horizontal position 
One theory for the lack of clot formation on the bileaflet valves in the mitral po-
sition was that the large pressure differential affected the flow regime in a manner 
that inhibited clotting. To test this, the outlet hose to the drain was moved down 
to the level of the header vessel, reducing the hydrostatic pressure in the system. 
The chamber was then turned on its side to eliminate the influence of gravity, so 
that the only difference between the mitral position and the aortic position was the 
chamber geometry. The St. Jude valve was then tested in the mitral position with 
the CarboMedics valve in the aortic position. Despite the reduction in the pressure 
differential, no clot was found on the St. Jude valve. However, an interesting result 
was found with the CarboMedics valve. Even with the chamber on its side, clot was 
found to develop on the aortic chamber walls, similar to that shown in Figure 7.24c. 
It had been theorised that the chamber wall clot could be the result of vortices es-
tablished by the competing influence of upward flow and the downward acceleration 
due to gravity, but the fact that the clot developed on the walls in the horizontal 
position indicated that it was due to an interaction between the wall and the valve 
instead. 
7.2.8 Influence of valve size on clot formation 
To further assess the interaction between the chamber wall and the bileaflet valves, a 
St. Jude valve with significantly smaller diameter (18.5 mm instead of 22.4 mm) was 
tested in the straight-walled aortic section of the compliant chamber. The results with 
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Figure 7.34: Milk clot on valves in the aortic chamber with sinuses of Valsalva. Valves 
were tested with 10% Fromase for 20 minutes at 2 L/min. 
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(a) 	 (b) 
Figure 7.35: Influence of valve size on clot formation. The 18.5 mm St. Jude valve 
was tested in the straight-walled aortic section of the compliant chamber. The most 
significant clot was found around the downstream housing (a) but when this was 
removed, a small clot was observed attached to the leaflet at the pivot point (b). 
Valve was tested with 10% Fromase for 20 minutes at 2 L/min. 
the smaller valve were sufficiently different from those with the larger diameter. These 
are shown in Figure 7.35. The major clotting occurred around the housing of the 
valve, both up- and downstream of the valve. Downstream, a coarse clot developed 
along the entire diameter of the aortic wall adjacent to the valve housing. A large 
portion of this clot remained attached to the valve as shown in Figure 7.35a and had 
to be removed to obtain more detailed information regarding clotting. The large clots 
observed adjacent to the hinges, between the leaflets of the other bileafiet valves were 
not present with the smaller St. Jude valve. There were, however, instances of small 
clots forming on the leaflets at the pivot points, as shown in Figure 7.35b. These may 
have been less dependent on wall effects than the other clots on the bileaflet valves. 
7.3 Residence time experiments 
The residence time of coagulating fluid in the vicinity of the test valves was deter- 
mined using a dye injection technique. It was suspected that the spread of residence 
time at each test position was significant, so this was determined for each valve type 
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Mitral Exposure Time Aortic Exposure Time 
Mitral Valve Aortic valve Initial 	Final 	Initial 	Final 
SE Metal BS Standard 2.5 (0) 13.5 (2.9) 14.0 (1.4) 40.5 (2.7) 
St Jude BS Standard 2.5 (0) 12.5 (1.8) 13.0 (1.1) 33.0 (3.3) 
BS Standard BS Standard 2.5 (0) 13.0 (1.1) 14.5 (1.1) 38.0 (2.1) 
BS Standard St Jude 2.5 (0) 14.0 (1.4) 12.5 (0) 36.0 (1.4) 
BS Standard SE Metal 2.5 (0) 13.7 (2.2) 12.5 (1.8) 43.0 (3.3) 
Average time 2.5 (0) 13.3 (1.9) 13.3 (1.4) 38.1 (4.3) 
Table 7.1: Residence time in the rigid heart chamber. Numbers in parentheses are 
the standard deviation of four runs at each position (or the standard deviation of all 
the runs at each position for the average values). 
at each position. The initial time was taken as the time when the concentration of 
dye was the highest, while the final time was taken as the time when the dye con-
centration had been reduced by 75%. Further details of this analysis are included in 
the Appendix. 
The Starr-Edwards metal ball valve, the Bjork-Shiley Standard valve, and the 
St. Jude Medical valve were tested as representatives of the three clinical valve 
types (caged-ball, tilting disc, and bileafiet). All three were tested in both the mitral 
position and the aortic position, in series with another Bjork-Shiley Standard valve. 
The results of these tests are included in Table 7.1. Placement of a valve in one 
position did not appear to influence the residence time of fluid at the other position, 
justifying the decision to test two different valves at the same time in the rigid heart 
chamber. There was, however, a significant difference in the average residence times 
in the mitral position and in the aortic position. In the mitral position, valves were 
exposed to renneted milk that had been coagulating for 2.5 to 13.3 seconds, whereas 
the valves in the aortic position were exposed to milk that had been coagulating for 
13.3 to 38.1 seconds. When one considers the coagulation graph shown in Figure 3.4, 
this may have represented significant differences in the coagulation phase of the milk 
at the time it encountered the different test positions. 
The data obtained from the residence time experiments in the rigid test chamber 
was used to set up the flexible heart chamber. The variation between the mitral 
and aortic positions in this chamber was significantly less, with the mitral residence 
time between 13.7 and 22.5 seconds, and the aortic residence time between 15 and 
25 seconds. This meant that valves in both positions should have been exposed to 
milk at the critical stage of coagulation. The spread of residence time at the aortic 
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position was also considerably less in the flexible heart chamber (10 seconds compared 
to 25 seconds), indicating that the compliant ventricle was more efficient at expelling 
coagulating fluid from the chamber. 
Chapter 8 
Discussion 
The use of milk as a blood analogue fluid has often been met with skepticism in 
the past, due to the different natures of initiation of the clotting reactions. The 
primary objective of this work was to show that despite these differences, the final 
deposition product resulting from renneted milk resembles that from blood in similar 
flow conditions. As this is the case, the nature of activation may not be critical in 
modeling the flow-induced clotting of prosthetic heart valves. Further, as it has been 
shown that the materials used in modern mechanical heart valves are still capable 
of activating the coagulation cascade [146], the mere implantation of the foreign 
material may lead to a hypercoagulable state [285, 236]. With blood that is already 
in a hypercoagulable state, fluid mechanics will determine whether or not thrombosis 
will occur, so modeling flow-induced clotting appears to be justified. 
In order to model the flow-induced clotting of heart valves, an appropriate test 
system must be used. However, there is a lack of consistency in the choice of test 
chamber for modeling the fluid dynamic environment of the left side of the human 
heart. The extent to which chamber design may impact clotting is unknown, as is 
the effect of different test parameters on clot development. Therefore, the secondary 
objective of this research was to assess the influence of these variables on in vitro 
clotting of mechanical heart valves. 
8.1 Fluid Mechanics and Clot Formation 
Shear stress, turbulence, and mass transfer are all known to affect the development of 
thrombosis in vivo. In regions of high flow, for example, the thrombi that develop are 
primarily composed of platelets, while clots in regions of stasis contain significantly 
more fibrin. Previous research at this institute has demonstrated similarities between 
161 
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the fluid mechanically-induced clotting of blood and milk. The present work has 
expanded upon those results to aid further understanding of the similarities between 
coagulation of the two fluids. 
The results with the stagnation point flow chamber show that milk clotting is 
significantly influenced by local fluid dynamics. The flow channel that developed in 
each of the tests resulted in two distinct flow regimes in the chamber, and this led to 
very different clotting patterns. Although it was not possible to correlate these results 
directly with stagnation point flow work performed with blood and platelets, it was 
possible to use the results to assess the influence of mass transfer and shear stress on 
milk coagulation. In regions of stasis, such as the area outside the flow channel, milk 
deposition and aggregation appeared to be governed by diffusion. The aggregates 
were small and evenly distributed, as would occur if the micelles could only contact 
each other by diffusing through the milk serum. The presence of a small amount of 
shear enhanced coagulation, generating much larger aggregates. Above a minimum 
shear rate, the aggregates became aligned with the direction of the flow and generated 
a denser clot. However, there was also a maximum shear rate above which clot would 
no longer adhere. These results compare very favourably with platelet deposition, in 
which low levels of shear stress have also been shown to enhance platelet adhesion, 
and alignment of platelets in appropriately sheared environments has been observed. 
Additionally, a maximum shear stress above which platelet adhesion is prohibited 
has been noted. 
Two different types of clot also developed inside the heart chamber. In the bound-
ary layer along most of the chamber walls and the leaflets of the valves, a smooth clot 
developed that was similar in gross appearance to the clot outside the flow channel 
in the stagnation point flow chamber. However, in areas associated with turbulence 
and elevated shear, a coarser, more adherent clot developed. This clot was presum-
ably similar to the clot that formed in the flow channel in the stagnation point flow 
chamber. Turbulence and shear stress would have enhanced the collisions between 
particles, leading to a more structured clot. Similar effects were noted in the work 
with blood in model stenoses [183, 184]. Although there was no opportunity to mi-
croscopically assess the clot on the heart valves in the present work, the differences 
in gross morphology of the two types of clot indicated that further analysis would 
have revealed differences in the microscopic structure as well. 
The ability of fluid mechanics to influence milk aggregation is dependent on the 
time at which the mechanical stimulus is applied. During the lag phase, insufficient 
hydrolysis has occurred to allow casein micelles to aggregate. Thus only diffusion- 
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limited adhesion to the surface of the test objects appears to occur, resulting in a 
smooth clot that is easily removed from the heart valves and the walls of the chambers. 
However, if the mechanical stimulus is applied near the start of the flocculation 
phase, after sufficient hydrolysis of the casein micelles, then the capture efficiency is 
increased, and a denser, more adherent clot is possible. On the other hand, if the 
stimulus is applied too late in the coagulation cycle, clots that have formed in the 
bulk fluid may be broken, generating a spongier clot that does not show preferential 
adhesion to surfaces. The importance of applying the mechanical stimulus at the 
appropriate point in the coagulation cycle was demonstrated by Christy's work with 
modified Lee-White tests. Only agitation during the start of the flocculation phase 
generated coarse clots that showed preferential adhesion to the test tube walls. This 
indicates a limitation of the milk test: the testing system must be designed so that 
that heart valves are exposed to milk at the appropriate stage in the coagulation 
cycle for fluid mechanics to enhance coagulation. 
8.2 Milk Clot on Heart Valves 
The fact that milk clot adhered to all valve types showed that the milk technique 
has potential for working with all modern mechanical heart valves. Localised clotting 
was found on the caged-ball, tilting disc, and bileafiet valves when they were tested 
in a suitable environment. However, localised clotting did not occur on the flexible 
trileaflet valve. It was suspected that this was due to improper functioning of the 
valve in the existing system: it did not appear to be opening fully throughout the run. 
Currently, flow through the valves follows a sinusoidal pulse, generated by the piston-
displacement pump. The true cardiovascular waveform has a much sharper spike 
during systole, and it is suspected that this may aid in opening the trileaflet valve. 
Further work is needed to determine whether the milk technique can be adapted to 
identify the thrombogenic sites of the flexible trileaflet valve. 
8.2.1 Reproducibility 
The location of milk clot on the caged-ball and tilting disc valves was highly repro-
ducible for valves tested in the same location and with the same test conditions. In 
general, it occurred around the fixed struts and at the pivot points of the discs. For 
the bileaflet valves, clotting was slightly more varied; it occurred primarily behind 
the hinges with secondary clotting along the outer edge of the leaflets, but there were 
cases where it occurred in one location and not the other. For all of the valves, varia- 
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tions were found in the extent of clot that formed, even when all test conditions were 
kept constant from one run to the next. Since much of the clotting occurs in regions 
of turbulence, and the growing clot alters the environment in which it forms, it is 
difficult to ensure that clot development is identical from one run to the next. The 
fact that clot occasionally broke off prior to the end of the test also impacted on the 
reproducibility of the results. Thus, for comparison with in vitro thrombogenicity, a 
minimum of five runs under identical conditions is recommended. 
8.2.2 Comparison with previous work 
The majority of clotting observed in the current work compared favourably with 
clotting sites identified by other researchers with the milk technique [72, 73, 76]. 
Lewis and Keggen both reported clotting on the struts of Bjork-Shiley valves, and 
Christy noted that an additional clot occasionally developed both up- and down-
stream in the minor orifice of the valve. Keggen also observed clot formation around 
the hinges of a CarboMedics valve, adhering to the downstream housing between 
the two leaflets. This clotting location was observed with all of the bileaflet valves 
tested in the present work. Lastly, Lewis observed clot at the apex of the struts 
of the Starr-Edwards valve, as was found in this work. However, Lewis also noted 
significant clot forming at the upstream orifice of the Starr-Edwards metal ball valve, 
projecting into the flow. This clot was not observed to any significant extent in the 
current work. However, in Lewis's work with the Starr-Edwards metal ball valve, the 
sewing ring was still attached, whereas in the present work the sewing ring had been 
removed. The topography of the sewing ring could have provided more attachment 
points for milk to form upstream of the Starr-Edwards valve in Lewis's work. 
8.2.3 Comparison between milk and blood clotting 
Milk clot occurred in the same sites that thrombi have been reported to occur for all 
of the rigid valves tested. For the caged-ball valves, localised milk clotting occurred 
on the struts, thickest at the apex and frequently trailing downstream. The struts 
have also been associated with thrombosis in vivo, sometimes interfering with poppet 
motion [286]. Additionally, caged ball valves have been associated with a relatively 
high rate of embolism [287, 288], indicating that additional clot forming on the struts 
may be wiped free whenever the heart contracts. This did not happen in the compli-
ant chamber used with this work, but that was presumably due to the fact that the 
chamber walls did not collapse significantly near the valve. There were cases where 
the milk clot broke free prior to the end of the test, but this occurred primarily in 
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the aortic test position. It seemed to happen when the clot was attached to the wall, 
and the wall clot broke off prior to the end of the run. 
The struts on the tilting disc valves, particularly any retaining parts downstream 
of the disc, were the primary sites associated with milk clotting in the in vitro test 
chambers. Additionally, milk clot developed downstream of the actual disc pivot 
points, where stagnation would have occurred. For the Björk-Shiley valves, the 
Medtronic Hall valve, and the Omniscience valve, striking similarities were observed 
between milk clot location and reported sites of thrombus formation. For the Ultra-
cor valve, however, there was little reported information on clotting of the valve in 
vivo. It is therefore unknown if the clotting observed in the rigid heart chamber or 
in the flexible heart chamber is representative of thrombus formation. However, it 
seems more plausible that the clotting pattern observed in the flexible heart chamber 
is truly representative of blood clotting. The downstream retainers of the Ultracor 
valve are similar to those of the Omniscience valve, for which thrombus locations 
have been documented. In the flexible heart chamber, the milk clot that developed 
on the downstream side of the Ultracor valve resembled blood clot found on the Om-
niscience valve in vivo, whereas the clot on the downstream side in the rigid heart 
chamber did not. This may have been due to the influence of compliance on valve 
function. In the rigid heart chamber, the Ultracor disc did not appear to rotate, 
and this resulted in extensive clot forming upstream where the struts contacted the 
disc, and downstream on the trailing edges of the disc. In the flexible chamber, there 
would have been significant crossflow patterns induced by the contraction and ex-
pansion of the ventricle, as in the human heart, and this appeared to be sufficient 
to induce disc rotation; the disc itself was generally free from clot. More knowledge 
of the thrombogenic nature of the Ultracor valve is needed to allow comparison of 
clotting in milk to that in blood. 
Localised clot formation on the bileaflet valves also compared favourably to re-
ported sites of thrombosis in vivo. All valves clotted around the hinge mechanism, 
and there were often cases where milk clot adhered to the downstream outer edge of 
the leaflets. The hinge mechanism has frequently been reported as the thrombogenic 
site of bileaflet valves, and there are reports of clot developing behind the leaflets in 
vivo as well. In addition to these general clotting sites, the milk test was successful 
at identifying the hinge pocket as the thrombogenic site of the Parallel valve. This 
was significant because it was not identified as being thrombogenic in animal trials of 
the valve, even though it was subsequently prone to clotting in human clinical trials. 
The fact that strongly adhesive milk clot was consistently found in the hinge pockets 
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of the Parallel valve, but not in the hinge pockets of other bileafiet valves, showed 
that the milk test has the potential for differentiating between similar valves with 
different clotting potentials. 
8.2.4 Identification of clot initiation sites 
The shortened 5-minute runs in the rigid heart chamber showed that the milk test has 
the ability to identify the origin of clotting on heart valves. In these runs, small clots 
were found in the hinge pockets of the Parallel valve but nowhere else on the valve. 
This indicated that the hinge pockets were the initiation sites of clot formation on 
the Parallel valve. By using appropriately shortened test durations with other valves, 
it should be possible to identify the clot initiation sites on them as well. 
The identification of the hinge as the site of clot initiation with the Parallel valve 
compared favourably to the reported site of thrombus initiation in vivo. One Parallel 
valve that had been explanted prior to presenting any signs of thrombosis was found 
to have thrombotic material present in the inflow hinge pocket and attached to the 
pivot itself [63]. There was one case of comparable milk clot forming in the inflow 
pocket of the Parallel valve during a 5-minute run, although milk clot was more 
frequently found on the outflow side. In all cases, the milk clot was firmly attached 
to the pivot inside the hinge mechanism. Had more explants been able to provide 
information on clot origin, it is likely that thrombus would have been detected in 
the outflow pockets as well. Both the inflow and outflow pockets contained fluid 
mechanical conditions suspected to be conducive to thrombus formation. 
8.2.5 Comparison with velocimetry work 
Fluid mechanic features of heart valves 
Velocimetry studies have identified several flow features around heart valves which 
are associated with thrombus formation, and these correlated well with sites of milk 
clot formation in the current work. Regions of flow separation and high turbulent 
shear stresses have been detected downstream of fixed struts [289, 171, 202, 170], 
corresponding to the milk clot found on the struts of the caged-ball valves and the 
tilting disc valves. Regions of stagnation have also been observed on the edges of 
the discs at the pivot points [199], where clot has been found in the present work. 
The minor orifices of the Bjork-Shiley valves have been associated with elevated 
levels of turbulence [185, 202], and these regions have often been subject to excessive 
milk clotting. In the Omni- style of valves, a stagnant zone was detected adjacent 
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to the retainers [170, 289], which is where milk clot consistently adhered. With the 
Medtronic Hall valve, the strut in the minor orifice was found to generate significantly 
more flow separation than the strut in the major orifice [199], which may account for 
the fact that the minor strut was covered in clot, whereas most of the major strut 
remained clot-free. Additionally, high turbulent shear stresses [171] were associated 
with the hole in the centre of the Medtronic Hall valve, where milk clot was also 
found to occur. 
Flow through the bileaflet valves generated regions of turbulence and stagnation 
as well. Peak turbulent shear stresses were measured just distal to the valve leaflets 
[185]. This presumably correlates with the milk clot that was frequently found on the 
outer edge of the downstream leaflets. Flow separation, flow reversal, and stagnation 
were observed adjacent to the hinge regions in the central flow area [290, 289, 170]. 
This is the location that primary milk clotting was observed in the bileaflet valves. 
Flow through the thrombogenic hinge region of the Parallel valve is discussed further 
in the next section. 
Flow through the Parallel valve hinge 
The hinge mechanism of the Parallel valve differs significantly from those of the 
other bileaflet valves. The Parallel hinge pocket consists of an inflow ramp, a central 
rectangular recess, and an outflow ramp. To this is mated the leaflet pivot, with 
a backwards facing step, inserted into the central recess. Flow through the hinge 
mechanism passes from the inflow ramp over the main pivot face, down over the 
pivot relief face, and then out the outflow ramp. In comparison, the St. Jude hinge 
consists of a round, convex peg extending from the leaflet which is mated to a round, 
concave hole in the valve housing. The inflow and outflow tracts form a butterfly 
shape with the pivot in the centre. 
LDV studies have shown that the differences in hinge geometry have a marked 
impact on flow through the hinge region. In studies of the Parallel valve, Gross et 
al [63] found that an extensive recirculation zone persisted throughout the cardiac 
cycle in the upstream hinge pocket, a region of disturbed flow developed along the 
pivot trailing surface, and a smaller stagnation zone was present in the outflow tract. 
These are all associated with thrombus formation. Subsequent velocimetry work by 
Ellis et al [64] showed that recirculation zones also develop in the upstream hinge 
pocket of the St. Jude valve but are wiped free during retrograde flow. The leakage 
jets of the St. Jude Medical valve appear to have a superior advantage over those of 
the Parallel valve. 
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The milk test confirmed the presence of clot in the hinge pockets of the Parallel 
valve, where LDV had identified recirculation zones and stagnation points. The firmly 
adherent clot attached to the pivot was associated with the disturbed flow around 
the pivot trailing surface. For the St. Jude valve, similar clots were not found. This 
corresponds to the LDV work showing that stagnation zones around the pivot in the 
St. Jude valve are wiped free during systole. Clotting agents do not persist in the 
region long enough to aggregate. These results illustrated the potential of the milk 
clotting technique to complement velocimetry studies. 
8.3 Influence of Test Chamber on Clotting 
8.3.1 Compliance 
The addition of compliance appeared to induce different flow patterns in the ventric-
ular chamber, with the velocity components parallel to the valves changing as the 
chamber expanded and contracted. This seemed to result in improved rotation of the 
tilting disc valves. Thus the clotting pattern on the Ultracor valve was different in 
the compliant chamber than it was in the rigid heart chamber. Compliance also had 
the benefit of minimising the lag time between the two test positions. As identified 
by the dye injection work, the difference in the initial exposure times to renneted 
milk was less than two seconds for valves in the mitral and aortic positions. This 
meant that the valves in both positions should have been exposed to milk at the same 
phase in clotting, so variations in clotting between the two positions should only have 
been due to the chamber shape in the vicinity of the valve. The compliant chamber 
was also more efficient at expelling renneted milk from the ventricle with each pulse, 
leading to the residence time of coagulating milk in the vicinity of the valve being 
more dependent on the local fluid dynamics induced by the valve than artefacts of 
the test chamber. 
However, there were also problems induced by compliance. Shedding of the wall 
clot appeared to occur more often, potentially resulting in clot impinging on the 
valve in the aortic position. Generally, such clot appeared to be of a different nature 
and could be separately identified from the localised clot on the valves, but it seems 
plausible that if wall clot broke off early in a run it could become incorporated into 
the localised clot that formed on the valve. There was also a problem with consistency 
in the existing flexible heart chamber. Because the ventricle was only attached to the 
housing at the location of the valves, with the rest of the conduit free to move within 
a water-filled housing, the motion of the chamber walls could vary considerably from 
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one pulse to the next. This differs from the native heart, in which the cardiac muscles 
contract consistantly with each pulse. Additionally, the distention of the walls during 
systole could vary between tests, which could affect the flow pattern and the residence 
time in the ventricle. There were two reasons as to why this occurred. The first reason 
was that the amplitude of the pulse generated by the piston-displacement pump was 
changed for different valve configurations in order to maintain a flow rate of 2 L/min 
with constant hydrostatic pressure in the system. The pulse amplitude is controlled 
by the magnitude of piston displacement, which directly correlates to the volume 
change inside the chamber housing. The other reason for the variance was that it 
was difficult to maintain a constant volume inside the water-filled chamber housing 
from one run to the next. Although the quantity of water inside the housing did 
not change, an air pocket consistently developed inside the container, and its volume 
increased over time (although the change was very slight between tests). The walls of 
the housing had been sealed with an instant gasket, and there were no obvious leaks 
in the system, but the development of the air pocket persisted. It appeared that 
the leak may have been generated by the piston-driven pump itself; grease from the 
pump occasionally migrated into the housing. It seems plausible that air could have 
been pulled in to the housing at the same location. This variance did not appear to 
impact the resultant clot locations, but it would be desirable to improve this for the 
sake of reproducibility. 
8.3.2 Mitral chambers 
It is difficult to assess the influence of the mitral chamber geometry on valve clotting 
due to the other variations in the test systems. In the rigid heart chamber, the mitral 
valve appeared to be exposed to renneted milk too early in the clotting cycle to ex-
perience significant clot adhesion and aggregation. Little localised clotting occurred, 
even on the thrombogenic Parallel valve. Three modifications could be made to ex-
pose the mitral valve to renneted milk at the critical stage of clotting: the rennet and 
CaCl2 streams could be mixed together upstream of the atrial chamber, the rennet 
concentration could be increased to shorten the lag stage in clotting, or the flow rate 
could be significantly reduced. However, due to the spread of residence times in the 
rigid heart chamber, all options would result in bulk clotting inside the test chamber. 
Additionally, changing the flow rate would change the fluid dynamics in the chamber, 
and it is likely that the lower flow rate would impair valve function. Therefore, it 
does not appear to be possible to properly test heart valves in the mitral position of 
the rigid heart chamber. 
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The problem of exposure time has been eliminated with the mitral position in the 
compliant test chamber, but the geometry still does not appear to be appropriate for 
inducing clotting on all valve types. While localised clotting was consistently found 
on the caged-ball and tilting disc valves, it was not found on most of the bileafiet 
valves. It did occur in the thrombogenic hinge pockets of the Parallel valve, which 
was promising, but it still did not form the larger clots behind the hinges that were 
observed in other test positions. This could lead to the erroneous conclusion that 
the other bileaflet valves are nonthrombogenic, or significantly better than the other 
valve types. Since clinical studies have not identified significant differences in the 
thrombo embolism rates between tilting disc and bileaflet valves [49, 50], this con-
clusion cannot be supported. Additionally, as bileaflet valves are subject to clotting 
around their hinges in vivo, a thrombogenicity model should be capable of replicating 
such clotting. Thus the mitral position in the compliant test chamber is still not an 
adequate model for thrombogenicity assessment. Whether this is due to the irregular 
compliance of the ventricle, or the local geometry is not known. 
8.3.3 Aortic chambers 
The differences in the aortic chambers had less impact on valve clotting. In the three 
chambers tested, localised clotting occurred on all of the valves except for the flexible 
trileaflet. It is possible that this valve was inappropriately sized for the diameter of 
the test chamber. It had an outer diameter of only 25 mm 1 , while the diameter of 
the aortic chamber was 28 mm and the sinuses expanded to 40 mm. This meant 
that a large recirculation zone could develop between the valve and the wall, which 
may have resulted in the bulk clotting that occurred on the downstream side of the 
valve. Alternatively, as mentioned previously, the valve may have been functioning 
improperly due to the sinusoidal nature of the flow pulse. 
For the other valves, the aortic chamber geometry affected the trailing edges of the 
clots rather than their initiation sites. When valves were tested in the straight-walled 
chamber, the clots extended directly downstream of the valve. This occasionally 
resulted in bulk clots forming on the downstream side of the valve, as shown in 
Figure 7.32a. In the chamber with separate sinuses, the downstream clots extended 
out to the sinuses. This was generally not observed in the chamber with the elliptical 
recess. Wall clot also differed between the three chambers, with a large, coarse 
clot filling one or more of the separate sinuses. The coarse clot was seen on the 
downstream walls of the other chambers as well, but not to the same extent. There 
'The leaflets did not appear to open significantly beyond this diameter, even at peak systole 
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were two cases where this clot actually broke off prior to the end of the run, removing 
the downstream clot on the aortic valve with it. Morsi et al had studied flow through 
three similar aortic chambers and found the highest shear stresses were generated 
with the separate sinuses of Valsalva [264]. This could account for an increased 
frequency of wall clot dislodgment in this model. 
8.3.4 Wall effects 
The proximity of the chamber wall appears to influence clot development in some of 
the valve styles. While the caged-ball and tilting disc valves showed similar clotting 
patterns in both positions of the flexible heart chamber, the bileaflet valves did not. 
In the mitral position, where the chamber wall was distant to the valve, no localised 
clotting occurred. However, localised clotting was found in the aortic position, where 
the chamber walls are much closer to the downstream side of the heart valve. Inter-
estingly, the shape of the chamber walls did not seem as important as its proximity, 
since the localised clotting was observed in all of the aortic chambers tested. 
The results with the small St. Jude valve in the aortic position appear to confirm 
the theory that clotting around the bileaflet valves is affected by the proximity to 
the chamber walls. Clotting with this valve was different from that of the larger 
St. Jude model: the bulk clots between the leaflets adjacent to the hinge housing 
were not observed. It is possible that the clots that form between the leaflets are 
a result of recirculating vortices established by the jets emerging from the hinges 
encountering chamber walls. If the hinges are sufficiently distant to the chamber 
walls, these recirculating zones may not occur, or at least, may not occur in the 
vicinity of the hinges. Although the ventricular chamber was designed to mimic the 
native ventricle, it is possible that the mounting of the valve in the mitral position 
does not correspond exactly to placement in vivo, resulting in the valve being more 
distant to the chamber walls than would occur naturally. Alternatively, the variance 
in compliance of the flexible chamber may change the locations of the walls enough 
from one pulse to the next that recirculating vortices do not persist in the vicinity 
of the wall. The impact of the wall on the flow patterns should be assessed further 
with visualisation studies. 
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8.4 Influence of Test Conditions on Clot Formation 
8.4.1 Test duration 
There was no difference in clotting between the 20 minute and 30 minute runs, 
justifying the use of the shorter run times in the flexible heart chamber. There 
is clearly a minimum time needed for clot formation to occur, as shown by the 5-
minute tests with the Parallel and St. Jude valves, but testing the valves for more 
than 20 minutes appears to be excessive. In fact, since there were still instances of 
clot breaking free from the valve prior to the end of the 20 minute runs, as well as 
bulk clotting occurring downstream of the aortic valve, even shorter tests may be 
preferable. If ultrasonic monitoring proves compatible with the heart chamber, it 
should be used to optimise the test duration. 
8.4.2 Rennet concentration 
The rennet concentration had the most significant impact on clot development. At 
the lowest rennet concentration, no localised clotting occurred. It was suspected 
that this was due to the bulk of the milk passing through the test chamber prior to 
reaching the critical stage needed for clotting. Increasing the rennet concentration 
from 5 to 7.5 % was sufficient to induce localised coagulation on the heart valves. At 
higher concentrations, localised clotting occurred consistently, but there were more 
instances of clot breaking free prior to the end of the test. It seems plausible that 
at the higher concentrations, some of the milk was at the critical stage of clotting, 
while an additional percentage was already at an advanced stage in the coagulation 
cycle. As indicated by Christy's work with the modified Lee-White test, milk at the 
advanced stage of coagulation does not show preferential adhesion when agitated. 
Thus, it appears that there is an optimal rennet concentration for use with the milk 
technique. 
8.4.3 Orientation 
Orientation appeared to influence valve performance more than it influenced the 
locations of clot formation. In particular, in the mitral position, the Omniscience 
valve did not close at 2 L/min when the major flow orifice was directed to the outside, 
or posterior, wall of the chamber. Clinically, it has been noted that this valve is 
significantly more thrombogenic in the posterior position than the anterior position 
[259]. In the flexible chamber, it appears that a much higher downstream pressure 
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would have been needed to close the valve during systole in the posterior orientation. 
This would have generated a higher pressure differential across the valve, which could 
be associated with more turbulence than occurs in the anterior position, potentially 
leading to more clotting. 
It has been shown elsewhere that valve orientation impacts on local fluid dynamics 
[291, 263], resulting in different recommendations for the orientation of replacement 
valves [52, 292, 293]. It was, therefore, suspected that orientation might influence clot-
ting in this test chamber. However, even mounting valves in the optimal orientation 
as assessed hemodynamically has not completely eliminated thrombus development 
[259]. The long tests in the milk chamber are intended to represent the worst-case 
scenario of potential clotting, so any potential clotting should be observed. It is 
possible that a shortened test, similar to the one that identified differences in the 
clotting potential of the St. Jude and Parallel valves, could identify differences in the 
onset of clotting with different valve orientations. 
8.4.4 Flow rate 
The flow rate in the system had a significant impact on clot formation, primarily 
because it determined the point in the coagulation cycle at which the milk contacted 
the valve. There were instances where it was discovered that the flow rate had 
increased prior to the end of the run and localised clotting was not observed on the 
valves. In these cases, the concentration of rennet and the residence time of the milk 
in the chamber would have been reduced, both of which would have led to milk at 
an earlier stage in the clotting cycle contacting the valve. Conversely, there were 
also cases where the flow rate was significantly reduced prior to the end of the run, 
generally due to clot on the aortic valve impairing valve function. In these cases, 
the opposite phenomenon occurred. Both the rennet concentration and the residence 
time in the test chamber increased, resulting in bulk clotting occurring around the 
valves. This indicated that there is a need for better monitoring of the flow rate 
through the heart chamber. 
8.5 Benefits of the milk test 
The use of renneted milk allows for the dynamic clotting of heart valves to be observed 
in a safe, carefully controlled environment. While velocimetry tests can identify fluid 
mechanical factors that are associated with thrombus formation, renneted milk may 
be used to test whether those fluid mechanical factors are sufficient to induce localised 
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clotting on a particular valve model. Then, as the milk test proceeds, it is able to 
provide an indication of how the changing fluid dynamic environment resulting from 
the growing clot may affect the final clot development. Finally, the milk test can 
be used to observe the effect of clot on valve function. There have been multiple 
instances of milk clot reducing the opening angle of bileafiet and tilting disc valves, 
and the work with the Parallel valve showed that a clot that might have no effect on 
the performance of one valve may be detrimental to another. This information could 
allow assessment of the implications of thrombosis in a particular valve model. 
Another advantage of the milk test is the ability to vary testing time, something 
not practical with animal trials. By stopping the test at exactly 5 minutes, it was 
possible to compare the St. Jude and the Parallel valves at an early stage in clotting. 
This clearly showed a difference between the two valves: the St. Jude had not yet 
clotted whereas the Parallel valve had. Additionally, stoppage at this time interval 
allowed visualisation of the origin of clotting in the Parallel valve. The origin of 
clotting is necessary information for assessing a particular valve, and the comparison 
between early-stage clotting may provide a means for distinguishing between the 
clotting potential of different models. Thus, the milk test may be able to predict the 
relative thrombogenicity of different heart valve prototypes. 
With the development of the flexible heart chamber surrounded by water, it should 
be possible to incorporate real-time monitoring with the milk test. Preliminary work 
by Marosek and Curtis showed potential for observing clot development inside a 
straight-walled chamber over time. If this can be extended to use with the flexible 
heart chamber, crucial information regarding the onset of clotting and the influence 
of clot on valve motion may be obtained. Real-time monitoring of coagulation is 
not possible with animal models or velocimetry tests, so this potentially represents a 
significant benefit of the milk technique for thrombogenicity assessment. 
8.6 Limitations of the Milk Test 
The milk test is not able to model the full biochemical pathway of thrombosis, in-
cluding the initiation of the coagulation cascade. However, as studies indicate that 
the blood of mechanical heart valve recipients is in a hypercoagulable state, modeling 
the activation of coagulation may not be necessary. The fact that the milk clotting 
results compare favourably to in vivo sites of thrombosis indicate that modeling the 
fluid dynamic environment in vitro may be sufficient. 
Another aspect of blood coagulation that cannot be simulated by the milk test is 
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the reversibility of the clotting cascade. Once rennet and CaC12 are added to milk, 
the ensuing coagulation is inevitable. With blood, this is not the case. Thus, there 
is the potential that the renneted milk test could identify clotting sites that might 
not actually occur in vivo. To account for that, it would again be recommendable 
to compare the milk clotting results with velocimetry work, which could indicate 
whether the fluid dynamics in the area of milk coagulation appeared suitable to 
initiate thrombus formation. 
Currently, it is possible to compare the locations of milk clot to those of thrombus 
formation, but there is not yet enough evidence to indicate whether the milk test can 
determine the extent of clotting. As discussed by Keggen [76], one reason for this is 
that the milk test is conducted over a fixed time period whereas a thrombosed valve 
may be detected at any point in the clotting process. In fact, the thrombus is often 
only detected when it causes catastrophic failure. However, the extent of clot that is 
sufficient to cause failure varies significantly for different types of valves. Tilting disc 
valves have long been associated with sudden and acute failure due to thrombosis 
of the minor orifice [266]. Even smaller thrombi can interfere with bileaflet valve 
function [277]. On the other hand, a caged-ball valve may continue to function long 
after a thrombus has developed [294]. Thus, a miniscule thrombus on a bileaflet 
valve that has caused a leaflet to stick may be detected early in the clotting process, 
whereas a thrombus on the struts of a caged-ball valve may never be detected in 
a patient's lifetime [294]. Therefore, comparing the extent of clotting for different 
styles of valves does not appear to be as significant as identifying the locations prone 
to thrombosis and the potential impact of clotting on valve performance. 
At present, neither test chamber is ideal for modeling thrombosis on all valve 
types. The rigid chamber does not simulate the compliant nature of the native 
heart, and this may impact tilting disc rotation, which in turn may impact clot 
formation. This seemed especially relevant with the Ultracor valve, which clotted 
differently in the rigid test chamber than it did in the flexible one. In the flexible 
chamber, the motion of the ventricle is variable and does not truly represent the 
motion of the native heart. This may have been the reason that the bileaflet valves 
did not clot in the mitral position. Since these valves are known to clot clinically, 
the milk technique should be able to model this. Lastly, the flexible trileaflet valve 
did not demonstrate localised clotting in either of the test chambers; instead, bulk 
clot occurred downstream of the valve and random patches of clot were found on the 
leaflets upstream. Further work is needed to develop a test system that can model 





The coagulation of renneted milk is strongly influenced by fluid dynamics. In a 
stagnation point flow chamber, deposition of milk was governed by shear stress. 
In stagnant regions, coagulation appeared to be diffusion-limited, with very 
small aggregates forming that were uniformly dispersed on the stagnation plate. 
Milk coagulation was enhanced by moderate levels of shear stress, resulting 
in larger aggregates depositing. Above a minimum shear stress value, these 
aggregates aligned with the flow, but there was also a maximum shear stress 
above which deposition was not observed. On heart valves, the resultant milk 
coagulum also depended on local fluid dynamics. A smooth clot developed in 
the boundary layer of objects, while a coarser, more adherent clot developed in 
regions of turbulence and recirculation, where particle collisions were enhanced. 
The coagulation of milk shows similarities to blood coagulation on both a micro-
scopic and macroscopic scale. The deposition of renneted milk micelles under 
shear stress was found to be similar to that of platelets in flowing conditions. 
Both demonstrated critical shear stress levels for alignment and adhesion. The 
macroscopic deposition of milk clot on commercial heart valves was found to 
occur in the same locations as thrombus formation in vivo, when the valves 
were tested in an appropriate environment. This confirmed the suitability of 
the renneted milk test for modeling flow-induced clotting of heart valves. 
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The renneted milk test can be used to identify clot initiation sites. The short-
ened tests with the Parallel valve in the rigid heart chamber resulted in clot 
formation occurring only in the hinge pockets, the region identified as the origin 
of thrombus formation in situ. Information regarding clot origin is crucial to 
the understanding of flow-related thrombogenicity of heart valves. 
The renneted milk test is able to discriminate between the different clotting 
potentials of similar valves. Clear differences were observed between the clotting 
of the Parallel valve and the clinically successful St. Jude valve. In short runs 
in the aortic position, the St. Jude valve did not clot at all whereas the Parallel 
valve already had clot around its pivots. 
In general, caged-ball and tilting disc valves show consistent and reproducible 
clotting, independent of the flow chamber in which they are tested, whereas 
bileaflet valves are more affected by chamber design. Clotting adjacent to the 
bileaflet hinges is associated with recirculation zones, the development of which 
may be influenced by the proximity of the chamber walls. 
A critical coagulation period exists for the development of localised milk clotting 
on heart valves. If renneted milk contacts the heart valve before this critical 
period, only a smooth, indiscriminate clot is found covering the valve. On the 
other hand, if renneted milk contacts the heart valve after this critical period, 
a spongier clot develops that shows less preferential adhesion to surfaces. 
It is possible to determine objectively the residence time of coagulating fluid 
in the vicinity of heart valves by using a dye injection technique. Colour decay 
may be analysed as a function of time to identify the exposure times of valves 
in different test positions to renneted milk. 
The mitral positions of both the rigid and flexible heart chambers appear to be 
inadequate at modeling flow-induced thrombosis. No localised clotting occurs 
in the mitral position of the rigid heart chamber, presumably due to the short 
residence time of coagulating milk prior to encountering the mitral valve. In 
the flexible heart chamber, localised clotting does not occur around the bileaflet 
valves, possibly due to the distance between the ventricular walls and the mitral 
valve or to the non-physiological nature of the compliance. 
Compliance appears to improve the milk test by inducing more consistent disc 
rotation in the tilting disc valves, by reducing the chamber-induced spread 
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of residence times of coagulating fluid in the vicinity of test valves, and by 
minimising the lag time between the mitral and aortic test positions. However, 
compliance also appears to increase clot shedding and non-uniformity of flow. 
Incorporation of the sinuses of Valsalva does not appear to influence the location 
of milk clot on the existing heart valves, although attachment to the wall of 
the downstream valve clot is affected. However, as chamber design has been 
shown to influence valve clotting on some valves, and the potential influence of 
the sinuses on novel valve types is unknown, it would seem advisable to mimic 
the native sinuses in future work. 
Orientation did not influence the development of milk clot on the valves tested 
in the flexible heart chamber, corresponding to the fact that no orientation has 
been shown to completely eliminate thrombus formation in vivo. 
It was not possible to model thrombosis on a flexible trileaflet valve proto-
type. This may have been due to the non-physiological nature of the pulsatile 
waveform or improper sizing of the valve for the existing test chambers. 
9.2 Recommendations for Future Work 
Further comparisons of the flow-induced clotting of milk and blood may be 
obtained from experiments with a branching flow model or a model stenosis. 
Both have been used elsewhere to correlate the coagulation of blood with local 
fluid dynamics. It should be possible to design both models for use with ultra-
sonic monitoring, so that deposition of milk clot on the chamber wall may be 
monitored continuously and compared with blood coagulation. 
Coagulation in the existing stagnation point flow chamber was limited by poor 
mixing of the rennet and milk streams. If an improved mixing technique is 
developed, the stagnation point flow experiments should be repeated for quan-
titative and qualitative comparison to the stagnation point flow work with 
blood. 
Deposition in the stagnation point flow chamber is dependent on both flow rate 
and rennet concentration (reflecting collision frequency and capture efficiency, 
respectively). In the existing work, only the flow rate was varied between tests. 
This meant that the coagulation phase of the milk impinging upon the cover 
slip differed for different flow rates. It would be interesting to repeat the work 
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with additional rennet concentrations at the same flow rates in order to isolate 
the effects of collision frequency and capture efficiency on milk deposition in a 
sheared environment. 
Further analysis of the variations of clot formed under different flow conditions 
should be pursued, to determine whether differences in micelle alignment or 
adhesive strength can be delineated. SEM has shown that platelet alignment 
depends on shear stress in a stagnation point flow chamber; it would be inter-
esting to perform a similar study with milk clot formed in regions of high and 
low shear in the stagnation point flow chamber, for comparison with the differ-
ent types of milk clot observed on the valves in the heart chamber. Differences 
in adhesion could potentially be assessed with atomic force microscopy (AFM). 
This was briefly pursued with the current work, but there were difficulties in 
correlating the results obtained with specific locations on the sample. This was 
due to the fact that a postgraduate in the Physics department performed the 
AFM work who was not familiar with the milk results'. 
The use of ultrasound to monitor clot development in the flexible heart chamber 
should be pursued. Acoustic impedence, and hence reverberations, should be 
minimised due to the thin walls of the perspex housing, the presence of the 
flexible silicone ventricle, and the similarities in acoustic transmission between 
milk and water. The chamber housing has been designed so that the mitral 
valve sits within the allowable focal distance of the existing ultrasound probe. 
A silicone aortic conduit has also been produced to allow observation of the 
aortic valve. A brief investigation with the ultrasound system showed that it 
was possible to identify the mitral valve inside the chamber, but resolution with 
the current probe is not ideal and interpretation of the resultant image was not 
obvious. It was decided that a proper investigation of the use of ultrasound 
with the flexible heart chamber could form the basis for a separate research 
project. 
Testing in a rigid left ventricle with the same shape as the flexible ventricle 
should be pursued. This would provide a chamber shape that was more physi-
ological than the existing rigid heart chamber, while eliminating the variations 
'The postgraduate had limited experience with AFM of fluid samples, so there were difficulties 
in testing the clot initially, while I was present. Results obtained in my absence revealed differences 
in adhesion but were not considered useful since there was no way of correlating the AFM results 
with macroscopic clot. 
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in flow from one pulse to the next. With the exception of the Parallel valve, 
clotting generally did not occur on the bileaflet valves in the mitral position of 
the flexible heart chamber. As clotting has been seen in vivo around the hinges 
of all bileaflet valves, an acceptable milk test should be capable of reproducing 
this clotting. The reasons for the lack of clot formation in the mitral position 
of the flexible heart chamber are unclear. It may have been due to the manner 
in which the chamber collapsed, which was not truly representative of heart 
muscle contractions. It would be interesting to discover whether clot formation 
could be observed in a rigid, physiological model of the left ventricle. 
For optimal representation of the contractile nature of the native heart, a flex-
ible heart chamber could be developed from a material with several embedded 
PVDF (polyvinylidene fluoride) transducers [295]. PVDF can be made to flex 
in the presence of a varying electric field. Thus, electric pulses could be applied 
to the heart chamber to induce controlled contraction of the chamber walls, 
similar to the mechanism by which the myocardium contracts in a true heart. 
This would minimise the contractile variability between pulses and tests and 
should allow for a better representation of true physiological flows. 
Experiments should be conducted with a true cardiovascular waveform to de-
termine whether that has an impact on valve performance or clot formation. 
It was suspected that the flexible trileaflet valve may not have been opening 
properly with a sinusoidal pulse, so it would be desirable to test that valve 
again with a physiological waveform. 
Monitoring of the pressure and flow rate in the heart chamber should be at-
tempted. Clotting in the flexible heart chamber was very sensitive to changes 
in flow rate during the course of the run. The existing technique for determin-
ing the flow rate in the system (timed collection of a volume of fluid) does not 
allow for continuous monitoring and requires the water flushing the milk down 
the drain to be turned off. This can result in bulk clotting in the drain, which 
is undesirable. An improved technique for continuous monitoring of the flow 
would be preferable. 
Flow visualisation inside the flexible test chamber should be pursued, for com-
parison with the milk clotting results obtained here. A novel technique for 
analysing flow inside the chamber could involve the use of shear-sensitive cholesteric 
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liquid crystal mixtures 2 . The crystals change colour as shear stress increases 
and could potentially be used to visualise shear stress distribution in the heart 
chamber. 
2 llallcrest, Inc., 1820 Pickwick Lane, Glenview, IL 60025 USA 
Appendix A 
Milk Rig Operating Procedure 
A.1 Initialisation of the system 
Attach taps to the required number of 5-gallon milk containers (ensuring that 
the taps are initially closed) and connect the containers to the manifold system. 
Fill the CaC12 and rennet containers and turn on the pumps for a few minutes 
to flush out the lines. 
Turn on the mains water supply to the water tank and fill until water level 
reaches the overflow height. 
Open the valve to the deaeration column and ensure that the two valves on the 
vacuum line are open to the water jet ejector, with the valve to atmosphere 
closed. 
Open the water jet ejector 1/4 turn. 
Turn on the milk pump and adjust the level setpoint to 60, which gives an 
actual level of approximately 70 % in the header vessel. 
Adjust the water jet ejector to obtain a vacuum of approximately 0.2 bar, to 
give a head of water in the deaeration column that is approximately 3 inches 
above the bottom of the raschig rings. 
When the level in the header tank reaches 70, turn on the pulsatile pump. 
Frequency should be set to 70, with the amplitude approximately 15. 
Turn on the water pump and the 6 kW heater. Adjust the temperature setpoint 
to 38°, which gives a temperature of 37° at the test chamber. 
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Use a graduated cylinder and a stopwatch to determine the flow rate in the 
system by collecting the water at the drain. 
Adjust the amplitude on the pulsatile pump until the desired flow rate is 
reached. 
A.2 Running the test 
Once the setpoint temperature is achieved and steady state is obtained in the 
sytem, close the valve to the water reservoir tank and open the valve to the 
first milk tank. 
Open the valve to flush water down the drain. 
When approximately half of the first milk tank is emptied, turn on the CaC12 
and rennet pumps. Simultaneously start stopwatch. 
When the first milk tank is nearly empty, switch valves to the second milk tank. 
Disconnect the first tank from the manifold and dump any remaining milk into 
the second container. Repeat if a third tank is required. 
When the desired experimental time is reached, turn off the CaCl2 and rennet 
pumps and switch the manifold valves from milk flow to water flow. 
Flush water through the system for 5 minutes. 
Turn off the pulsatile pump, the heater, and the milk pump. 
Clamp off the lines up- and downstream of the test chamber. 
Remove the screws on the top of the test chamber and disassemble. 
Carefully remove the valves from the chamber, trying not to disturb any ad-
herent clot. When using the flexible chamber, spring loaded calipers must be 
used to remove the valves. 
Photograph the valves and the chamber, if necessary. 
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A.3 Cleaning procedure 
Use a cloth to remove the wall clot from the test chamber. 
Reassemble the chamber with the next valves to be tested in place. 
Turn back on the pulsatile pump, the milk pump, and the heater. Set the 
heater setpoint to 500. 
Turn off the mains water supply. It is desired to empty the water reservoir 
so that there is a level of approximately 2 inches in the tank by the time the 
temperature is reached. 
When the temperature reaches 500 , turn off the pumps. 
Disconnect the tube at the top of the header vessel and connect it to the water 
reservoir. 
Disconnect the tube from the drain and attach it to the header vessel. 
Add 50 g of Tergazyme to the header vessel and turn on the pulsatile pump. 
Add 100 g of NaOH (powder) to the water reservoir and turn on the milk pump. 
Turn on the milk pump and the pulsatile pump and run the system with the 
detergents for at least 2 hours, until no milk clot is visible in the downstream 
section. Hence, turn off the pulsatile pump. 
Disconnect the hose from the header vessel and reattach to the drain. Turn on 
the pulsatile pump to expel the Tergazyme. 
Open the valve to atmosphere on the water jet ejector line and close the valve 
to the deacration column. 
Pump all of the caustic back into the water reservoir. 
Drain all of the caustic through the valve manifold into the milk containers. 
Clean the milk containers with the caustic solution and then pour down the 
drain. 
Rinse the milk containers with hot water to remove all traces of caustic. 
Disconnect the hose to the water reservoir and reattach to the top of the header 
tank. 
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The supplier's specifications for the rennet used in the current work are included 
here. 
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Extra thermolabile clotting enzyme for cheese 
Introduction 
Fromase XL is an extra thermolabile variant of 
the microbial coagulant derived from the sod 
fungus Rhizomuco,' miehe, 
In most cases the standard Fromase TL meets 
all the requirements of the cheesemaker 
In a number of cases however, and for various 
reasons a product with in increased 
thermolability is needed. 
Such reasons include for instance the need to 
use lower whey pasteurisation temperatures 
when the whey is used for whey protein 
manufacturIng or the need to be able to destroy 
residual clotting activity in slightly acidic whey.  
In those cases the normal Fromas? TL quality 
may not be sufficient to satisfy the 
technological requirements 
Research into increased thermolability led to the 
development of Frómase5 XL. 
The increased thermolability of Fromasee  XL has 
also been shown tobean advantage in the 
production of some cheese varieties such as 
Emmentaler, where the enzyme is already partly 
inactivated during the cooking of the curds This 
has been shown to lead to a better controlled 
eye formation Other varieties of cheeses have 
also been produced with good results using 
Fromasee XL, 
Properties of Fromasel XL 
A. General bIochemiCal properties 
Fromase® XL is an acid furgal protease with a 
molecular weight of ápprox. 40;000. 
The overall amino acid composition of F romasee 
XL is very similar to that of animal rennet. Its 
stability in solUtion is excellent between pH 30 
and 6.5. 
The specificity of Fromase XL onthebeta 
chain of insulin is very similar to that of: animal 
rennet, with  preference for those linkages 
involving aromatic amino acids. 
Like animal rennet, Fromasa XL induces milk 
clotting through hydrolytic cleavage of 
thePhenylananlne-methionine linkage of kappa 
casein. 
B. Effect of temper ture 
The relative activity of animal rennet Fromdse 
TL and Fromasee  XL is given in graph I 
Fromase XL has the same effect as calf rennet 
and Fromase TL in the usual clotting 
temperature range At higher temperatures the 
effect of the enzymes show marked differences 
lo 
;13 	12  
The therrnOlability. of , Frorrrnse XL is clearly ,  
superior to that of calf rennet Fromase 5 XL is 
like calf rennet partly inactivated during 
scalding. 
C Effect of ph 
In graph 11it is shown that Fromase ® XL is 
somewhat more sensitive with reference to the 
pH than Fromase TL orcàlfrennet in the 
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D. Effect of calcium ion concentration 	F. Inactivation of Fromase ® XL in whey 
Fromase5 XL and calf rennet have the same It is essential to ensure that Fromase 5 is 
sensitivity to the calcium ion concentration 	inactivated in whey Graph IV shows the activity 
Fromas.eo TL is slightly more sensitive These of Fromasea  XL and IL with reference to the 
studies were carried out using Berridge substrate whey pH 
the concentration of 10 mM of C6Cl 2 	 Fromasee TL is inhibited under conditions normal 
corresponds to 1 11 g of anhydrous CaCl2 per 	for the pasteurisation of whey if excessive 
liter 	 acidification by prolonged storage before 
pasteurisation is avoided Fromase®  XL is even 
superior to calf rennet. in thisrespect, when 
Fromase5 XL is added, directly -to reconstituted 
whey at pH 6 0 less than 1% residual activity is 
found after 15 sec pasteurization at 68°C To 
achieve the same degree of inactivation of calf 
rennet or bovine rennet the temperature must be 
- 	 2°C higher i a 15 Sec at 70°C 
100 	 . 
E Flocculation times and enzyme 
concentration 
Animal rennet is known to follow the law of 
Storch und Segelke: 
t = Ci * *+C2 
This is also the case.for Fromasel XL and TI. 
When however raw milk is used, Fromàsea  XL 
and TL do not follow this law andthe deviation 
observed varies with different types of milk. It 
has been shown that all the Rhizomucor, miehei 
enzymes act in this way, corresponding in fact 
to competitive inhibition by an inhibitor present 
in raw milk which is however destroyed at. a. 
temperature above 68°C. This charàctèristic is 
especially evident in the manufacture of 
Emmental cheese from raw milk. Due to this 
inhibition the addition rates of Fromase 0 XL and 
TL in raw milk have to be increased about 20-
25% compared to calf rennet to obtain a 
coagulation time of 25-30 minutes. 
Graph V shows the influence of pH and 
temperature on the residual activity of Fromase 0 
XL in whey after pasteurization.  
0400112 . 	 0-c. a I410.0 000p.100,. 
10 l 	 .2f e10ll. a. 
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For more infOrmation please contact: 
Gist-BIocádes B.V. 
Dairy Ingredients Group 











constant depending on the 
type of milk used and the type 
of rennet 
or our local representative: 
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DSM Food Specialties 
15, Rue des Comtesses 
BP 239, 59472 Secbn C4clex France 
Téléphone 33 (0) 3 20 96 45 45 Télécopo 33 
PrOduct name 	: FROMASE22OXL 
Batch number 	 F 4376 
I}_1 U 
20 96 45 W 
Milk clotting activity , IMCU /ml 238 
PH 3  5 
Density 1.12 
Sodium chloride 	fl 160 
Sodium berizoatO, gill 4.6 






Coliforms / ml 
meets specifications 
Salmonella! 25 ml 
meets specifications  
Escherichia Call, / 25 ml 
meets specifications 
Staphylococcus aureus / ml 
negative 
Llsterla monocytogenes! 25 ml 
R Cassaigna Quality Control Manager 
Print Data: October 25,2001 
PRODUCTION DATE 0912001 
BEST BEFORE.OATE: 0912002 
This certificate is a non signed computer form edited by the autholized persons, after validation of the 
batch by the Quality Control Manaaer 
Appendix C 
Residence Time Studies 
The residence time of coagulating fluid in the vicinity of the heart valves was deter-
mined by dye injection. A pulse of dye was injected into the flow at the point where 
the rennet line was normally attached, and the decay of dye was filmed with a digital 
video camera. ImagePro software was then used to analyse the colour change in a 
chosen section of the video. There are two means by which colour can be identified: 
the RGB (red, green, blue) system and the HSI (hue, saturation, intensity) system. 
A specific colour is uniquely defined by three coordinates in either of these systems; 
ImagePro identifies colour with HSI coordinates. For the present work, it was decided 
that the saturation coordinate was most significant as it reflected the concentration 
of dye in the chamber, which could then be correlated with the residence time of 
coagulating fluid in the vicinity of the heart valve. 
Videos were initially acquired at 25 frames/second, then reduced to 2 frames/second 
with Adobe Premiere'. As analysis of each frame was performed manually, it was 
decided to reduce the population further, and only every fifth frame imported to 
ImagePro was analysed, resulting in a gap of 2.5 seconds between successive frames. 
A selection of images is included in Figure C, showing the migration of dye through 
the chamber 2 . A section immediately upstream of the valve was then selected for 
analysis. This is indicated by the rectangle upstream of the mitral valve in Fig-
ure C.2. ImagePro then determined average values of hue, saturation, and intensity 
for all of the pixels in the selected area. These numbers were saved into an Excel 
file for each frame, and subsequently analysed. A sample of the Excel file is included 
in this appendix. From this data, the time that the maximum saturation occurred 
in each run was determined, as well as the time that the saturation was reduced to 
'The original videos were too large to be opened by ImagePro. 
2 Only every second frame is shown, representing a gap of 5 seconds between successive images 
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25% of its initial value. For the rigid heart chamber, the initial time was taken as 
the time that dye first entered the mitral chamber. This is where the rennet and 
CaC12 streams were mixed together, initiating appreciable coagulation in the system. 
In the flexible chamber, the rennet and CaCl2 streams were mixed together immedi-
ately downstream of the injection points, so the initial time was taken as the time 
when the dye was first injected into the system. Dye injection was then performed a 
minimum of four times with the test valve in each position. 
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Figure CA: Migration of dye through the rigid test chamber. The time between 










APPENDIX C. RESIDENCE TIME STUDIES 	 193 
Figure C.2: ImagePro analysis of one video frame obtained from dye injection work. 
The white rectangle in the picture encloses the selection for which saturation values 
were obtained in the mitral position. 
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Averace 	Min 	Max Std Dev 
H 138.15 7 211 91.94 
S 5.85 4 11 2.31 
121.91 107 131 4.79 
H 205.42 203 208 1.76 
S 144.26 117 157 10.12 
I 65.32 53 76 4.56 
H 211.48 208 218 1.32 
S 139.24 112 151 10.17 
79.83 70 89 4.06 
H 213.65 212 218 1.53 
S 108.34 87 123 8.32 
94.46 87 103 3.91 
H 217.12 216 219 1.36 
S 68.19 58 72 4.16 
I 102,99 98 110 3.91 
H 220.2 215 229 3.09 
S 43.86 29 49 5.08 
I 109.26 98 114 3.6 
H 224.38 215 233 4.67 
S 29.18 17 40 5.47 
I 	1 113.26 103 123 3.89 
H 226.58 221 239 4.9 
S 18.87 13 20 1.82 
I 116.35 102 123 4.33 
H 219.8 211 249 10.87 
S 14.09 9 16 1.82 
I 117.06 103 126 4.95 
H 218.42 8 239 36.34 
S 10.62 4 18 3.29 
I 117.75 101 124 4.06 
H 193.07 0 250 83.59 
S 8.66 4 15 2.93 
I 117.05 101 126 4.29 
H 162.46 0 249 100.54 
S 6.78 4 16 2.36 
I 1 	119.35 109 133 4.31 
H 168.78 0 249 92.15 
S 8.54 4 19 4.74 
I 120.06 104 134 4.68 
H 181 0 249 90.87 
S 8.47 4 12 1.7 
I 1 	117.41 106 125 4.27 
H 165.09 0 239 103.9 
S 7.78 
1 
4 15 2.11 
118.99 102 126 4.29 
H 115.81 0 239 114.33 
S 5.18 2 13 2.96 
118.32 111 129 3.06 
H 127.25 7 211 100.1 
S 5.32 4 10 2.14 
119.34 107 127 4.5 
Time Hue Saturation Intensity 
0.0 138.2 5.8 121.9 
2.5 205.4 144.3 65.3 
5.0 211.5 139.2 79.8 
7.5 213.6 108.3 94.5 
10.0 217.1 68.2 103.0 
12.5 220.2 43.9 109.3 
15.0 224.4 29.2 113.3 
17.5 226.6 18.9 116.3 
20.0 219.8 14.1 117.1 
22.5 218.4 10.6 117.8 
25.0 193.1 8.7 117.1 
27.5 162.5 6.8 119.4 
30.0 168.8 8.5 120.1 
32.5 181.0 8.5 117.4 
35.0 165.1 7.8 119.0 
37.5 115.8 5.2 118.3 
40.0 127.2 5.3 119.3 
Max Satn 	144.3 
At time 2.5 
25% Satn 40.05 
At time 	15 
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